RESULT_COUNT: 726,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
JUNO,JUNO:UW,BBG007K3F2J4,Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval,2017-10-20 23:59:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jwCW8zJfQ9Y/gilead-gild-car-t-therapy-yescarta-clinches-fda-approval-cm863004,Gilead Sciences Inc GILD announced that the FDA has approved its chimeric antigen receptor T cell CAR T therapy Yescarta axicabtagene ciloleucel for treatment of refractory aggressive non Hodgkin lymphoma which includes DLBCL transformed follicular lymphoma TFL and primary
JUNO,JUNO:UW,BBG007K3F2J4,"Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences",2017-10-20 11:31:00 +0000,https://finance.yahoo.com/news/celgene-could-best-car-t-113100536.html?.tsrc=rss,Celgene&apos;s partnership strategy gives it exposure to multiple companies&apos; research on next-generation cell therapy.
JUNO,JUNO:UW,BBG007K3F2J4,Gilead Slaps Mega-Price on Its Newly Approved CAR-T,2017-10-19 23:31:00 +0000,https://finance.yahoo.com/news/gilead-slaps-mega-price-newly-233100308.html?.tsrc=rss,Gilead Sciences&apos; premium price for Yescarta could help offset hep C headwinds.
JUNO,JUNO:UW,BBG007K3F2J4,Does Gilead Now Have A New Multi-Billion-Dollar Franchise?,2017-10-19 20:48:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p7Athhyn3y0/does-gilead-now-have-a-new-multi-billion-dollar-franchise-cm861865,Gilead Sciences GILD jumped early Thursday after the Food and Drug Administration approved what is known as a CAR T drug dubbed Yescarta to treat an aggressive form of non Hodgkin lymphoma ibd display video id 2381354 width 50 float left autostart true The late
JUNO,JUNO:UW,BBG007K3F2J4,S&P 500 Futures: These 5 Top Stocks Are Big Overnight Movers,2017-10-19 13:47:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rInOpbhNS8Q/sp-500-futures-these-5-top-stocks-are-big-overnight-movers-cm861652,Futures for the S amp P 500 index Nasdaq 100 and Dow industrials fell Thursday morning as European equities retreated on the 30th anniversary of the Black Monday stock market crash Meanwhile there are several notable stocks that were moving overnight on their own
JUNO,JUNO:UW,BBG007K3F2J4,S&P 500 Futures: These 5 Top Stocks Are Big Overnight Movers,2017-10-19 11:10:53 +0000,http://finance.yahoo.com/r/63b32f79-65fb-3094-bd50-0ef7751044be/these-5-top-stocks-are-moving-late-on-news-sp-500-futures?src=A00220&yptr=yahoo&.tsrc=rss,"Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics."
JUNO,JUNO:UW,BBG007K3F2J4,"These Are 5 Notable Stocks Moving Overnight, Including This Top Biotech: S&P 500 Futures",2017-10-19 07:49:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-FvjrntWKrk/these-are-5-notable-stocks-moving-overnight-including-this-top-biotech-sp-500-futures-cm861652,Futures for the S amp P 500 index Nasdaq 100 and Dow industrials fell slightly Thursday morning But there are several notable stocks that were movers late Wednesday on news and will likely open significantly open or lower today ibd display video id 449433 width 50 float
JUNO,JUNO:UW,BBG007K3F2J4,Trianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform,2017-10-18 12:00:00 +0000,https://finance.yahoo.com/news/trianni-juno-therapeutics-sign-licensing-120000928.html?.tsrc=rss,"SAN FRANCISCO, Oct. 18, 2017 /PRNewswire/ -- Trianni, Inc. (""TRIANNI"") today announced that Juno Therapeutics (JUNO) has entered into a license agreement for The Trianni Mouse™, a best-­in-class monoclonal antibody discovery platform.  Juno intends to use The Trianni Mouse with its proprietary high throughput, single cell sequencing technology and direct-­to-­CAR screening to rapidly identify fully-human binders for conversion to chimeric antigen receptors in its engineered T cell programs.  ""TRIANNI is pleased to bolster Juno's lead generation capabilities through a license to The Trianni Mouse,"" stated Dr. David Meininger, TRIANNI's Chief Business Officer."
JUNO,JUNO:UW,BBG007K3F2J4,Celgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science?,2017-10-17 21:51:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CEItNXh7o0I/celgene-blood-cancer-treatment-just-the-tip-of-its-disruptive-science-cm859983,Celgene CELG a pioneer and leading player in blood cancer treatment has become a biotech juggernaut thanks largely to a drug that proved key in fighting the tricky disease multiple myeloma ibd display video id 2326965 width 50 float left autostart true In multiple
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : October 16, 2017",2017-10-16 13:55:11 +0000,http://finance.yahoo.com/r/500ff7c3-161a-356d-b3c4-827f355b8243/etfs-with-exposure-to-juno-therapeutics-inc-october-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-10-16 13:43:30 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-134330841.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field,2017-10-16 13:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I9RrLF1kayM/kite-pharma-cancer-treatment-stands-out-in-hot-car-t-field-cm859985,Kite Pharma is edging closer to approval for a cutting edge cancer treatment that fights the disease by rebuilding a patient s own cells 160 a technology that could benefit thousands of people and pave the way for blockbuster drugs ibd display video id 2326965 width 50 float
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-10-13 12:02:25 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120225058.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics Stock May Still Be Worth Buying,2017-10-07 18:51:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JZc7BwHPWtE/heres-why-juno-therapeutics-stock-may-still-be-worth-buying-cm856706,What happened Juno Therapeutics NASDAQ JUNO a clinical stage adoptive cell therapy company saw its shares rise by 7 last month according to data from S amp P Global Market Intelligence The biotech s shares have been edging higher lately primarily due to
JUNO,JUNO:UW,BBG007K3F2J4,Here&apos;s Why Juno Therapeutics Stock May Still Be Worth Buying,2017-10-07 17:00:00 +0000,http://finance.yahoo.com/r/ee7eef72-d34d-38e7-b173-a45ff4e1aaf7/heres-why-juno-therapeutics-stock-may-still-be-wor.aspx?yptr=yahoo&.tsrc=rss,Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.
JUNO,JUNO:UW,BBG007K3F2J4,2 Medical Breakthroughs Set to Reward Early Investors,2017-10-06 18:18:06 +0000,https://finance.yahoo.com/news/2-medical-breakthroughs-set-reward-181806690.html?.tsrc=rss,The biggest advances yet to come have wealth-multiplying potential.
JUNO,JUNO:UW,BBG007K3F2J4,"New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production",2017-10-06 12:15:00 +0000,https://finance.yahoo.com/news/research-key-drivers-growth-bed-121500435.html?.tsrc=rss,"NEW YORK, Oct. 06, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bed ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno Therapeutics, Inc., LendingClub Corporation, MiMedx Group, Inc., Ooma, Inc. and SCANA Corporation",2017-10-03 23:01:00 +0000,https://finance.yahoo.com/news/lifshitz-miller-llp-announces-investigation-230100695.html?.tsrc=rss,"NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Foundation Medicine, Inc. (FMI) Lifshitz & Miller announces an investigation on behalf of FMI investors concerning whether FMI issued false and misleading statements ..."
JUNO,JUNO:UW,BBG007K3F2J4,Bluebird Bio: So Much for That Gilead Boost,2017-10-02 19:56:00 +0000,http://finance.yahoo.com/r/7ffe85c6-5d44-3a05-8ed7-4a34596036cc/bluebird-bio-so-much-for-that-gilead-boost-1506974212?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ..."
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-10-02 12:05:02 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120502460.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,"&quot;Fast Money&quot; final trades: JUNO, JD and more",2017-09-29 21:25:00 +0000,https://finance.yahoo.com/video/fast-money-final-trades-juno-212500076.html?.tsrc=rss,"The “Fast Money” traders share their final trades for the day including Olin Corp, JD.com, General Electric and Juno Therapeutics."
JUNO,JUNO:UW,BBG007K3F2J4,Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical',2017-09-28 21:34:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfxMfWXn6qM/novartis-could-acquire-this-biotech-why-a-deal-is-very-logical-cm852694,Advanced Accelerator Applications AAAP launched to a record high Thursday on rumors Swiss drug giant Novartis NVS could attempt to take it over a potential deal one analyst called very logical ibd display video id 2322998 width 50 float
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish,2017-09-27 15:55:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kY_i7k9ipl0/juno-therapeutics-inc-juno-3-reasons-to-be-bullish-cm851983,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO which is a biotech operator that is focused on cancer treatments has seen its stock languish during September Yet this has come after a
JUNO,JUNO:UW,BBG007K3F2J4,Insiders Bullish on Certain Holdings of JKK,2017-09-27 14:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/czwcMK6L-mQ/insiders-bullish-on-certain-holdings-of-jkk-cm851758,A look at the weighted underlying holdings of the iShares Morningstar Small Cap Growth ETF JKK shows an impressive 10 5 of holdings on a weighted basis have experienced insider buying within the past six months Juno Therapeutics Inc Symbol JUNO which makes up 0 57 of the
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish,2017-09-27 10:54:57 +0000,https://finance.yahoo.com/news/juno-therapeutics-inc-juno-3-105457613.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO), which is a biotech operator that is focused on cancer treatments, has seen its stock languish during September.  From early June, JUNO stock has logged a return of over 80%.  Just some of the rivals include Kite Pharma Inc (NASDAQ:KITE), Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Cellectis SA (ADR) (NASDAQ:CLLS), bluebird bio Inc (NASDAQ:BLUE), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Novartis AG (ADR) (NYSE:NVS)."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares",2017-09-26 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-closes-offering-including-200500091.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on public offering of 7,015,000 shares of its common stock at a price to the public of $41.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase up to an additional 915,000 ..."
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised),2017-09-25 14:50:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/djKGG8vIvjY/heres-why-these-3-biotech-stocks-might-stop-rallying-revised-cm850299,Biotech stocks have bounced back strongly this year after a poor show last year despite challenges like rising competition slowdown in growth of mature products and generic competition for certain key drugs Strong clinical results faster FDA approvals success of new products and
JUNO,JUNO:UW,BBG007K3F2J4,Is Costco Wholesale Corporation (COST) Stock Readying An Out-Performance?,2017-09-25 14:48:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rqFtrewNcFk/is-costco-wholesale-corporation-cost-stock-readying-an-out-performance-cm850364,InvestorPlace Stock Market News Stock Advice amp Trading Tips If you like to shop after a price drop consider shares of Costco Wholesale Corporation NASDAQ COST But if you want added buyer protection and enjoy additional cost cutting measures a modified bullish fence on
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : September 25, 2017",2017-09-25 14:40:46 +0000,http://finance.yahoo.com/r/2335ebdf-a32e-3777-bce7-4088a79b83c5/etfs-with-exposure-to-juno-therapeutics-inc-september-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Here&apos;s Why These 3 Biotech Stocks Might Stop Rallying (Revised),2017-09-25 12:57:12 +0000,https://finance.yahoo.com/news/apos-why-3-biotech-stocks-125712548.html?.tsrc=rss,"The momentum in the biotech sector is likely to continue. However, it&apos;s a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date."
JUNO,JUNO:UW,BBG007K3F2J4,"Robbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of Shareholders",2017-09-22 21:53:00 +0000,https://finance.yahoo.com/news/robbins-arroyo-llp-investigating-officers-215300918.html?.tsrc=rss,"Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juno Therapeutics, Inc. breached their fiduciary duty to shareholders by engaging in self-dealing and issuing materially false and misleading statements regarding the side effects of its lead product candidate, JCAR015."
JUNO,JUNO:UW,BBG007K3F2J4,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 21:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6AIkN0MWtQ/oddly-juno-therapeutics-is-jumping-113-today-cm849862,What happened Despite a 6 1 million share follow on public stock offering shares of Juno Therapeutics NASDAQ JUNO are rallying 11 3 higher at 3 p m EDT So what Juno Therapeutics shares have been rallying since competitor Gilead Sciences NASDAQ GILD acquired
JUNO,JUNO:UW,BBG007K3F2J4,Juno Tenders $250M Follow-on Public Offering of Common Stock,2017-09-22 21:47:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WLljq_3wHY0/juno-tenders-250m-follow-on-public-offering-of-common-stock-cm849852,Juno Therapeutics Inc s JUNO shares dropped more than 7 after the company announced that it has launched a proposed 250 million follow on public offering of 6 1 million shares of common stock at 41 per share The offering subject to customary closing conditions is expected to close on
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 09/22/2017: ICPT,JUNO,VSAR",2017-09-22 20:27:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bwFVWyC3IkM/health-care-sector-update-for-09222017-icptjunovsar-cm849834,Top Health Care StocksTop Health Care Stocks JNJ 0 22 JNJ 0 22 PFE 0 01 PFE 0 01 ABT 2 09 ABT 2 09 MRK 0 66 MRK 0 66 AMGN 0 33 AMGN 0 33 Health care stocks overturned prior declines in late trade with the NYSE Health Care Index climbing nearly 0 2 shortly before the closing
JUNO,JUNO:UW,BBG007K3F2J4,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 20:00:00 +0000,http://finance.yahoo.com/r/03bfbe08-3495-39a0-b0df-4566490b66cf/oddly-juno-therapeutics-is-jumping-113-today.aspx?yptr=yahoo&.tsrc=rss,Optimism that it can develop CAR-T cancer drugs that are better than its competitors&apos; is trumping news that the company is diluting investors by selling more shares.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Tenders $250M Follow-on Public Offering of Common Stock,2017-09-22 19:11:07 +0000,https://finance.yahoo.com/news/juno-tenders-250m-public-offering-191107333.html?.tsrc=rss,Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 09/22/2017: JUNO,ALDX,VSAR",2017-09-22 19:08:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4VyBAVCE2ew/health-care-sector-update-for-09222017-junoaldxvsar-cm849776,Top Health Care StocksTop Health Care Stocks JNJ 0 30 JNJ 0 30 PFE 0 36 PFE 0 36 ABT 1 28 ABT 1 28 MRK 0 69 MRK 0 69 AMGN 0 61 AMGN 0 61 Health care stocks were paring some of their prior declines in recent trading with the NYSE Health Care Index losing just over 0 1 while
JUNO,JUNO:UW,BBG007K3F2J4,"Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers",2017-09-22 16:13:00 +0000,http://finance.yahoo.com/r/f297b878-ca78-352e-94f9-6512ceb5264b/versartis-shares-down-after-phase-3-study-misses-primary-endpoint.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA on Thursday issued a safety announcement saying Intercept's liver disease treatment Ocaliva is being dosed incorrectly in some patients.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 15:41:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NrIOSO31NmU/juno-therapeutics-inc-juno-stock-to-buy-or-not-to-buy-cm849713,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a great summer for 160 Juno Therapeutics Inc NASDAQ JUNO JUNO stock is up 50 over the past month and has more than doubled year to date It s been quite the reversal of
JUNO,JUNO:UW,BBG007K3F2J4,"Pre-Market Most Active for Sep 22, 2017 :  VSAR, ERIC, NOK, AZN, MT, S, INTC, TVIX, AAPL, FCAU, JUNO, ESV",2017-09-22 12:55:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LKz7Mg5G2zw/pre-market-most-active-for-sep-22-2017-vsar-eric-nok-azn-mt-s-intc-tvix-aapl-fcau-juno-esv-cm849488,The NASDAQ 100 Pre Market Indicator is down 6 24 to 5 928 67 The total Pre Market volume is currently 5 009 089 shares traded The following are the most active stocks for the pre market session Versartis Inc VSAR is 18 3 at 3 30 with 2 768 677 shares traded
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Biogen,2017-09-22 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000470.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Biogen tumbled on Thursday after receiving a downgrade from Raymond James that took it down two notches from ""strong buy"" to ""market ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 11:03:58 +0000,https://finance.yahoo.com/news/juno-therapeutics-inc-juno-stock-110358957.html?.tsrc=rss,"It’s been a great summer for Juno Therapeutics Inc (NASDAQ:JUNO).  JUNO stock is up 50% over the past month and has more than doubled year-to-date.  It’s been quite the reversal of fortunes after a rough period that saw JUNO stock reach $70 in 2015, then plummet to $20, as investors lost faith in its CAR-T platform."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Prices $250 Million Follow-on Offering,2017-09-22 01:13:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-prices-250-million-011300156.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price to the public of $41.00 per share."
JUNO,JUNO:UW,BBG007K3F2J4,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 20:39:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ehlFKBmeH0/immunize-juno-therapeutics-inc-juno-stock-with-this-trade-cm849309,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO has a lot going for it off and on the price chart That doesn t mean you shouldn t immunize JUNO stock against the always real bearish threats To do that we
JUNO,JUNO:UW,BBG007K3F2J4,"3 Big Stock Charts for Thursday: Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and Cerner Corporation (CERN)",2017-09-21 20:39:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qgTJyrpmQLg/3-big-stock-charts-for-thursday-apple-inc-aapl-amazoncom-inc-amzn-and-cerner-corporation-cern-cm849307,InvestorPlace Stock Market News Stock Advice amp Trading Tips This morning s market activity was softer as the Nasdaq Composite is taking a breather trading lower on what appears to be profit taking as well as some negative movement in one of the index s Canary in
JUNO,JUNO:UW,BBG007K3F2J4,"IPXL Mulls Merger, QURE Attracts Attention, No Let Up In ICPT Ocaliva Concerns",2017-09-21 20:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n1Br6rKkbIA/ipxl-mulls-merger-qure-attracts-attention-no-let-up-in-icpt-ocaliva-concerns-20170921-01187,"IPXL Mulls Merger, QURE Attracts Attention, No Let Up In ICPT Ocaliva Concerns"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Opens New Headquarters and Research Center,2017-09-21 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-opens-headquarters-research-200500092.html?.tsrc=rss,"Juno Therapeutics, Inc.  , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle."
JUNO,JUNO:UW,BBG007K3F2J4,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 16:01:35 +0000,https://finance.yahoo.com/news/immunize-juno-therapeutics-inc-juno-160135366.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn&#8217;t mean you shouldn&#8217;t immunize JUNO stock against the always-real bearish threats. To do that, we&#8217;ll explore a fully-hedged, collar-based therapy program. Let me explain."
JUNO,JUNO:UW,BBG007K3F2J4,FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers,2017-09-21 14:10:00 +0000,http://finance.yahoo.com/r/cc589e9d-19b6-3fef-9909-b9e28af18edb/fda-oks-biocryst-s-rapivab-for-pediatric-indication.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The approval marks ""the first new influenza antiviral for pediatric use in over 10 years,"" said BioCryst president and CEO Jon Stonehouse in the news release."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to launch $225 million follow-on offering,2017-09-20 20:30:13 +0000,http://finance.yahoo.com/r/2f8f3bac-8023-3160-a9d9-04edfa9b4833/Story.aspx?guid=E2085371-8011-45F2-BF78-A085D7BD96FE&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Shares of Juno Therapeutics Inc. fell more than 1% late Wednesday after the biopharmaceutical company announced the launch of a proposed follow-on public offering worth $225 million. Juno said it expects ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Launches Follow-on Offering,2017-09-20 20:17:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-launches-offering-201700853.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the launch of a proposed follow-on public offering of $225 million of shares of its common stock."
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why These 3 Biotech Stocks Might Stop Rallying,2017-09-20 17:38:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AnZVFW7nW4s/heres-why-these-3-biotech-stocks-might-stop-rallying-cm848516,Biotech stocks bounced back strongly this year after a poor show last year despite challenges like rising competition slowdown in growth of mature products and generic competition for certain key drugs Strong clinical results faster FDA approvals success of new products and
JUNO,JUNO:UW,BBG007K3F2J4,"Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade",2017-09-19 15:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8fAs25q_ko/yes-juno-therapeutics-juno-just-became-a-great-car-t-trade-cm847784,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO is poised to benefit from a rising acquisition trend Three weeks ago when Gilead Sciences Inc NASDAQ GILD announced it would
JUNO,JUNO:UW,BBG007K3F2J4,"Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade",2017-09-19 11:09:37 +0000,https://finance.yahoo.com/news/yes-juno-therapeutics-juno-just-110937168.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend.  Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice.  If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it."
JUNO,JUNO:UW,BBG007K3F2J4,"Stull, Stull & Brody Announces Lawsuit Against Certain Officers and Directors of Juno Therapeutics, Inc. (NASDAQ: JUNO)",2017-09-18 22:30:00 +0000,https://finance.yahoo.com/news/stull-stull-brody-announces-lawsuit-223000256.html?.tsrc=rss,"NEW YORK, Sept. 18, 2017-- Stull, Stull & Brody announces that a lawsuit was commenced in the United States District Court for the Western District of Washington against certain executive officers and ..."
JUNO,JUNO:UW,BBG007K3F2J4,SPDR S&P Biotech ETF Experiences Big Outflow,2017-09-15 16:35:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gz3KhXTMUqg/spdr-sp-biotech-etf-experiences-big-outflow-cm846330,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 87 4 million dollar outflow that s a 2 1 decrease week over week from 49 600 000
JUNO,JUNO:UW,BBG007K3F2J4,Dolby Laboratories is a stock to watch after Apple’s new iPhone launch,2017-09-14 18:29:42 +0000,http://finance.yahoo.com/r/fac02885-b703-382c-bf2c-2cbdb206e509/Story.aspx?guid=CA99488A-9978-11E7-8EBC-4ADA47F6D2CA&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Also in focus: Juno Therapeutics, Loxo Oncology and NovoCure. By Harry Boxer."
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : September 13, 2017",2017-09-13 22:45:18 +0000,http://finance.yahoo.com/r/48c579ab-d9f2-3031-953f-51a727d83a27/etfs-with-exposure-to-juno-therapeutics-inc-september-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-09-12 12:03:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120312505.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017",2017-09-11 17:45:58 +0000,http://finance.yahoo.com/r/a806d445-dd06-32c9-b45a-631ea7c2c331/juno-therapeutics-inc-juno-us-earnings-analysis-q2-2017-by-the-numbers-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Juno Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Juno Therapeutics, Inc. – ZIOPHARM Oncology, Inc., Incyte Corporation, Repligen Corporation and Mirati Therapeutics Inc. (ZIOP-US, INCY-US, RGEN-US and MRTX-US) that have also reported for this period. Highlights ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-09-11 14:08:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-140812961.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,CAR-T Mania: Could Juno Therapeutics Get Acquired Next?,2017-09-10 10:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NSC3dU34uHc/car-t-mania-could-juno-therapeutics-get-acquired-next-cm843367,Gilead Sciences NASDAQ GILD 160 recently acquired Kite Pharma NASDAQ KITE but that doesn t mean an acquisition of Juno Therapeutics NASDAQ JUNO is off the table Juno Therapeutics next generation CAR T JCAR017 could wind up being safer than its
JUNO,JUNO:UW,BBG007K3F2J4,CAR-T Mania: Could Juno Therapeutics Get Acquired Next?,2017-09-10 09:00:00 +0000,http://finance.yahoo.com/r/6fb824cb-4a74-3b0a-aed7-214824617990/car-t-mania-could-juno-therapeutics-get-acquired-n.aspx?yptr=yahoo&.tsrc=rss,Juno Therapeutics is developing next-generation CAR-Ts that it believes could be better than what its competitors offer.
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-09-08 14:23:02 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142302529.html?.tsrc=rss,Juno Therapeutics Inc NASDAQ/NGS:JUNO
JUNO,JUNO:UW,BBG007K3F2J4,Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August,2017-09-08 02:49:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WL3NlMUrit8/why-gene-editing-pioneer-editas-skyrocketed-288-in-august-cm842697,What happened Editas Medicine NASDAQ EDIT is researching the use of gene editing to treat disease After the company updated investors on its progress on Aug 9 shares soared 18 8 last month according to S amp P Global Market Intelligence So what Editas
JUNO,JUNO:UW,BBG007K3F2J4,Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August,2017-09-08 01:30:00 +0000,http://finance.yahoo.com/r/66d85f8a-16d0-3d69-9118-02e1946e99b1/why-gene-editing-pioneer-editas-skyrocketed-288-in.aspx?yptr=yahoo&.tsrc=rss,Editas Medicine continues to make progress toward clinical trials of its gene-editing approach.
JUNO,JUNO:UW,BBG007K3F2J4,Are These Healthcare Stocks Top Takeover Targets?,2017-09-07 21:10:00 +0000,http://finance.yahoo.com/r/d40d0cac-b80e-31ea-8f8f-6ff649b83d38/are-these-healthcare-stocks-top-takeover-targets.aspx?yptr=yahoo&.tsrc=rss,"Big-cap biopharma could come knocking if Juno Therapeutics’ next-generation CAR-T is safer than its competitors, and Medtronic&apos;s already investing billions in Mazor Robotics, a maker of surgical robots."
JUNO,JUNO:UW,BBG007K3F2J4,Breaking Down Barclays' New Bullish Calls On Biotech,2017-09-07 19:32:52 +0000,https://finance.yahoo.com/news/breaking-down-barclays-bullish-calls-193252995.html?.tsrc=rss,"Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a Positive view, as it expects the outperformance of the sector relative to the S&P 500 to continue in the next 12-18 ..."
JUNO,JUNO:UW,BBG007K3F2J4,5 Things You'll Want to Know From Celgene Corporation's Latest Presentation,2017-09-07 13:53:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oBJnE0iBScM/5-things-youll-want-to-know-from-celgene-corporations-latest-presentation-cm842109,It s been a busy week for biotech and healthcare conferences Drugmakers big and small have been making the rounds answering questions about their current status and future prospects Celgene Corporation NASDAQ CELG is no exception Bob Kellogg Celgene s CFO fielded questions
JUNO,JUNO:UW,BBG007K3F2J4,5 Things You&apos;ll Want to Know From Celgene Corporation&apos;s Latest Presentation,2017-09-07 11:47:00 +0000,http://finance.yahoo.com/r/6db966e4-076b-3d8a-af84-527b22f9af29/5-things-youll-want-to-know-from-celgene-corporati.aspx?yptr=yahoo&.tsrc=rss,Celgene CFO Bob Kellogg discusses what&apos;s in store for the big biotech.
JUNO,JUNO:UW,BBG007K3F2J4,This year’s best-performing ETF could rise even higher,2017-09-07 11:00:00 +0000,https://finance.yahoo.com/news/best-performing-etf-could-rise-110000482.html?.tsrc=rss,Biotech stocks have been on a bionic run. Here&apos;s what&apos;s driving the move.
JUNO,JUNO:UW,BBG007K3F2J4,This year’s best-performing ETF could rise even higher,2017-09-07 11:00:00 +0000,http://finance.yahoo.com/r/ee12315e-c108-37f8-bc59-ce0cb3f009b8/104693951?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104693951&yptr=yahoo&.tsrc=rss,Biotech stocks have been on a bionic run. Here's what's driving the move.
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 3-Aug-17 9:00pm GMT,2017-09-06 20:06:24 +0000,https://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-070936577.html?.tsrc=rss,Q2 2017 Juno Therapeutics Inc Earnings Call
JUNO,JUNO:UW,BBG007K3F2J4,"Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD",2017-09-06 16:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YhXEKrFaXWo/notable-etf-inflow-detected-xbi-juno-exel-acad-cm841734,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 121 7 million dollar inflow that s a 3 0 increase week over week in outstanding
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Shares Vaulted 46% Higher in August,2017-09-05 12:49:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wwez9_ovmmA/why-juno-therapeutics-shares-vaulted-46-higher-in-august-cm840865,What happened After Gilead Sciences NASDAQ GILD scooped up competitor Kite Pharma NASDAQ KITE for 11 9 billion and Novartis NYSE NVS secured an approval from the Food and Drug Administration for Kymriah 160 shares of Juno Therapeutics NASDAQ JUNO
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Shares Vaulted 46% Higher in August,2017-09-05 11:15:00 +0000,http://finance.yahoo.com/r/d7f4d5bf-dc64-3b11-9b80-533e47e03fc5/why-juno-therapeutics-shares-vaulted-46-higher-in.aspx?yptr=yahoo&.tsrc=rss,Optimism is soaring following the FDA approval of Novartis&apos; CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.
JUNO,JUNO:UW,BBG007K3F2J4,3 Biotech Stocks That Skyrocketed This Week,2017-09-02 15:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8LVW5NCWp7U/3-biotech-stocks-that-skyrocketed-this-week-cm840596,If you like excitement biotech stocks provided plenty of it over the last several days And most of the buzz stemmed from the 11 9 billion buyout of Kite Pharma NASDAQ KITE announced by Gilead Sciences NASDAQ GILD on Monday But while Kite Pharma stock shot up nearly
JUNO,JUNO:UW,BBG007K3F2J4,3 Biotech Stocks That Skyrocketed This Week,2017-09-02 14:33:00 +0000,http://finance.yahoo.com/r/957941a9-5d2c-3e1f-87f0-3d970214e93d/3-biotech-stocks-that-skyrocketed-this-week.aspx?yptr=yahoo&.tsrc=rss,"Abeona, Sangamo, and Juno ride the huge wave resulting from Gilead Sciences&apos; acquisition of Kite Pharma."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition",2017-09-02 14:20:00 +0000,http://finance.yahoo.com/r/7fcc7744-73dd-3685-998e-bce8e6bc7a72/more-immunotherapy-buyouts-likely-after-kite-sale.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,More Immunotherapy Buyouts Likely After Kite Sale
JUNO,JUNO:UW,BBG007K3F2J4,5 Top Performing Stocks of the Top ETF of August,2017-09-01 15:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xTyVOkvZJZI/5-top-performing-stocks-of-the-top-etf-of-august-cm840241,A turbulent August ended up with positive returns for U S stocks dodging fears over North Korea tension In fact the technology sector continues to be investors hot favorite and was the clear winner last month with ARK Innovation ETF ARKK topping the list of the best performing ETF of
JUNO,JUNO:UW,BBG007K3F2J4,5 Top Performing Stocks of the Top ETF of August,2017-09-01 14:09:02 +0000,https://finance.yahoo.com/news/5-top-performing-stocks-top-140902874.html?.tsrc=rss,Inside the top performing ETF of August and its top stocks.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at September 2017 Investor Conferences,2017-08-31 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-present-september-2017-200500143.html?.tsrc=rss,"Juno Therapeutics, Inc. today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development."
JUNO,JUNO:UW,BBG007K3F2J4,What Analysts Recommend for Vertex Pharmaceuticals after 2Q17,2017-08-31 15:14:33 +0000,http://finance.yahoo.com/r/b4a0ea88-acd7-3ff5-93f7-9d8ca5fcd8e1/what-analysts-recommend-for-vertex-pharmaceuticals-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Around 80% of the analysts tracking Vertex Pharmaceuticals in August 2017 gave the stock some form of a “buy” rating.
JUNO,JUNO:UW,BBG007K3F2J4,"Gilead Sciences: No, the Novartis Approval Wasn't Good News",2017-08-31 14:55:00 +0000,http://finance.yahoo.com/r/d24c8d2f-97e4-3758-ae55-2a6b4afb6803/gilead-sciences-no-the-novartis-approval-wasnt-good-news-1504191311?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The CAR-T party continues today following Gilead Sciences (GILD) acquisition of Kite Pharma (KITE) on Monday, and approval of a CAR-T treatment from Novartis (NVS) yesterday. And Morgan Stanley's Matthew ..."
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-08-31 12:09:44 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120944517.html?.tsrc=rss,Short interest is moderately high for JUNO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold JUNO had net inflows of $713 million over the last one-month.
JUNO,JUNO:UW,BBG007K3F2J4,Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap,2017-08-30 20:49:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pcMabnKGw6w/why-novatis-475k-car-t-cancer-treatment-is-actually-cheap-cm839366,The cancer treatment industry is celebrating a massive victory on Wednesday as Novartis NVS received approval for its innovative new lymphoblastic leukemia treatment making it the first approved CAR T therapy in the world After achieving unprecedented results in patients with this deadly
JUNO,JUNO:UW,BBG007K3F2J4,"Novartis: A New $475,000 Drug",2017-08-30 17:59:00 +0000,http://finance.yahoo.com/r/1aa47894-7cc2-3f90-9f70-36bdfc0cd64c/novartis-a-new-475-000-drug-1504115985?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The FDA issued a landmark decision today when it granted approval for Novartis’s (NVS) new leukemia Kymriah.  As Bernstein’s Tim Anderson notes: Today's approval marks a paradigm shift in how cancer patients are treated as this represents the first CAR-T approval by any company.  It shows how Novartis' R&D efforts are often focused on high science, and the company’s overall ability in R&D is (only) one of the reasons it has been one of our top picks since the start of the year.  As part of the deal, Novartis can only recognize revenue from the drug if the patient demonstrates a clinical response by the end of the first month."
JUNO,JUNO:UW,BBG007K3F2J4,Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost?,2017-08-30 16:38:00 +0000,http://finance.yahoo.com/r/aa6d4dc3-fd9d-3ac1-a8f9-3fac57d0ebfb/novartis-wins-fda-approval-for-car-t-so-why-is-gilead-getting-a-boost-1504111101?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Swiss drug maker Novartis (NVS) won a landmark FDA approval today for the first-ever CAR-T cancer drug.  As MarketWatch reports: CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia.  Novartis said on Wednesday that it will work with the Centers for Medicare and Medicaid Services so medicine prices can be ""based on the clinical outcomes achieved, which would eliminate inefficiencies from the health care system."" For Kymriah, Novartis is also working with CMS ""to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month."" Novartis did not give any specifics as to what the price range might be."
JUNO,JUNO:UW,BBG007K3F2J4,Stock Indexes Up; These Cement Plays Rally,2017-08-30 16:13:26 +0000,http://finance.yahoo.com/r/c5f695d2-c426-32f1-8f48-1abb7cb244c5/stock-indexes-up-these-cement-plays-rally?src=A00220&yptr=yahoo&.tsrc=rss,Playing storm-related stocks can be tricky. Stock action after Hurricane Irene in 2011 shows why.
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Gilead Overpays; Next Takeout Targets,2017-08-30 15:11:00 +0000,http://finance.yahoo.com/r/05625e52-de06-3e4a-b424-374872e2727e/gilead-overpays-next-takeout-targets-1504105883?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Wedbush  We are upgrading Kite Pharma to Neutral from Underperform, as we expect the deal to close.  With little overlap expected in terms of manufacturing or development staff, the deal was sold by Gilead management as centered around their belief in axi-cel [therapy candidate, axicabtagene ciloleucel] and pipeline-expansion opportunity, which we view as limited.  Gilead is buying Kite at $180 a share (about $11.9 billion), and we expect deal to close in the fourth quarter."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Soars: Stock Adds 20.1% in Session,2017-08-30 14:53:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2qCfCL-0FQA/juno-therapeutics-juno-soars-stock-adds-201-in-session-cm839089,Juno Therapeutics Inc JUNO was a big mover last session as the company saw its shares rise over 20 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 54 1
JUNO,JUNO:UW,BBG007K3F2J4,"North Korea, Harvey Can't Keep the Market Down",2017-08-30 13:48:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TmCSd0P3HRk/north-korea-harvey-cant-keep-the-market-down-cm838923,The September episode of the Zacks Ultimate Strategy Session will be available for viewing no later than Thursday September 7th Sheraz Mian David Bartosiak Tracey Ryniec Neena Mishra CFA FRM and Brian Bolan will cover the investment landscape from most every angle in this
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Soars: Stock Adds 20.1% in Session,2017-08-30 12:52:12 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-soars-stock-125212873.html?.tsrc=rss,"Juno Therapeutics (JUNO) saw a big move last session, as its shares jumped over 20% on the day amid huge volumes."
JUNO,JUNO:UW,BBG007K3F2J4,Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal,2017-08-30 12:49:12 +0000,https://finance.yahoo.com/news/juno-bluebird-hot-acquisition-targets-124912268.html?.tsrc=rss,"Gilead&apos;s (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets."
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-08-30 12:04:40 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120440217.html?.tsrc=rss,Short interest is moderately high for JUNO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold JUNO had net inflows of $713 million over the last one-month.
JUNO,JUNO:UW,BBG007K3F2J4,"Indecision Won't Kill You, But It Will Take Your Money",2017-08-30 00:49:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/490sbc5vNyU/indecision-wont-kill-you-but-it-will-take-your-money-cm838900,Welcome back to Mind Over Money I m Kevin Cook your field guide and story teller for the fascinating arena of Behavioral Economics This episode is all about the risk reward 160 mechanics 160 of decision making Sometimes we avoid making decisions and often we never learn from our bad ones
JUNO,JUNO:UW,BBG007K3F2J4,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR",2017-08-29 23:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NveLk96LAXw/achv-focuses-on-achievement-imgn-strikes-chord-with-jazz-fda-snubs-acor-20170829-01275,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition,2017-08-29 21:50:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nk3tL-k5Ur8/juno-therapeutics-juno-continues-gains-after-gilead-kite-acquisition-cm838832,Shares of Juno Therapeutics JUNO continued to soar on Tuesday The stock has now gained nearly 40 since the announcement that fellow CAR T cancer therapy designer Kite Pharma KITE is being acquired by biotech behemoth Gilead Sciences GILD Along with Kite and Bluebird Bio BLUE Juno is
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 08/29/2017: IMGN,JAZZ,JUNO,ACOR",2017-08-29 20:28:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vWVybPkW-xQ/health-care-sector-update-for-08292017-imgnjazzjunoacor-cm838824,Top Health Care StocksTop Health Care Stocks JNJ 0 30 JNJ 0 30 PFE 0 01 PFE 0 01 ABT 0 24 ABT 0 24 MRK 0 33 MRK 0 33 AMGN 0 30 AMGN 0 30 Health care stocks have turned narrowly higher again this afternoon with the NYSE Health Care Index adding slightly more than 0 1 in value
JUNO,JUNO:UW,BBG007K3F2J4,"Analysts Mixed On Gilead-Kite, But One Key Rival Stands To Benefit",2017-08-29 20:12:48 +0000,http://finance.yahoo.com/r/a7fce0af-7831-3ae5-b27b-5ba740285a70/analysts-mixed-on-gilead-kite-but-one-key-rival-stands-to-benefit?src=A00220&yptr=yahoo&.tsrc=rss,"Analysts were mixed Tuesday on Gilead&apos;s takeout of Kite, but rivals Juno and Bluebird stand to benefit from the headlines."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition,2017-08-29 19:52:07 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-continues-gains-195207952.html?.tsrc=rss,Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Stock Is Blasting Off Today,2017-08-29 19:51:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/noIWs005k_s/why-juno-therapeutics-stock-is-blasting-off-today-cm838800,What happened Shares of Juno Therapeutics NASDAQ JUNO 160 are up by double digits for the second day in a row on extremely heavy volume The catalyst behind this continued surge higher is the nearly 12 billion buyout of rival adoptive cell therapy company Kite
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 08/29/2017: CTLT,JUNO,ACOR",2017-08-29 19:08:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/td-966v5-kE/health-care-sector-update-for-08292017-ctltjunoacor-cm838795,Top Health Care StocksTop Health Care Stocks JNJ 0 25 JNJ 0 25 PFE 0 01 PFE 0 01 ABT 0 54 ABT 0 54 MRK 0 29 MRK 0 29 AMGN 0 04 AMGN 0 04 Health care stocks have turned narrowly mixed this afternoon with the NYSE Health Care Index declining nearly 0 1 in value reversing a
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Stock Is Blasting Off Today,2017-08-29 17:50:49 +0000,http://finance.yahoo.com/r/60959532-a62b-3896-9899-4494be661d8c/why-juno-therapeutics-stock-is-blasting-off-today.aspx?yptr=yahoo&.tsrc=rss,Gilead&apos;s buyout of Kite Pharma sparks yet another rally in fellow CAR-T developer Juno Therapeutics.
JUNO,JUNO:UW,BBG007K3F2J4,"Tuesday's ETF Movers: FBT, XOP",2017-08-29 17:49:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o1vPE1KZRKg/tuesdays-etf-movers-fbt-xop-cm838716,In trading on Tuesday the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs up about 1 2 on the day Components of that ETF showing particular strength include shares of Juno Therapeutics up about 19 8 and shares of Incyte Genomics up about 2 9 on the
JUNO,JUNO:UW,BBG007K3F2J4,JUNO Crosses Above Average Analyst Target,2017-08-29 14:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jMLrp62ZAjk/juno-crosses-above-average-analyst-target-cm838487,In recent trading shares of Juno Therapeutics Inc Symbol JUNO have crossed above the average analyst 12 month target price of 30 75 changing hands for 36 48 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal",2017-08-29 13:56:00 +0000,http://finance.yahoo.com/r/08854454-98f0-39e3-a5fa-68ac7c0363a8/juno-therapeutics-stock-climbs-wedbush-sees-advantages-from-gilead-kite-deal.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Juno Therapeutics stock was upgraded at Wedbush as Gilead's proposed deal for Kite Pharma raises awareness of Juno's treatments.
JUNO,JUNO:UW,BBG007K3F2J4,Morning Movers: Finish Line Tumbles on Guidance; Hain Jumps on Earnings,2017-08-29 12:49:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/APYWnlUg4kU/morning-movers-finish-line-tumbles-on-guidance-hain-jumps-on-earnings-cm838333,Stocks are sinking in pre open action after North Korea launched a missile that flew over Japan Stocks are sinking in pre open action afterNorth KoreaNorth Korea launched a missile that flew over JapanJapan Getty Images Getty Images S amp P 500 futures have fallen 0 5
JUNO,JUNO:UW,BBG007K3F2J4,"UQM Technologies, Kite Pharma Jump on Monday",2017-08-29 12:48:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CBe3akDfR-o/uqm-technologies-kite-pharma-jump-on-monday-cm838317,The U S stock market opened mixed with investors looking to the impact of Hurricane Harvey The U S stock market opened mixed with investors looking to the impact of Hurricane Harvey Shares of UQM Technologies Inc UQM jumped about 49 in Monday morning trading after the company announced
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Trending Tickers: bluebird bio Inc. and Juno Therapeutics Inc.,2017-08-29 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-122000766.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 29, 2017 / U.S. markets were dragged down by energy and insurance shares Monday as Hurricane Harvey wreaked Havoc in Texas over the weekend. The Dow Jones Industrial ..."
JUNO,JUNO:UW,BBG007K3F2J4,"So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye",2017-08-28 23:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u-P5ugC_xG0/so-long-to-kite-juno-clls-mbio-blcm-are-sympathy-plays-pgnx-catches-eye-20170828-01048,"So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye"
JUNO,JUNO:UW,BBG007K3F2J4,Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle?,2017-08-28 17:52:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lc0s9bdfbHg/gilead-sciences-to-buy-kite-pharma-for-119-billion-is-it-enough-to-move-the-needle-cm838086,What happened Gilead Sciences NASDAQ GILD prompted by its falling sales of its hepatitis C drugs over the past year has finally pulled the trigger on a much anticipated buyout On Monday it offered to acquire Kite Pharma NASDAQ KITE for 11 9 billion in an all cash
JUNO,JUNO:UW,BBG007K3F2J4,"Monday's ETF Movers: XBI, OIH",2017-08-28 17:49:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nnvYcCHH4is/mondays-etf-movers-xbi-oih-cm838058,In trading on Monday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 3 on the day Components of that ETF showing particular strength include shares of Kite Pharma up about 28 4 and shares of Juno Therapeutics up about 17 5 on the day And underperforming other
JUNO,JUNO:UW,BBG007K3F2J4,Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today,2017-08-28 17:40:00 +0000,http://finance.yahoo.com/r/de897895-c983-3d25-a84a-15080e096c7e/why-bluebird-bio-inc-and-juno-therapeutics-inc-sho.aspx?yptr=yahoo&.tsrc=rss,The biotechs&apos; surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.
JUNO,JUNO:UW,BBG007K3F2J4,Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle?,2017-08-28 16:00:00 +0000,http://finance.yahoo.com/r/50474fa1-d19d-3682-8e63-b6606a37bd9a/gilead-sciences-to-buy-kite-pharma-for-119-billion.aspx?yptr=yahoo&.tsrc=rss,"With the deal, the antiviral drug specialist dives headfirst into CAR-T cancer therapies."
JUNO,JUNO:UW,BBG007K3F2J4,Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug,2017-08-28 15:45:00 +0000,http://finance.yahoo.com/r/7af19119-44a7-3944-b9a3-cb7ef58f4135/gilead-kite-a-breakthrough-a-12-billion-deal-another-expensive-drug?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, is making a gutsy move into the cutting edge of cancer treatment, spending $11.9 billion in cash to buy Kite Pharma, developer of a treatment that attacks tumors by genetically modifying patients’ own white blood cells."
JUNO,JUNO:UW,BBG007K3F2J4,Biotech stocks surge on Gilead's Kite Pharma acquisition,2017-08-28 15:41:09 +0000,http://finance.yahoo.com/r/671493af-ede5-39f3-bda3-8da1f836c478/Story.aspx?guid=46F3FB7F-6A26-4FA2-B28D-4CFAFEA3959C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics: Celgene's Next Target?,2017-08-28 15:09:00 +0000,http://finance.yahoo.com/r/39ba05ae-4932-36e0-b959-172c830ea6b8/juno-therapeutics-celgenes-next-target-1503932949?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"As is typical following announcements of an acquisition, companies conducting research similar to Kite Pharma (KITE) have popped after Gilead Sciences' (GILD) announcement that it had agreed to the CAR-T ..."
JUNO,JUNO:UW,BBG007K3F2J4,Gilead’s Deal to Buy Kite Pharma Is a Game-Changer,2017-08-28 14:41:45 +0000,https://finance.yahoo.com/news/gilead-deal-buy-kite-pharma-144145057.html?.tsrc=rss,Kite Pharma stock rose 29% on the news.
JUNO,JUNO:UW,BBG007K3F2J4,"Pre-Market Most Active for Aug 28, 2017 :  KITE, WFM, GILD, JUNO, TVIX, MYCC, QQQ, FCAU, BHP, Q, DB, BABA",2017-08-28 12:58:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pEcC1kQoL9c/pre-market-most-active-for-aug-28-2017-kite-wfm-gild-juno-tvix-mycc-qqq-fcau-bhp-q-db-baba-cm837729,The NASDAQ 100 Pre Market Indicator is up 8 to 5 830 53 The total Pre Market volume is currently 2 024 812 shares traded The following are the most active stocks for the pre market session Kite Pharma Inc KITE is 40 42 at 179 52 with 973 864 shares traded Over
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Earns Relative Strength Rating Upgrade,2017-08-28 07:00:00 +0000,http://finance.yahoo.com/r/11c2747d-69b0-349f-baf7-76433c2ad483/juno-therapeutics-earns-relative-strength-rating-upgrade?src=A00220&yptr=yahoo&.tsrc=rss,"Juno Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO",2017-08-26 02:50:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-investigation-initiated-former-025000500.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : August 25, 2017",2017-08-25 23:16:01 +0000,http://finance.yahoo.com/r/9221140d-6653-3311-9816-0a00a032952b/juno-therapeutics-inc-value-analysis-nasdaqjuno-august-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Juno Therapeutics, Inc. a score of 50. Our analysis is based on comparing Juno Therapeutics, Inc. with the following peers – ZIOPHARM Oncology, Inc., Incyte Corporation, Repligen Corporation and Mirati Therapeutics Inc. (ZIOP-US, INCY-US, RGEN-US and MRTX-US). Investment Outlook Juno Therapeutics, Inc. has a fundamental score of ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma at New 52-Week High: What's Driving the Stock?,2017-08-24 20:38:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5E3sgvPjfng/kite-pharma-at-new-52-week-high-whats-driving-the-stock-cm836783,Kite Pharma Inc s KITE shares hit a new 52 week high of 143 00 on Thursday before eventually closing at 138 17 Shares of the company have risen sharply so far this year as its CAR T therapy axicabtagene ciloleucel previously KTE C19 is nearing an FDA approval In fact Kite Pharma
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma at New 52-Week High: What&apos;s Driving the Stock?,2017-08-24 18:34:06 +0000,https://finance.yahoo.com/news/kite-pharma-52-week-high-183406866.html?.tsrc=rss,Kite Pharma (KITE) shares hit a new 52-week high as the company&apos;s CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.
JUNO,JUNO:UW,BBG007K3F2J4,3 Biopharma Picks for Big Rewards with Less Risk,2017-08-23 23:38:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mYt6GBw1neM/3-biopharma-picks-for-big-rewards-with-less-risk-cm836271,InvestorPlace Stock Market News Stock Advice amp Trading Tips Investors may initially shy away from biopharma companies given the complexity of the science behind the treatments After all a company s stock will only do as well as their treatments pass FDA hurdles and are
JUNO,JUNO:UW,BBG007K3F2J4,"Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers",2017-08-22 13:46:00 +0000,http://finance.yahoo.com/r/78e38463-9c55-3c0c-8f0e-ecd4de02b635/omeros-shares-lower-after-completing-stock-offering-juno-dips-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.
JUNO,JUNO:UW,BBG007K3F2J4,This Stock Could Be the Tesla of Healthcare,2017-08-20 19:37:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AZ070ir6vHs/this-stock-could-be-the-tesla-of-healthcare-cm834416,Some farsighted or just plain lucky investors bought shares of Tesla Motors NASDAQ TSLA early on They took a huge risk but that risk paid off Tesla stock is up nearly 1 400 since the company went public in 2010 Stocks like Tesla are a pretty rare species And they re
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO",2017-08-19 02:50:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-investigation-initiated-former-025000127.html?.tsrc=rss,"NEW ORLEANS , Aug. 18, 2017 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC (""KSF""), announces that KSF ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Cramer Remix: This sell-off isn’t done, things could get ...",2017-08-17 23:11:00 +0000,https://finance.yahoo.com/video/cramer-remix-sell-off-isn-231100220.html?.tsrc=rss,Jim Cramer made sense of the recent sell-off in the market and warned investors that the worst isn’t over.
JUNO,JUNO:UW,BBG007K3F2J4,Cramer's lightning round: I don't want to recommend any o...,2017-08-17 22:58:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-dont-want-225800133.html?.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name."
JUNO,JUNO:UW,BBG007K3F2J4,Cramer&apos;s lightning round: I don&apos;t want to recommend any oil stocks right now,2017-08-17 22:48:48 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-don-224848422.html?.tsrc=rss,"Jim Cramer shares his take on callers&apos; favorite stocks at lightning speed, including one oil name."
JUNO,JUNO:UW,BBG007K3F2J4,Cramer's lightning round: I don't want to recommend any oil stocks right now,2017-08-17 22:48:48 +0000,http://finance.yahoo.com/r/c7b853b2-cf96-305e-b4d4-ea679963791a/104658803?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104658803&yptr=yahoo&.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : August 17, 2017",2017-08-17 13:05:41 +0000,http://finance.yahoo.com/r/404b9a0a-053b-33c8-8432-3d12c2789be8/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-august-17-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,See what the IHS Markit Score report has to say about Juno Therapeutics Inc.,2017-08-12 12:04:49 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120449515.html?.tsrc=rss,Short interest is moderately high for JUNO with between 10 and 15% of shares outstanding currently on loan.  The net inflows of $221 million over the last one-month into ETFs that hold JUNO are among the lowest of the last year and appear to be slowing.
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO",2017-08-12 02:50:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-investigation-initiated-former-025000303.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP...",2017-08-10 21:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dfs-8IbGlus/gainers--losers-of-aug10-sgmo-vtvt-edit-acrs-cemp-20170810-01601,"Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP..."
JUNO,JUNO:UW,BBG007K3F2J4,Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment,2017-08-09 20:01:00 +0000,https://finance.yahoo.com/news/editas-medicine-achieves-milestone-under-200100438.html?.tsrc=rss,"CAMBRIDGE, Mass., Aug. 09, 2017-- Editas Medicine, Inc., a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc.. The ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up",2017-08-09 16:38:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MS_GGct0iGw/kite-pharma-kite-q2-loss-narrower-than-expected-shares-up-cm829533,Kite Pharma Inc KITE reported narrower than expected loss in the second quarter of 2017 and beat estimates for sales Shares of the biotech company rose 5 8 on Tuesday In fact this year so far Kite Pharma s stock is up 167 9 which compares favorably with a 9 7 increase registered by
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Trending Tickers: Ionis Pharmaceuticals and Juno Therapeutics,2017-08-09 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000450.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 9, 2017 / The market's recent rally stalled Tuesday as early gains were wiped out after President Donald Trump warned North Korea that any threats will be ""met with ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference,2017-08-08 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-present-2017-wedbush-200500933.html?.tsrc=rss,"Juno Therapeutics, Inc. today announced that it will webcast its presentation at the 2017 Wedbush PacGrow Healthcare Conference at 3:40 p.m. ET on Tuesday, August 15, 2017."
JUNO,JUNO:UW,BBG007K3F2J4,​When an ‘investigation’ of a biotech really isn’t,2017-08-08 17:30:13 +0000,http://finance.yahoo.com/r/473190cf-95a0-3b8d-aaf0-9f42590570fb/when-an-investigation-of-a-biotech-really-isn-t.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"On Tuesday morning, a biotech investor with more than 4,500 Twitter followers posted the headline along with a link to the release.  The release had been issued by a San Francisco-based law firm that represents shareholders in fraud suits.  The firm, Schubert Jonckheer & Kolbe LLP, was merely soliciting investors to join a potential case stemming from a sharp decline in Juno’s stock last year following the deaths of two patients in a trial of one of its experimental drugs."
JUNO,JUNO:UW,BBG007K3F2J4,Executives of Juno Therapeutics Under Investigation,2017-08-08 12:00:00 +0000,https://finance.yahoo.com/news/executives-juno-therapeutics-under-investigation-120000260.html?.tsrc=rss,"A motion to dismiss a class action lawsuit against Juno and its CEO, CFO and Chief Medical Officer was recently denied by the U.S. District Court for the Western District of Washington.  The class action alleges that the defendants recklessly failed to tell investors that patients were dying from toxic side effects associated with JCAR015 during the treatment's Phase II trial.  The plaintiffs allege that the defendants falsely represented that the deaths were attributable to the use of fludarabine in combination with JCAR015 when they actually knew that fludarabine had nothing to do with the deaths, and instead were attributable to JCAR015 alone.  Juno is exposed to substantial potential liability through the class action."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass",2017-08-04 22:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vqSM8N6U090/juno-therapeutics-juno-q2-loss-widens-revenues-surpass-cm827597,Juno Therapeutics Inc JUNO reported second quarter 2017 loss of 75 cents per share including stock based compensation expenses wider than both the Zacks Consensus Estimate of a loss of 74 cents and the year ago loss of 65 cents per share Juno s shares have significantly outperformed
JUNO,JUNO:UW,BBG007K3F2J4,"It's been a summer bummer at the box office, however the ...",2017-08-04 21:25:00 +0000,https://finance.yahoo.com/video/summer-bummer-box-office-however-212500288.html?.tsrc=rss,"The “Fast Money” traders discuss their final trades for the day including ICICI Bank, Marriott International, Facebook and Juno Therapeutics."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass",2017-08-04 20:35:08 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-q2-loss-203508633.html?.tsrc=rss,"Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important,2017-08-04 00:00:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l16rarK2VpU/juno-therapeutics-cash-position-and-potential-cash-cow-jcar017-are-still-whats-important-cm826942,It s been a pretty good year for Juno Therapeutics NASDAQ JUNO so far The clinical stage biotech s share price is up more than 50 year to date Its financial position in the first quarter looked great thanks to its collaboration with Celgene NASDAQ CELG And at
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics&apos; Cash Position and Potential Cash Cow JCAR017 Are Still What&apos;s Important,2017-08-03 22:34:00 +0000,http://finance.yahoo.com/r/559936ee-2565-324c-8825-79da8d385cd7/premium-juno-therapeutics-cash-position-and-potent.aspx?yptr=yahoo&.tsrc=rss,The clinical-stage biotech is sitting on a sizeable pile of cash to fund development of its promising cancer treatment.
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics Tops Sales Views, But Losses Widen And Miss",2017-08-03 21:13:50 +0000,http://finance.yahoo.com/r/011f987a-3dd0-3ae1-a4e2-267f1032bef8/juno-therapeutics-tops-sales-views-but-losses-widen?src=A00220&yptr=yahoo&.tsrc=rss,"Juno&apos;s second-quarter sales topped the consensus, but losses increased vs. the year-earlier quarter."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports Second Quarter 2017 Financial Results,2017-08-03 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-reports-second-quarter-200500594.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the second quarter 2017."
JUNO,JUNO:UW,BBG007K3F2J4,"Investor Network: Juno Therapeutics, Inc. to Host Earnings Call",2017-08-03 18:00:00 +0000,https://finance.yahoo.com/news/investor-network-juno-therapeutics-inc-180000359.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Juno Therapeutics, Inc. (NASDAQ: JUNO ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 5:00 PM ..."
JUNO,JUNO:UW,BBG007K3F2J4,3 Reasons the Best Is Yet to Come for Celgene,2017-08-03 02:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T88UgkLb6BU/3-reasons-the-best-is-yet-to-come-for-celgene-cm826180,Celgene Corp s NASDAQ CELG second quarter revenue and sales came in nearly 50 higher than they were two short years ago yet the company doesn t appear to be anywhere near peaking A flurry of R amp D activity should provide it with a steady stream of label expansion and new
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?,2017-07-27 20:58:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lfHC-Er9GKc/juno-therapeutics-juno-q2-earnings-surprise-in-store-cm822837,Juno Therapeutics Inc JUNO is expected to report second quarter 2017 results on Aug 3 Last quarter the company delivered a negative earnings surprise of 9 09 Year to date Juno s shares have soared 58 9 while the industry recorded an increase of 12 The company s poor track
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3",2017-07-27 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-report-second-quarter-200500878.html?.tsrc=rss,"Juno Therapeutics, Inc. will announce financial results for the second quarter 2017 on Thursday, August 3, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?,2017-07-27 18:27:06 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-q2-earnings-182706968.html?.tsrc=rss,"Although Juno Therapeutics&apos; (JUNO) product portfolio shows a dearth of any revenue figures, the company&apos;s most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2."
JUNO,JUNO:UW,BBG007K3F2J4,3 Key Things Every CAR-T Investor Should Watch,2017-07-25 11:58:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6FKYACoJ7Rs/3-key-things-every-car-t-investor-should-watch-cm820638,A long awaited breakthrough in cancer treatment chimeric antigen receptor T cell CAR T therapy could finally hit the market later this year First to market advantage will likely to go Novartis NYSE NVS with its drug named CTL019 Recently a panel of FDA advisors
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Juno's Top Holder Sells $216 Million in Stock,2017-07-25 11:31:00 +0000,http://finance.yahoo.com/r/1671c017-0714-36b6-97fe-521d4a9187da/junos-top-holder-sells-216-million-in-stock-1500637510?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The top holder in Juno Therapeutics just bailed in a big way, chopping his stake nearly in half.  CL Alaska sold eight million shares of Juno (JUNO) on July 13 for $216 million.  CL Alaska is an entity controlled by Douglas K. Bratton through Crestline Management."
JUNO,JUNO:UW,BBG007K3F2J4,3 Key Things Every CAR-T Investor Should Watch,2017-07-25 10:02:00 +0000,http://finance.yahoo.com/r/8b5930bc-aba1-3363-b912-d191104f702f/3-key-things-every-car-t-investor-should-know.aspx?yptr=yahoo&.tsrc=rss,The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn&apos;t mean CAR-T stocks are out of the woods just yet.
JUNO,JUNO:UW,BBG007K3F2J4,"Commit To Purchase Juno Therapeutics At $17.50, Earn 10.6% Using Options",2017-07-21 19:06:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RGpLfFBd-_Q/commit-to-purchase-juno-therapeutics-at-1750-earn-106-using-options-cm819515,Investors eyeing a purchase of Juno Therapeutics Inc Symbol JUNO shares but cautious about paying the going market price of 29 08 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Trending Tickers: Diffusion Pharmaceuticals Inc. and Juno Therapeutics Inc.,2017-07-21 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000799.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 21, 2017 / U.S. markets were mixed Thursday as a sharp drop in Home Depot shares dragged down the Dow Jones and S&P 500 Index, while the Nasdaq continued to climb to new ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics",2017-07-19 12:03:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DAq2yLLqSiI/better-buy-celldex-therapeutics-inc-vs-juno-therapeutics-cm817864,Celldex Therapeutics NASDAQ CLDX and Juno Therapeutics NASDAQ JUNO are both once promising clinical stage biotechs that have fallen on extremely hard times of late Over the past two and half years for example these former stars have each lost a staggering amount of
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics",2017-07-19 10:30:00 +0000,http://finance.yahoo.com/r/d7f548a4-902d-3d0e-8a6e-de56efec5b77/better-buy-celldex-therapeutics-inc-vs-juno-therap.aspx?yptr=yahoo&.tsrc=rss,Which of these two beaten-down cancer stocks is the more compelling comeback story?
JUNO,JUNO:UW,BBG007K3F2J4,InPlay from Briefing.com,2017-07-18 22:51:10 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
JUNO,JUNO:UW,BBG007K3F2J4,5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote,2017-07-18 14:08:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pKNcNeEiq00/5-car-t-stocks-in-focus-as-nvs-drug-wins-fda-advisory-panel-vote-cm817351,The CAR T chimeric antigen receptor T cells space got a significant boost recently with an FDA advisory panel issuing a positive recommendation for an experimental treatment in this corner of the immune oncology market Last week Swiss pharma giant Novartis NVS experimental CAR T
JUNO,JUNO:UW,BBG007K3F2J4,5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote,2017-07-18 12:10:12 +0000,https://finance.yahoo.com/news/5-car-t-stocks-focus-121012021.html?.tsrc=rss,It&apos;s time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis&apos; (NVS) experimental CAR-T treatment.
JUNO,JUNO:UW,BBG007K3F2J4,Never Will I Ever Buy Preclinical Biotech Stocks. No Way!,2017-07-15 21:45:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WWx4dfisbYw/never-will-i-ever-buy-preclinical-biotech-stocks-no-way-cm816555,It s Never Will I Ever week on Industry Focus and we re explaining what we ll never invest in and why It s incredibly difficult to develop new game changing medicine How difficult Over 160 90 of drugs that enter phase 1 human trials end 160 up in the dustbin
JUNO,JUNO:UW,BBG007K3F2J4,Never Will I Ever Buy Preclinical Biotech Stocks. No Way!,2017-07-15 19:40:00 +0000,http://finance.yahoo.com/r/aaf391ab-1375-3c10-9e27-8462c48f2287/never-will-i-ever-buy-preclinical-biotech-stocks-n.aspx?yptr=yahoo&.tsrc=rss,"Only 10% of clinical-stage drugs make it across the FDA finish line, and that makes buying pr-clinical biotech stocks the riskiest game in town."
JUNO,JUNO:UW,BBG007K3F2J4,Can Bellicum Pharmaceuticals Stock Bounce Back?,2017-07-14 19:47:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wTxubSWjWmM/can-bellicum-pharmaceuticals-stock-bounce-back-cm816330,How you view a stock depends heavily on your point of reference Bellicum Pharmaceuticals NASDAQ BLCM for example saw its share price fall nearly 14 in one day in late June That s certainly not great but it s not disastrous either On the other hand if you bought
JUNO,JUNO:UW,BBG007K3F2J4,Can Bellicum Pharmaceuticals Stock Bounce Back?,2017-07-14 18:41:00 +0000,http://finance.yahoo.com/r/3d3e0750-a36a-39b7-8ac7-a49b906210f4/can-bellicum-pharmaceuticals-stock-bounce-back.aspx?yptr=yahoo&.tsrc=rss,Good results from phase 2 studies of its lead candidate could be just the spark that this beaten-down biotech stock needs.
JUNO,JUNO:UW,BBG007K3F2J4,A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared,2017-07-14 00:46:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Kn63CJBHf4/a-new-cancer-treatment-is-on-the-way-and-cancer-better-be-scared-cm815937,A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis NYSE NVS ground breaking drug for pediatric and young adult B cell acute lymphoblastic leukemia or ALL The recommendation clears the way for a formal FDA green light and it begins a
JUNO,JUNO:UW,BBG007K3F2J4,[$$] 3 Drug Stocks That Can Ride Novartis' Coattails,2017-07-13 20:49:00 +0000,http://finance.yahoo.com/r/fe861c52-51bc-30d3-874d-e8f465d76261/3-drug-stocks-that-can-ride-novartis-coattails-1499978962?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,A first-of-its kind cancer therapy by the Swiss drugmaker Novartis is one step closer to hitting the market after a panel of Food and Drug Administration experts unanimously voted Wednesday to recommend regulatory approval.  The drug from Novartis (NVS) could drastically advance the treatment of children with an aggressive form of leukemia.  It could also provide the Swiss drugmaker with a new revenue stream.
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Stock Still a Strong Buy?,2017-07-13 15:51:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8TTYLEIinc/is-juno-therapeutics-stock-still-a-strong-buy-cm815608,What happened Shares of the clinical stage biotech Juno Therapeutics NASDAQ JUNO rose by a healthy 22 last month according to S amp P Global Market Intelligence The drugmaker s shares seemed to get a lift from two different catalysts during the month First off the
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Stock Still a Strong Buy?,2017-07-13 14:30:00 +0000,http://finance.yahoo.com/r/93549107-b17b-3826-9285-d0957740d649/is-juno-therapeutics-stock-still-a-strong-buy.aspx?yptr=yahoo&.tsrc=rss,Investors are piling into this speculative biotech stock -- but is it a buy after rallying 22% in June?
JUNO,JUNO:UW,BBG007K3F2J4,Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug,2017-07-12 21:08:24 +0000,http://finance.yahoo.com/r/8f5f1893-2747-3ba9-8de9-374ebf7633bc/novartis-grabs-key-fda-panel-approval-of-experimental-cancer-drug?src=A00220&yptr=yahoo&.tsrc=rss,An FDA panel voted to recommended an experimental immuno-oncology treatment from Novartis Wednesday.
JUNO,JUNO:UW,BBG007K3F2J4,Billions of Dollars on the Line for Celgene With These 3 Small Biotechs,2017-07-09 12:45:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wE-hC8DNMsQ/billions-of-dollars-on-the-line-for-celgene-with-these-3-small-biotechs-cm813518,Few big drugmakers have forged as many strategic partnerships as Celgene NASDAQ CELG At last count the biotech had 47 partners and collaborators including its most recent collaboration deal with BeiGene Many investors might not realize just how much money Celgene
JUNO,JUNO:UW,BBG007K3F2J4,Billions of Dollars on the Line for Celgene With These 3 Small Biotechs,2017-07-09 11:28:00 +0000,http://finance.yahoo.com/r/d5b4c444-20a8-3696-9d0c-60e4f32908e3/billions-of-dollars-on-the-line-for-celgene-with-t.aspx?yptr=yahoo&.tsrc=rss,"Celgene&apos;s future fortunes depend heavily on Acceleron Pharma, bluebird bio, and Juno Therapeutics."
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Ionis Pharmaceuticals,2017-07-07 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000412.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 7, 2017 / Juno Therapeutics spiked Wednesday trading despite any substantial news to explain the breakout. Shares closed up nearly 7%. Shares of Ionis Pharmaceuticals also ..."
JUNO,JUNO:UW,BBG007K3F2J4,Novartis Faces Key FDA Panel On Cancer Drug; Why Kite Could Be The Winner,2017-07-06 20:25:11 +0000,http://finance.yahoo.com/r/bc36bec3-54b4-3ec4-a4c2-2b80e748c861/novartis-is-going-before-the-fda-but-kite-could-benefit-more?src=A00220&yptr=yahoo&.tsrc=rss,"Kite should benefit from an FDA hearing on an experimental cancer treatment from rival Novartis later this month, an analyst said Thursday."
JUNO,JUNO:UW,BBG007K3F2J4,The Cure For Cancer? Look At Your Blood,2017-06-30 17:10:32 +0000,http://finance.yahoo.com/r/dc2e0f7e-738c-30ab-bf2a-12edd93714f9/drugmakers-make-science-fiction-reality-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,What once seemed sci-fi is becoming real in treating blood cancers: doctoring patients&apos; blood to kill tumors. The FDA is about to consider the first such drug.
JUNO,JUNO:UW,BBG007K3F2J4,Bluebird Bio: Too Much Good News?,2017-06-30 14:40:00 +0000,http://finance.yahoo.com/r/4f7a2953-e80e-3444-b70e-61b5c6bdcb41/bluebird-bio-too-much-good-news-1498833622?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bluebird Bio (BLUE) has had a great run this year, soaring more than 73% since the start of 2017.  The drug maker emerged as a big winner from the American College of Clinical Oncology’s (ASCO) annual confab, which is part of the reasons why the stock has spiked 40% in the past month, and peaked above $120 a share along the way.  High hopes for bb2121, the experimental cancer drug Bluebird Bio is developing with Celgene (CELG), are a big ingredient in the stock’s performance."
JUNO,JUNO:UW,BBG007K3F2J4,"Pricing, Competition Remain Headwinds for Pharma in 2017",2017-06-29 23:03:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2bAOJobSSZc/pricing-competition-remain-headwinds-for-pharma-in-2017-cm810281,Although fears regarding the drug pricing issue have waned it will nevertheless remain a headwind until the Trump administration comes out with a policy for controlling drug prices Drug pricing is an issue that weighed on pharma and biotech stocks for more than a year The sector
JUNO,JUNO:UW,BBG007K3F2J4,"Celgene, Gilead and Other Red-Hot Biotech Stocks Just Got Run Over",2017-06-29 18:25:00 +0000,http://finance.yahoo.com/r/e8b5cc68-dc71-3c45-972f-d36f5cfc8919/celgene-gilead-stocks-lower-as-selloff-hits-biotech.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Ouch.
JUNO,JUNO:UW,BBG007K3F2J4,This ETF Holds Stocks Insiders Want to Own,2017-06-29 15:05:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/twg9rEbCp00/this-etf-holds-stocks-insiders-want-to-own-cm809829,A look at the weighted underlying holdings of the First Trust NYSE Arca Biotechnology Index Fund Symbol FBT shows an impressive 13 0 of holdings on a weighted basis have experienced insider buying within the past six months Juno Therapeutics Inc Symbol JUNO which makes up 3 61
JUNO,JUNO:UW,BBG007K3F2J4,Biotech Stocks Showing Signs of Resurgence,2017-06-26 12:30:00 +0000,https://finance.yahoo.com/news/biotech-stocks-showing-signs-resurgence-123000078.html?.tsrc=rss,The Nasdaq Biotechnology Index (NBI) surged last week as Research and Development for the advancement of rare cancer therapies and anti-cancer drug candidates heat up with new partnerships with Mayo Clinic as part of a process for creating and delivering treatments to reach the patients who need them the most.  The Oncology segment is one of the largest markets in medicine that's expected to grow to $165 billion by 2021.
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Antares Pharma,2017-06-26 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000276.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Both Juno Therapeutics and Antares Pharma saw some nice gains on Friday, with Juno closing over 7%. Despite any big news on that particular day, traders are ..."
JUNO,JUNO:UW,BBG007K3F2J4,2 Top Biotech Stocks to Buy on Sale,2017-06-24 13:50:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aB6MXa_ld6g/2-top-biotech-stocks-to-buy-on-sale-cm807744,Biotech stocks have been soaring over the last few years due to an uptick in innovation and a growing demand for healthcare services across the board As a result valuations across this high flying space have ballooned making it increasingly difficult to suss out attractive
JUNO,JUNO:UW,BBG007K3F2J4,"Thursday 6/22 Insider Buying Report: ATNX, JUNO",2017-06-22 16:23:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b_D4bAGqgo8/thursday-622-insider-buying-report-atnx-juno-cm806939,Bargain hunters are wise to pay careful attention to insider buying because although there are many various reasons for an insider to sell a stock presumably the only reason they would use their hard earned dollars to make a purchase is that they expect to make money Today we look at
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : June 20, 2017",2017-06-20 12:25:53 +0000,http://finance.yahoo.com/r/1761f1a2-8c57-340b-98a8-dc819cc8e83f/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-june-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Featured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland,2017-06-20 12:15:00 +0000,https://finance.yahoo.com/news/featured-company-news-juno-therapeutics-121500721.html?.tsrc=rss,"Research Desk Line-up: Axovant Sciences Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biopharma ..."
JUNO,JUNO:UW,BBG007K3F2J4,Bullish Two Hundred Day Moving Average Cross - JUNO,2017-06-19 17:21:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ogmMXFQXUc/bullish-two-hundred-day-moving-average-cross-juno-cm805186,In trading on Monday shares of Juno Therapeutics Inc Symbol JUNO crossed above their 200 day moving average of 23 99 changing hands as high as 24 06 per share Juno Therapeutics Inc shares are currently trading up about 2 4 on the day The chart below shows the one year performance of
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma,2017-06-17 13:00:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-presents-transcend-nhl-130000065.html?.tsrc=rss,"Juno Therapeutics, Inc.  , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland."
JUNO,JUNO:UW,BBG007K3F2J4,2 Incredibly Cheap Biotech Stocks,2017-06-16 17:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DCnN66hYRnY/2-incredibly-cheap-biotech-stocks-cm804492,Biotech stocks sport some of the richest valuations in the market today making it hard to suss out any attractive bargains within this high flying group The average forward price to earnings ratio among large cap biotechs after all presently stands at a stately 45 2 Having
JUNO,JUNO:UW,BBG007K3F2J4,Court Decides It Lacks Jurisdiction Before FDA Approval Occurs,2017-06-14 13:00:00 +0000,https://finance.yahoo.com/news/court-decides-lacks-jurisdiction-fda-130000577.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.S. Distri"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Cancer treatment: scaling up a vein-to-vein solution,2017-06-12 17:16:35 +0000,"http://finance.yahoo.com/r/dfa5d5dd-2b45-3f71-b77a-5b723986374b/e2c8eaa2-415b-11e7-9d56-25f963e998b2,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The huge tumour protruding from Jami Cameron's pelvis was shrinking before her eyes. Having battled lymphoma since 1994, she thought she had run out of options. The 53-year-old had tried numerous rounds ..."
JUNO,JUNO:UW,BBG007K3F2J4,3 Beaten-Up Biotech Stocks: Are They Bargains?,2017-06-12 14:30:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yZbbBUYCDPU/3-beaten-up-biotech-stocks-are-they-bargains-cm801991,Beaten up biotech stocks can sometimes represent fantastic bargains In the same breath biotech companies that have fallen on hard times often do so for a very good reason and are therefore best avoided by investors With this theme in mind let s consider if the downtrodden trio
JUNO,JUNO:UW,BBG007K3F2J4,3 Beaten-Up Biotech Stocks: Are They Bargains?,2017-06-12 12:42:00 +0000,http://finance.yahoo.com/r/f6a009d5-5c31-3ace-8c38-0df9aee7e182/3-beaten-up-biotech-stocks-are-they-bargains.aspx?yptr=yahoo&.tsrc=rss,"Celldex Therapeutics, Gilead Sciences, and Juno Therapeutics are all trading near their 52-week lows, but are they bargains?"
JUNO,JUNO:UW,BBG007K3F2J4,Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?,2017-06-09 16:30:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bXO_lV_7Wx8/why-is-kite-pharma-kite-stock-up-close-to-100-this-year-cm801256,Shares of Kite Pharma Inc KITE were up around 5 6 on Thursday In fact shares of this small biotech are up a massive 93 3 this year so far outperforming the 1 8 increase registered by the Zacks classified Biomed Genetics industry during this period Here we analyze the factors that led
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Down 4.5% Since Earnings Report: Can It Rebound?,2017-06-09 12:29:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x2fM2j5OAss/juno-therapeutics-juno-down-45-since-earnings-report-can-it-rebound-cm801018,It has been about a month since the last earnings report for Juno Therapeutics Inc JUNO Shares have lost about 4 5 in the past month underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Down 4.5% Since Earnings Report: Can It Rebound?,2017-06-09 10:09:10 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-down-4-100910371.html?.tsrc=rss,Juno Therapeutics (JUNO) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
JUNO,JUNO:UW,BBG007K3F2J4,"Gainers & Losers Of June 8: ANAB, INO, SCLN, NLNK, JUNO...",2017-06-09 01:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_trYWFIyrIA/gainers--losers-of-june-8-anab-ino-scln-nlnk-juno-20170609-00035,"Gainers & Losers Of June 8: ANAB, INO, SCLN, NLNK, JUNO..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics: To Sell, Or Not To Sell…Good Question",2017-06-08 14:13:00 +0000,http://finance.yahoo.com/r/7e2b76a1-5269-37d2-be3a-a3263c8586b9/juno-therapeutics-to-sell-or-not-to-sellgood-question-1496931199?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Is it time to shed shares of Juno Therapeutics (JUNO)?  BTIG analyst Dane Leone thinks so.  The drug maker’s stock price is down 4% today to $22.75 a share after Leone cut his rating from a Neutral to a Sell with a $12 price target.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics stock drops 5% after BTIG downgrades to sell,2017-06-08 13:00:02 +0000,http://finance.yahoo.com/r/b9773515-f921-3ef9-ad15-0ceefcdbc144/Story.aspx?guid=3B618EC1-008B-4903-9763-2F29FC6BD4CB&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Juno Therapeutics Inc. shares dropped 5.2% in premarket trade Thursday after BTIG downgraded it to sell from neutral, with a $12 price target. Juno shares closed at $23.73 on Wednesday. The company is ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : June 8, 2017",2017-06-08 12:23:46 +0000,http://finance.yahoo.com/r/6c171af3-fd5c-3921-8884-1d4c7405b015/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-june-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Novartis touts new T-cell therapy data in race for FDA approval,2017-06-07 15:36:42 +0000,https://finance.yahoo.com/news/novartis-touts-t-cell-therapy-153642283.html?.tsrc=rss,"Novartis on Wednesday  touted new data from its T-cell therapy CTL019, saying it is on  a par with results of experimental molecules from Kite Pharma  and Juno Therapeutics that also target  aggressive blood cancers.  Three months after infusion, the overall response rate  (ORR)among 51 adult patients with relapsed or refractory diffuse  large B-cell lymphoma (DLBCL) was 45 percent, Novartis said,  with 37 percent complete responses (CR), or no sign of disease.  Novartis aims for $1 billion in annual sales for CTL019, a  drug made by taking T cells from a patient, reprogramming them  in the lab to fight cancer, and re-infusing them."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference,2017-06-06 20:05:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-present-goldman-sachs-200500117.html?.tsrc=rss,"Juno Therapeutics, Inc. today announced that it will webcast its presentation at the Goldman Sachs 38th Annual Global Healthcare Conference at 10:00 a.m. PT on Tuesday, June 13, 2017."
JUNO,JUNO:UW,BBG007K3F2J4,"Your first trade for Tuesday, June 6",2017-06-06 13:28:42 +0000,http://finance.yahoo.com/r/1d6a2341-3c6e-3cdb-8c50-8a06debbcc99/104512864?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104512864&yptr=yahoo&.tsrc=rss,"The ""Fast Money"" traders share their first moves for early trading."
JUNO,JUNO:UW,BBG007K3F2J4,"Your first trade for Tuesday, June 6",2017-06-06 13:28:42 +0000,https://finance.yahoo.com/news/first-trade-tuesday-june-6-132842822.html?.tsrc=rss,The &quot;Fast Money&quot; traders share their first moves for early trading.
JUNO,JUNO:UW,BBG007K3F2J4,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Incyte Corporation,2017-06-06 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000353.html?.tsrc=rss,"NEW YORK NY / ACCESSWIRE / June 6, 2017 / Both Juno Therapeutics and Incyte Corporation saw their shares drop on Monday after the companies released disappointing study and trial results over the weekend. ..."
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics Inc. Is Getting Beaten Up Today,2017-06-05 23:00:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v5CKZHZ7aoM/heres-why-juno-therapeutics-inc-is-getting-beaten-up-today-cm799035,What happened Shares of 160 Juno Therapeutics Inc NASDAQ JUNO a clinical stage biotech developing new cancer therapies are losing ground after the company presented data from a study with its lead candidate Although JCAR017 s efficacy data was impressive toxicity
JUNO,JUNO:UW,BBG007K3F2J4,"Gainers & Losers Of June 5: LOXO, CLSN, RDUS, GLYC, JUNO...",2017-06-05 22:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nkjIXwy7ShE/gainers--losers-of-june-5-loxo-clsn-rdus-glyc-juno-20170605-01326,"Gainers & Losers Of June 5: LOXO, CLSN, RDUS, GLYC, JUNO..."
JUNO,JUNO:UW,BBG007K3F2J4,"&quot;Fast Money&quot; final trades: JUNO, PCLN, and more",2017-06-05 21:59:00 +0000,https://finance.yahoo.com/video/fast-money-final-trades-juno-215900720.html?.tsrc=rss,"The “Fast Money” traders discuss their final trades for the day including Square, Juno Therapeutics, Priceline, and iShares MSCI."
JUNO,JUNO:UW,BBG007K3F2J4,Kite to launch mid-stage leukemia trial in fourth quarter 2017,2017-06-05 21:40:45 +0000,https://finance.yahoo.com/news/kite-launch-mid-stage-leukemia-214045670.html?.tsrc=rss,"Kite Pharma Inc and  Juno Therapeutics Inc on Monday presented new data for  their experimental T-cell therapies, but investors were not  overly impressed and shares of Juno fell nearly 11 percent.  Both companies are developing drugs in a new class called  chimeric antigen receptor T-cells (CAR-T) using a complicated  process of extracting immune system T-cells from an individual  patient, altering their DNA to sharpen their ability to spot and  kill cancer cells, and infusing them back into the patient.  Both Juno and Kite are developing CAR-Ts that target a  protein called CD19 found on cancerous blood cells."
JUNO,JUNO:UW,BBG007K3F2J4,Here&apos;s Why Juno Therapeutics Inc. Is Getting Beaten Up Today,2017-06-05 20:53:00 +0000,http://finance.yahoo.com/r/3856805d-eaa5-3c70-8ee4-e40193b1957c/heres-why-juno-therapeutics-inc-is-getting-beaten.aspx?yptr=yahoo&.tsrc=rss,Safety data from a clinical trial with its new lead candidate overshadowed impressive responses to the therapy.
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : June 5, 2017",2017-06-05 18:26:39 +0000,http://finance.yahoo.com/r/e68b42a4-1d62-3110-9bcf-fab6c622e120/etfs-with-exposure-to-juno-therapeutics-inc-june-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Major Averages Finish Lackluster Session Modestly Lower - U.S. Commentary,2017-06-05 16:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fE3mkS7Y0Xo/major-averages-finish-lackluster-session-modestly-lower--us-commentary-20170605-01122,Major Averages Finish Lackluster Session Modestly Lower - U.S. Commentary
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics CEO: We're 'encouraged' by recent cance...,2017-06-05 13:57:00 +0000,https://finance.yahoo.com/video/juno-therapeutics-ceo-were-encouraged-135700580.html?.tsrc=rss,Juno Therapeutics President & CEO Hans Bishop speaks with CNBC's Meg Tirrell from the ASCO conference on Monday.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma,2017-06-05 13:00:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-presents-updated-transcend-130000682.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma in a presentation at the 2017 Annual Meeting of the American Society for Clinical Oncology ."
JUNO,JUNO:UW,BBG007K3F2J4,Stocks to watch during ASCO,2017-06-02 16:49:00 +0000,https://finance.yahoo.com/video/stocks-watch-during-asco-164900354.html?.tsrc=rss,"CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017",2017-06-02 14:19:08 +0000,http://finance.yahoo.com/r/88614954-2767-39a8-9ff4-24579265968b/juno-therapeutics-inc-juno-us-earnings-analysis-q1-2017-by-the-numbers-june-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Juno Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Juno Therapeutics, Inc. – ZIOPHARM Oncology, Inc., Incyte Corporation, Repligen Corporation and Mirati Therapeutics Inc. (ZIOP-US, INCY-US, RGEN-US and MRTX-US) that have also reported for this period. Highlights ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,A New Era of Cancer Research as ASCO Kicks Off,2017-06-01 11:20:14 +0000,https://finance.yahoo.com/news/era-cancer-research-asco-kicks-112014857.html?.tsrc=rss,"Just ahead of the 2017 annual meeting of the American Society of Clinical Oncology, a new report shows that more than 240 immuno-oncology medicines and vaccines are currently in development."
JUNO,JUNO:UW,BBG007K3F2J4,"Insiders Love Bioverativ, Juno Therapeutics and More",2017-05-31 17:11:00 +0000,http://finance.yahoo.com/r/3b51e4b2-2108-350a-8905-3addc36d8ebf/insiders-love-bioverativ-juno-therapeutics-and-more.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Insiders at Bioverativ, Juno Therapeutics and three other companies have been buying up shares of their own stock recently."
JUNO,JUNO:UW,BBG007K3F2J4,Celgene&apos;s Stock May Be Incredibly Overvalued Right Now -- Here&apos;s Why,2017-05-31 12:06:00 +0000,http://finance.yahoo.com/r/bf6c9f14-c440-3467-851e-c72094a53932/celgenes-stock-may-be-incredibly-overvalued-right.aspx?yptr=yahoo&.tsrc=rss,Celgene&apos;s long thesis might be unraveling.
JUNO,JUNO:UW,BBG007K3F2J4,"Tuesday 5/30 Insider Buying Report: JUNO, SITE",2017-05-30 16:35:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GR7qu9sxGWc/tuesday-530-insider-buying-report-juno-site-cm796248,As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys On Friday Juno Therapeutics JUNO s Director Jay T Flatley made a 495 217 buy of
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Cancer Drug BLA Gets Priority Review Status,2017-05-29 14:31:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Iu6G3rbQTUw/kite-pharma-cancer-drug-bla-gets-priority-review-status-cm795855,Kite Pharma Inc KITE announced that its biologics license application BLA for its experimental CAR T therapy axicabtagene ciloleucel has been accepted for priority review by the FDA The biotech companyis looking to get axicabtagene ciloleucel approved for the treatment of
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : May 29, 2017",2017-05-29 12:22:33 +0000,http://finance.yahoo.com/r/99149be9-5519-3b1c-84bb-e03c334e3f20/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-may-29-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 4-May-17 9:00pm GMT,2017-05-27 12:50:37 +0000,https://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-212328961.html?.tsrc=rss,Q1 2017 Juno Therapeutics Inc Earnings Call
JUNO,JUNO:UW,BBG007K3F2J4,I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug,2017-05-25 21:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xeXBdnKpBpU/i-still-cant-believe-juno-therapeutics-spent-464-million-on-this-failed-drug-cm794838,In March Juno Therapeutics NASDAQ JUNO announced that it was ending development of JCAR015 after five patients with acute lymphoblastic leukemia ALL died from cerebral edema brain swelling in its phase 2 clinical trial The lethal side effect made it unlikely
JUNO,JUNO:UW,BBG007K3F2J4,I Still Can&apos;t Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug,2017-05-25 20:21:00 +0000,http://finance.yahoo.com/r/a4927e0c-f92e-376f-9cef-7c104e9e2418/i-still-cant-believe-juno-therapeutics-spent-464-m.aspx?yptr=yahoo&.tsrc=rss,A costly learning exercise.
JUNO,JUNO:UW,BBG007K3F2J4,New Strong Sell Stocks for May 24th,2017-05-24 16:35:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_iItlmBboS0/new-strong-sell-stocks-for-may-24th-cm793985,Here are 5 stocks added to the Zacks Rank 5 Strong Sell List today 1st Constitution Bancorp 160 FCCY is a bank holding company The Zacks Consensus Estimate for its current year earnings has been revised 4 4 downward over the last 30 days Atlas Air Worldwide Holdings Inc AAWW
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Appoints Jay Flatley to Board of Directors,2017-05-23 13:00:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-appoints-jay-flatley-130000694.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors."
JUNO,JUNO:UW,BBG007K3F2J4,Vetr Upgrades Juno To Buy Amid Volatile May,2017-05-22 20:48:22 +0000,https://finance.yahoo.com/news/vetr-upgrades-juno-buy-amid-204822573.html?.tsrc=rss,"The Vetr crowd on Monday upgraded its rating for Juno Therapeutics Inc (NASDAQ: JUNO ) from 4 stars, issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was mostly positive, with ..."
JUNO,JUNO:UW,BBG007K3F2J4,JUNO Makes Notable Cross Below Critical Moving Average,2017-05-17 22:11:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AfbVbJOh0V0/juno-makes-notable-cross-below-critical-moving-average-cm790883,In trading on Wednesday shares of Juno Therapeutics Inc Symbol JUNO crossed below their 200 day moving average of 24 93 changing hands as low as 24 51 per share Juno Therapeutics Inc shares are currently trading off about 7 on the day The chart below shows the one year performance of
JUNO,JUNO:UW,BBG007K3F2J4,"Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting",2017-05-17 21:10:00 +0000,http://finance.yahoo.com/r/5de8fd0e-5a6d-3c8b-8476-507373b08b4a/bluebird-kite-and-juno-delivering-car-t-cancer-study-updates-to-asco-17-meeting.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting,2017-05-17 21:00:00 +0000,https://finance.yahoo.com/news/juno-therapeutics-present-key-clinical-210000669.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with its collaborators on its investigational products JCAR017 and JCAR014 at the upcoming American Society of Clinical Oncology Annual Meeting 2017 in Chicago, Illinois, June 2-6."
JUNO,JUNO:UW,BBG007K3F2J4,3 Growth Stocks You Haven&apos;t Thought Of,2017-05-17 20:23:00 +0000,http://finance.yahoo.com/r/ec1b3bb7-c6c8-3c11-a527-b208b3803752/3-growth-stocks-you-havent-thought-of.aspx?yptr=yahoo&.tsrc=rss,These under-the-radar growth stocks are worth checking out.
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 4-May-17 9:00pm GMT,2017-05-12 09:21:17 +0000,http://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-212328961.html?.tsrc=rss,Q1 2017 Juno Therapeutics Inc Earnings Call
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : May 11, 2017",2017-05-11 23:01:41 +0000,http://finance.yahoo.com/r/2747a54b-d6af-336b-9f97-e3a00e0fe6ed/juno-therapeutics-inc-value-analysis-nasdaqjuno-may-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Juno Therapeutics, Inc. a score of 50. Our analysis is based on comparing Juno Therapeutics, Inc. with the following peers – ZIOPHARM Oncology, Inc., Incyte Corporation, Repligen Corporation and Mirati Therapeutics Inc. (ZIOP-US, INCY-US, RGEN-US and MRTX-US). Investment Outlook Juno Therapeutics, Inc. has a fundamental score of ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Blog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results,2017-05-11 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-aevi-genomics-announces-121500519.html?.tsrc=rss,"Upcoming AWS Coverage on Juno Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / May 11, 2017 / Active Wall St. blog coverage looks at the headline from Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference,2017-05-09 20:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-present-bank-america-200500681.html?.tsrc=rss,"Juno Therapeutics, Inc. today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.m. PT on Tuesday, May 16, 2017."
JUNO,JUNO:UW,BBG007K3F2J4,IYH's Underlying Holdings Could Mean 10% Gain Potential,2017-05-09 15:03:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1dsf7ebdaZY/iyhs-underlying-holdings-could-mean-10-gain-potential-cm786393,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
JUNO,JUNO:UW,BBG007K3F2J4,"Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death",2017-05-09 14:06:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y87Fepbfmhc/kite-pharma-kite-posts-q1-loss-reveals-car-t-patient-death-cm786363,Kite Pharma Inc KITE reported wider than expected loss in the first quarter of 2017 Shares of the biotech company declined more than 13 on Monday after it announced the death of a cancer patient enrolled in a study evaluating axicabtagene ciloleucel Kite Pharma s experimental CAR T
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : May 9, 2017",2017-05-09 12:58:01 +0000,http://finance.yahoo.com/r/6706718d-c8c8-3188-9410-bdc551ee6ada/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-may-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Vetr Urges Buy On Juno After Earnings,2017-05-08 21:09:13 +0000,http://finance.yahoo.com/news/vetr-urges-buy-juno-earnings-210913877.html?.tsrc=rss,"The Vetr crowd upgraded its rating for Juno Therapeutics Inc (NASDAQ: JUNO ) on Monday from 4 stars (Buy), issued five days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was ..."
JUNO,JUNO:UW,BBG007K3F2J4,Here's What's Dragging Kite Pharma Inc. Down Today,2017-05-08 19:03:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FWPlSzsGdk8/heres-whats-dragging-kite-pharma-inc-down-today-cm786051,What happened Shares of Kite Pharma Inc NASDAQ KITE 160 a biotech developing cell therapies for the treatment of cancer are getting beaten up after the company revealed a patient death associated with its lead candidate 160 As of 10 50 a m EDT on Monday the stock
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Kite Pharma (KITE) Stock Is Plummeting Today,2017-05-08 18:01:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FxTWdiXaLyY/heres-why-kite-pharma-kite-stock-is-plummeting-today-cm786037,Shares of Kite Pharma KITE slipped more than 13 in morning trading Monday after it was revealed that a cancer patient died from brain swelling following treatment with the company s CAR T therapy KTE C19 The patient s death which occurred in April was announced on a company conference
JUNO,JUNO:UW,BBG007K3F2J4,"KITE Plunges, Take Sector With It",2017-05-08 17:29:00 +0000,http://finance.yahoo.com/r/d954ed25-a03a-3ab2-b79c-70f7d0e1c69f/kite-plunges-take-sector-it-kite-ibb?partner=YahooSA&yptr=yahoo&.tsrc=rss,Kite stock plunged after it reported a clinical study death and worse-than-expected Q1 losses.
JUNO,JUNO:UW,BBG007K3F2J4,Here&apos;s What&apos;s Dragging Kite Pharma Inc. Down Today,2017-05-08 16:57:00 +0000,http://finance.yahoo.com/r/85220adf-8ac1-36da-a503-079699f018de/heres-whats-dragging-kite-pharma-inc-down-today.aspx?yptr=yahoo&.tsrc=rss,Kite Pharma&apos;s progress in the race to develop the first CAR-T therapy just took a turn for the worse.
JUNO,JUNO:UW,BBG007K3F2J4,Here&apos;s Why Kite Pharma (KITE) Stock Is Plummeting Today,2017-05-08 15:46:03 +0000,http://finance.yahoo.com/news/apos-why-kite-pharma-kite-154603964.html?.tsrc=rss,Shares of Kite Pharma (KITE) slipped more than 13% in morning trading Monday after it was revealed that a cancer patient died from brain swelling following treatment with the company&apos;s CAR-T therapy KTE-C19.
JUNO,JUNO:UW,BBG007K3F2J4,"Kite Pharma Discloses CAR-T Patient Death, Rattling Investors",2017-05-08 14:06:00 +0000,http://finance.yahoo.com/r/abf38671-070c-313f-982b-7392465f2a2e/kite-pharma-discloses-car-t-patient-death-rattling-investors.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss,2017-05-05 15:27:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bghWc58upA/juno-therapeutics-juno-posts-wider-than-expected-q1-loss-cm785029,Juno Therapeutics Inc JUNO reported first quarter 2017 loss of 71 cents per share including stock based compensation expenses wider than the Zacks Consensus Estimate of a loss of 66 cents The quarterly loss however narrowed from the year ago loss of 79 cents per share Shares of
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration,2017-05-05 15:24:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9HA4OUAbqh4/juno-therapeutics-q1-revenue-improves-thanks-to-celgene-collaboration-cm784984,When Juno Therapeutics NASDAQ JUNO announced its fourth quarter and full year 2016 results in March investors were most focused on the company s discontinuation of development of a once promising lead cancer drug Juno chose to refocus on its other pipeline candidates
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration,2017-05-05 15:02:00 +0000,http://finance.yahoo.com/r/3f253fe6-de2f-3b4e-a0cb-ad5fee1f7cfd/premium-juno-therapeutics-q1-results.aspx?yptr=yahoo&.tsrc=rss,"The clinical-stage biotech posts much higher top-line results in Q1 with an influx in cash from its big partner, Celgene."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss,2017-05-05 14:06:02 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-posts-wider-140602334.html?.tsrc=rss,"Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports First Quarter 2017 Financial Results,2017-05-04 20:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-reports-first-quarter-200500912.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the first quarter 2017."
JUNO,JUNO:UW,BBG007K3F2J4,"Investor Network: Juno Therapeutics, Inc. to Host Earnings Call",2017-05-04 17:10:00 +0000,http://finance.yahoo.com/news/investor-network-juno-therapeutics-inc-171000556.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Juno Therapeutics, Inc. (NASDAQ: JUNO ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 5:00 PM Eastern Time. To ..."
JUNO,JUNO:UW,BBG007K3F2J4,The Probable Reason Why Juno Therapeutics Rose 12.1% In April,2017-05-03 14:42:00 +0000,http://finance.yahoo.com/r/10754eff-3dee-3c3b-97f8-f93723e79553/the-probable-reason-why-juno-therapeutics-rose-121.aspx?yptr=yahoo&.tsrc=rss,Juno&apos;s shares rose by double digits last month on little news. That hints that its shares were simply bouncing back from the drubbing that they took in March.
JUNO,JUNO:UW,BBG007K3F2J4,3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash,2017-05-03 12:27:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-z1pkrH_AtU/3-debt-free-clinical-stage-biotech-stocks-that-are-swimming-in-cash-cm783215,Investing in biotech stocks is like playing roulette in a casino The odds are clearly against you with most discovery stage preclinical and clinical stage experimental drugs failing to meet their trial goals However if a drug or multiple drugs within a pipeline do succeed
JUNO,JUNO:UW,BBG007K3F2J4,3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash,2017-05-03 11:18:00 +0000,http://finance.yahoo.com/r/645b830f-6896-30c5-9b65-222e83280d7e/3-debt-free-clinical-stage-biotech-stocks-that-are.aspx?yptr=yahoo&.tsrc=rss,Funding isn&apos;t a big concern for these three drug developers.
JUNO,JUNO:UW,BBG007K3F2J4,Celgene Corporation: The Bear Case From a Bull,2017-05-02 13:28:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Vyb2BWDCDI/celgene-corporation-the-bear-case-from-a-bull-cm782466,I haven t been bashful in explaining how I feel about Celgene Corporation NASDAQ CELG stock Earlier this year I wrote an article asking if Celgene was simply the best biotech stock on the planet The answer was yes More recently I wrote about the one stock I d buy right
JUNO,JUNO:UW,BBG007K3F2J4,Celgene Corporation: The Bear Case From a Bull,2017-05-02 12:04:00 +0000,http://finance.yahoo.com/r/21657037-62b8-3fbf-be30-c2c3372a93b4/celgene-corporation-the-bear-case-from-a-bull.aspx?yptr=yahoo&.tsrc=rss,A pessimistic look at the potential for Celgene stock from someone who has been very optimistic about the biotech.
JUNO,JUNO:UW,BBG007K3F2J4,What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?,2017-05-01 21:28:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fBfWs8aY9o4/whats-in-store-for-juno-therapeutics-juno-in-q1-earnings-cm782309,Juno Therapeutics Inc JUNO is scheduled to report first quarter 2017 results on May 4 after the market closes Last quarter the company posted a negative earnings surprise of 4 76 Year to date Juno s shares gained 32 3 while the Zacks classified Medical Biomed Genetics
JUNO,JUNO:UW,BBG007K3F2J4,What&apos;s in Store for Juno Therapeutics (JUNO) in Q1 Earnings?,2017-05-01 18:52:06 +0000,http://finance.yahoo.com/news/apos-store-juno-therapeutics-juno-185206635.html?.tsrc=rss,"Juno Therapeutics Inc. (JUNO) is scheduled to report first-quarter 2017 results on May 4, after the market closes."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4",2017-04-27 20:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-report-first-quarter-200500424.html?.tsrc=rss,"Juno Therapeutics, Inc. will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m."
JUNO,JUNO:UW,BBG007K3F2J4,"Final Trade: SQ, JUNO & more",2017-04-25 21:58:00 +0000,http://finance.yahoo.com/video/final-trade-sq-juno-more-215800106.html?.tsrc=rss,"The &quot;Fast Money&quot; traders share their final trades of the day including Square, Juno Therapeutics and more."
JUNO,JUNO:UW,BBG007K3F2J4,Celgene research leader Dr. Rupert Vessey joins Juno board,2017-04-24 21:00:13 +0000,http://finance.yahoo.com/r/891cd1c6-e6cd-31f9-96dd-006459f539ac/juno-therapeutics-board-celgene-rupert-vessey.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Juno Therapeutics Inc. has added Celgene Corp. President of Research and Early Development Dr. Rupert Vessey to the Seattle-based biotech's board.  Vessey will serve as as Celgene's designated appointee to Juno's board, replacing Dr. Tom Daniel, who retired last summer but will remain on the board as an independent director.  Juno (JUNO) inked a $1 billion collaboration with Celegene in 2015."
JUNO,JUNO:UW,BBG007K3F2J4,Will Juno Therapeutics (JUNO) Continue to Surge Higher?,2017-04-21 12:05:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8OtAc6I5M5g/will-juno-therapeutics-juno-continue-to-surge-higher-cm776853,As of late it has definitely been a great time to be an investor in Juno Therapeutics Inc JUNO The stock has moved higher by 18 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the stock
JUNO,JUNO:UW,BBG007K3F2J4,Will Juno Therapeutics (JUNO) Continue to Surge Higher?,2017-04-21 09:26:09 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-continue-surge-092609651.html?.tsrc=rss,"As of late, it has definitely been a great time to be an investor in Juno Therapeutics Inc (JUNO)."
JUNO,JUNO:UW,BBG007K3F2J4,"Commit To Purchase Juno Therapeutics At $20, Earn 15.7% Annualized Using Options",2017-04-20 17:05:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zivxjoPysP0/commit-to-purchase-juno-therapeutics-at-20-earn-157-annualized-using-options-cm776526,Investors eyeing a purchase of Juno Therapeutics Inc Symbol JUNO stock but cautious about paying the going market price of 24 80 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status,2017-04-19 16:06:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B9xUSgLjRB8/novartis-nvs-ctl109-bla-gets-breakthrough-therapy-status-cm775840,Novartis NVS announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate CTL019 The company is evaluating CTL01 an experimental chimeric antigen receptor T cell CAR T therapy for the treatment of adult patients with relapsed and refractory r r
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Appoints Rupert Vessey to Board of Directors,2017-04-19 13:00:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-appoints-rupert-vessey-130000142.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr."
JUNO,JUNO:UW,BBG007K3F2J4,"Cancer drug company snags Genenexer as R&D chief, plans Bay Area office",2017-04-17 21:10:46 +0000,http://finance.yahoo.com/r/3ab48a03-32a5-3575-af00-aa2253b2526d/juno-cancer-immunotherapy-genentech-sunil-agarwal.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Juno Therapeutics Inc. has appointed Dr. Sunil Agarwal as president of research and development, and the Seattle biotech plans to open an office in the Bay Area.  The newly created position brings Juno's R&D operation under one executive.  In this role, Agarwal will be responsible for building out Juno’s drug development pipeline, integrating translational research into ongoing programs and prioritizing new research and development initiatives."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno names new head of research and development, plans Bay Area office",2017-04-17 20:15:10 +0000,http://finance.yahoo.com/r/23525710-5ec8-32af-907b-febb4f5ccf8b/juno-names-new-head-of-research-and-development.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Seattle biotech company Juno Therapeutics Inc. has appointed Dr. Sunil Agarwal as president of research and development.  The newly created position brings Juno's research and development operation under one executive.  In this role, Agarwal will be responsible for building out Juno’s drug development pipeline, integrating translational research into ongoing programs and prioritizing new research and development initiatives."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development,2017-04-17 13:00:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-appoints-sunil-agarwal-130000780.html?.tsrc=rss,"Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.D., as President of Research and Development."
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics' Stock Tumbled in the Past One Year,2017-04-13 16:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_WhBQ-gDtV0/why-juno-therapeutics-stock-tumbled-in-the-past-one-year-cm773876,Seattle WA based Juno Therapeutics Inc JUNO remains focused on the development of immuno oncology treatments The company is looking to revolutionize cancer treatments by engaging the body s immune system to treat the disease Juno is developing cell based cancer immunotherapies using CAR
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics&apos; Stock Tumbled in the Past One Year,2017-04-13 14:39:02 +0000,http://finance.yahoo.com/news/why-juno-therapeutics-apos-stock-143902747.html?.tsrc=rss,"Juno Therapeutics, Inc.&apos;s (JUNO) stock has significantly underperformed Zacks classified Medical-Biomed/Genetics industry in the past one year."
JUNO,JUNO:UW,BBG007K3F2J4,"If You Love Exelixis, You Should Check Out Juno Therapeutics",2017-04-09 16:54:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_rlIYt_IsKc/if-you-love-exelixis-you-should-check-out-juno-therapeutics-cm771849,Don t you wish you d bought Exelixis NASDAQ EXEL stock three years ago The biotech s share price is up more than 460 since then including more than 350 in just the past 12 months Exelixis 160 is without question one of the hottest biotech stocks around Juno
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Stock Slumped in March,2017-04-08 14:54:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SGMEt93sGxU/why-juno-therapeutics-stock-slumped-in-march-cm771746,What happened Juno Therapeutics NASDAQ JUNO a clinical stage biotech shed 12 3 of its value in March according to data from S amp P Global Market Intelligence This double digit move lower was sparked by the company s decision to mothball its lead chimeric
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Stock Slumped in March,2017-04-08 13:43:00 +0000,http://finance.yahoo.com/r/d210a12c-5976-3ef0-866e-8fa6e2c518de/why-juno-therapeutics-stock-slumped-in-march.aspx?yptr=yahoo&.tsrc=rss,Juno&apos;s stock slumped last month after its lead product candidate was mothballed.
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : April 7, 2017",2017-04-07 20:58:47 +0000,http://finance.yahoo.com/r/025060da-502d-32ed-bff6-06b9afb17095/etfs-with-exposure-to-juno-therapeutics-inc-april-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,The First CAR-T Drugs Have Left the Gate,2017-04-06 20:20:00 +0000,http://finance.yahoo.com/r/6a24f973-2854-321a-9bc9-e0b20cb6eb2a/the-first-car-t-drugs-have-left-the-gate.aspx?yptr=yahoo&.tsrc=rss,Investors should keep an eye on this promising way to treat cancer.
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Completes Filing for CAR-T Therapy with FDA,2017-04-03 13:39:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KXhoAsy1l2c/kite-pharma-completes-filing-for-car-t-therapy-with-fda-cm768897,Kite Pharma Inc KITE announced that it has completed the filing of a rolling submission of the Biologics License Application BLA for its lead pipeline candidate axicabtagene ciloleucel to the FDA We note that axicabtagene ciloleucel is Kite Pharma s anti CD19 chimeric antigen
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Completes Filing for CAR-T Therapy with FDA,2017-04-03 11:06:11 +0000,http://finance.yahoo.com/news/kite-pharma-completes-filing-car-110611306.html,Kite Pharma Completes Filing for CAR-T Therapy with FDA
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : March 31, 2017",2017-03-31 12:20:18 +0000,http://finance.yahoo.com/r/f75db685-15ca-3a7e-9c1d-908384445109/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-march-31-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : March 31, 2017",2017-03-31 12:20:18 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-march-31-2017/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : March 31, 2017"
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' CTL109 BLA Gets Priority Review Status from FDA,2017-03-30 17:01:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fMy07Nqlb14/novartis-ctl109-bla-gets-priority-review-status-from-fda-cm767846,Novartis A G NVS announced that the FDA has accepted and granted priority review designation to its biologics license application BLA for pipeline candidate CTL019 tisagenlecleucel T The company plans to apply for market authorization with European Medicines Agency later this
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' CTL109 BLA Gets Priority Review Status from FDA,2017-03-30 14:50:00 +0000,http://finance.yahoo.com/r/642777ff-2256-3f67-aa79-76de10c9f0e8/novartis-ctl109-bla-gets-priority-review-status-fda?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Novartis A.G. NVS announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T). The company ..."
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' CTL109 BLA Gets Priority Review Status from FDA,2017-03-30 14:50:00 +0000,http://www.investopedia.com/partner/zacks/novartis-ctl109-bla-gets-priority-review-status-fda/?partner=YahooSA,Novartis' CTL109 BLA Gets Priority Review Status from FDA
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' Leukemia Drug Secures Priority Review,2017-03-30 13:08:00 +0000,http://finance.yahoo.com/r/adb6fa04-13a4-3691-899a-abafc658bbde/novartis-leukemia-drug-secures-priority-review-nvs-kite?partner=YahooSA&yptr=yahoo&.tsrc=rss,CTL019 marks Novartis’ first regulatory submission for a CAR-T therapy.
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' Leukemia Drug Secures Priority Review,2017-03-30 13:08:00 +0000,http://www.investopedia.com/news/novartis-leukemia-drug-secures-priority-review-nvs-kite/?partner=YahooSA,Novartis' Leukemia Drug Secures Priority Review
JUNO,JUNO:UW,BBG007K3F2J4,Analysts Anticipate FBT Will Reach $122,2017-03-23 13:59:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIdDWnxk6RM/analysts-anticipate-fbt-will-reach-122-cm764591,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics",2017-03-21 15:08:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sr01qK_diXo/better-buy-ionis-pharmaceuticals-inc-vs-juno-therapeutics-cm763404,If you enjoy cutting edge medicine Ionis Pharmaceuticals Inc NASDAQ IONS and Juno Therapeutics Inc NASDAQ JUNO are two biotech stocks that belong on your radar Both develop groundbreaking therapies for serious diseases albeit with very different approaches They ve
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics",2017-03-21 13:07:00 +0000,http://finance.yahoo.com/r/0d162596-ca7f-3e38-95f3-8eacc3b08537/better-buy-ionis-pharmaceuticals-inc-vs-juno-thera.aspx?yptr=yahoo&.tsrc=rss,"Both Juno Therapeutics and Ionis Pharmaceuticals are pushing the envelope, but which biotech stock is the better pick right now?"
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics",2017-03-21 13:07:00 +0000,https://www.fool.com/investing/2017/03/21/better-buy-ionis-pharmaceuticals-inc-vs-juno-thera.aspx,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics"
JUNO,JUNO:UW,BBG007K3F2J4,The ​ABCs of Juno's failed flagship drug trial,2017-03-11 00:00:09 +0000,http://finance.yahoo.com/r/0d388b6d-d373-3ae6-89e3-b97e4b710258/the-abcs-of-junos-failed-flagship-drug-trial.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"This week the Business Journal ran a cover story on the collapse of Juno Therapeutics' flagship cancer drug trial .  The story looks at the murky causes behind five patient deaths, which spurred the Food and Drug Administration to suspend the trial twice , and ultimately led Juno to shut it down.  The report also estimates the impacts on Juno (JUNO), which has been the darling of Seattle's biotechnology industry since bursting on the scene only four years ago."
JUNO,JUNO:UW,BBG007K3F2J4,The ​ABCs of Juno's failed flagship drug trial,2017-03-11 00:00:09 +0000,http://www.bizjournals.com/seattle/news/2017/03/10/the-abcs-of-junos-failed-flagship-drug-trial.html?ana=yahoo,The ​ABCs of Juno's failed flagship drug trial
JUNO,JUNO:UW,BBG007K3F2J4,"Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?",2017-03-09 21:03:42 +0000,http://finance.yahoo.com/r/3dd76827-ea37-3286-9b04-fd937f914e76/could-this-drugmaker-take-on-celgene-juno-kite-with-leukemia-drug?src=A00220A&yptr=yahoo&.tsrc=rss,"Pfizer is angling to take on Celgene, Juno and Kite with a treatment for acute lymphoblastic leukemia."
JUNO,JUNO:UW,BBG007K3F2J4,"Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?",2017-03-09 21:03:42 +0000,http://www.investors.com/news/technology/could-this-drugmaker-take-on-celgene-juno-kite-with-leukemia-drug/?src=A00220A,"Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : March 9, 2017",2017-03-09 12:36:50 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-march-9-2017/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : March 9, 2017"
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Stock Now a Bargain Buy?,2017-03-08 19:14:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B6O5ehgG11M/is-juno-therapeutics-stock-now-a-bargain-buy-cm758058,What happened According to data from S amp P Global Market Intelligence shares of the clinical stage biotech Juno Therapeutics NASDAQ JUNO gained nearly 12 over the month of February without a discernible catalyst However these double digit gains have since
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Stock Now a Bargain Buy?,2017-03-08 17:28:00 +0000,http://finance.yahoo.com/r/8120646f-8b93-36e2-a3f7-3643b1ad30a1/is-juno-therapeutics-stock-now-a-bargain-buy.aspx?yptr=yahoo&.tsrc=rss,Juno's short-lived rally in February was undercut by a major misstep for its lead product candidate.
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Stock Now a Bargain Buy?,2017-03-08 17:28:00 +0000,http://www.fool.com/investing/2017/03/08/is-juno-therapeutics-stock-now-a-bargain-buy.aspx,Is Juno Therapeutics Stock Now a Bargain Buy?
JUNO,JUNO:UW,BBG007K3F2J4,"Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal",2017-03-08 15:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XBWuHu8s6qM/biotech-stock-roundup-trump-tweet-hits-biotech-stocks-concert-gains-on-vertex-deal-cm757792,Once again a tweet kept the biotech industry on edge with President Donald Trump declaring that he is working on a new system where there will be competition in the Drug Industry and pricing for the American people will come way down The tweet triggered a 1 6 decline in the
JUNO,JUNO:UW,BBG007K3F2J4,"Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal",2017-03-08 13:18:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-trump-tweet-131801487.html,"Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal"
JUNO,JUNO:UW,BBG007K3F2J4,"Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal",2017-03-08 13:18:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-trump-tweet-131801487.html?.tsrc=rss,Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Financials",2017-03-07 18:04:15 +0000,http://finance.yahoo.com/q/is?s=juno,"JUNO THERAPEUTICS, INC. Financials"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 16:41:58 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-juno-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017/,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 16:41:58 +0000,http://finance.yahoo.com/r/c639d20d-1cf0-3aac-9a24-0f9ee0cfa9c4/juno-therapeutics-inc-juno-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Juno Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Juno Therapeutics, Inc. – ZIOPHARM Oncology, Inc., Incyte Corporation and Repligen Corporation (ZIOP-US, INCY-US and RGEN-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more    
<b>(Read more...)</b>"
JUNO,JUNO:UW,BBG007K3F2J4,Bad News Biotechs: What's Next for Juno and PTC Therapeutics?,2017-03-04 13:13:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A-y6j-V9_h4/bad-news-biotechs-whats-next-for-juno-and-ptc-therapeutics-cm756266,March has been a month associated with bad news Remember Julius Caesar and the ides of March At least Julius had the opportunity to enjoy a couple of good weeks before disaster struck Bad news came early in the month for Juno Therapeutics NASDAQ JUNO and PTC
JUNO,JUNO:UW,BBG007K3F2J4,Bad News Biotechs: What's Next for Juno and PTC Therapeutics?,2017-03-04 11:42:00 +0000,http://www.fool.com/investing/2017/03/04/bad-news-biotechs-whats-next-for-juno-and-ptc-ther.aspx,Bad News Biotechs: What's Next for Juno and PTC Therapeutics?
JUNO,JUNO:UW,BBG007K3F2J4,Bad News Biotechs: What's Next for Juno and PTC Therapeutics?,2017-03-04 11:42:00 +0000,http://finance.yahoo.com/r/9c533c4d-01de-31f1-add8-a0fa2cf78d88/bad-news-biotechs-whats-next-for-juno-and-ptc-ther.aspx?yptr=yahoo&.tsrc=rss,Can Juno and PTC Therapeutics pick up the pieces after major pipeline setbacks?
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc. Tanked on Thursday,2017-03-03 02:12:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fqq2hgeGEhM/why-juno-therapeutics-inc-tanked-on-thursday-cm755763,What happened Juno Therapeutics NASDAQ JUNO ended down 10 6 on Thursday after announcing Wednesday after the bell that the biotech was discontinuing development of its lead treatment JCAR015 So what This shouldn t have come as much of a shock to investors JCAR015 has
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc. Tanked on Thursday,2017-03-03 00:37:00 +0000,http://www.fool.com/investing/2017/03/02/why-juno-therapeutics-inc-tanked-on-thursday.aspx,Why Juno Therapeutics Inc. Tanked on Thursday
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc. Tanked on Thursday,2017-03-03 00:37:00 +0000,http://finance.yahoo.com/r/d57906ee-ebc7-39d4-a75c-af183d683606/why-juno-therapeutics-inc-tanked-on-thursday.aspx?yptr=yahoo&.tsrc=rss,The biotech ditches its lead therapeutic candidate.
JUNO,JUNO:UW,BBG007K3F2J4,Vetr Crowd In Lockstep With Market In Opting To Sell Juno,2017-03-02 22:08:47 +0000,http://finance.yahoo.com/news/vetr-crowd-lockstep-market-opting-220847302.html?.tsrc=rss,"The Vetr crowd downgraded their rating for Juno Therapeutics Inc (NASDAQ: JUNO ) on Thursday, from 4.5 stars (Strong Buy), issued 30 days go, to 1.5 stars (Strong Sell). At the time of the downgrade, crowd ..."
JUNO,JUNO:UW,BBG007K3F2J4,Vetr Crowd In Lockstep With Market In Opting To Sell Juno,2017-03-02 22:08:47 +0000,http://finance.yahoo.com/news/vetr-crowd-lockstep-market-opting-220847302.html,Vetr Crowd In Lockstep With Market In Opting To Sell Juno
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics halts development of high-profile cancer drug; shares drop,2017-03-02 21:20:38 +0000,http://finance.yahoo.com/news/juno-therapeutics-halts-development-high-145254866.html?.tsrc=rss,"The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Tanks on Closing Leukemia Drug Program,2017-03-02 16:30:00 +0000,http://finance.yahoo.com/r/f7de714b-7140-3079-9092-8e085a8ade06/juno-tanks-closing-leukemia-drug-program-juno?partner=YahooSA&yptr=yahoo&.tsrc=rss,Juno and its partner Celgene are halting their leukemia drug JCAR015 program after patient deaths.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Tanks on Closing Leukemia Drug Program,2017-03-02 16:30:00 +0000,http://www.investopedia.com/news/juno-tanks-closing-leukemia-drug-program-juno/?partner=YahooSA,Juno Tanks on Closing Leukemia Drug Program
JUNO,JUNO:UW,BBG007K3F2J4,Juno (JUNO) Loss Wider; End of Cancer Drug Study Hits Stock,2017-03-02 16:15:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JKmjtOczYhc/juno-juno-loss-wider-end-of-cancer-drug-study-hits-stock-cm755325,Juno Therapeutics Inc JUNO reported wider than expected loss in the fourth quarter of 2016 Shares of the company declined in after hours trading as it announced that it has decided not to move forward with the ROCKET trial or cancer candidate JCAR015 In fact in the past one year
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics halts development of high-profile cancer drug; shares drop 8%,2017-03-02 14:52:54 +0000,http://www.cnbc.com/id/104315753?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104315753,Juno Therapeutics halts development of high-profile cancer drug; shares drop 8%
JUNO,JUNO:UW,BBG007K3F2J4,Juno (JUNO) Loss Wider; End of Cancer Drug Study Hits Stock,2017-03-02 14:38:02 +0000,http://finance.yahoo.com/news/juno-juno-loss-wider-end-143802507.html,Juno (JUNO) Loss Wider; End of Cancer Drug Study Hits Stock
JUNO,JUNO:UW,BBG007K3F2J4,Juno (JUNO) Loss Wider; End of Cancer Drug Study Hits Stock,2017-03-02 14:38:02 +0000,http://finance.yahoo.com/news/juno-juno-loss-wider-end-143802507.html?.tsrc=rss,Juno Therapeutics Inc. (JUNO) reported wider-than-expected loss in the fourth quarter of 2016. Shares of the company declined as it announced that it has decided not to move forward with the ROCKET trial or cancer candidate JCAR015.
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Climbs Well Of Lows But Remains Firmly Negative,2017-03-02 13:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xRzS23ldkXk/juno-therapeutics-climbs-well-of-lows-but-remains-firmly-negative-20170302-01262,Juno Therapeutics Climbs Well Of Lows But Remains Firmly Negative
JUNO,JUNO:UW,BBG007K3F2J4,"Early movers: JOY, SNAP, SHAK, BOX, AVGO, JUNO & more",2017-03-02 12:38:58 +0000,http://www.cnbc.com/id/104315469?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104315469,"Early movers: JOY, SNAP, SHAK, BOX, AVGO, JUNO & more"
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 1-Mar-17 10:00pm GMT,2017-03-02 07:59:06 +0000,http://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-075906975.html,Edited Transcript of JUNO earnings conference call or presentation 1-Mar-17 10:00pm GMT
JUNO,JUNO:UW,BBG007K3F2J4,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM",2017-03-02 05:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AeyT2lhQlYg/fda-approves-odactra-juno-abandons-rocket-vrml-abuzz-no-tremors-for-ndrm-20170302-00244,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM"
JUNO,JUNO:UW,BBG007K3F2J4,Juno ends flagship drug trial after deaths and FDA suspensions,2017-03-02 03:30:12 +0000,http://www.bizjournals.com/seattle/news/2017/03/01/juno-flagship-drug-rocket-trial-deaths-jcar015.html?ana=yahoo,Juno ends flagship drug trial after deaths and FDA suspensions
JUNO,JUNO:UW,BBG007K3F2J4,Yahoo says about 32 million accounts accessed using 'forged cookies',2017-03-02 01:01:04 +0000,http://sg.finance.yahoo.com/news/yahoo-says-32-million-accounts-010104222.html,"[Reuters] - ""Based on the investigation, we believe an unauthorised third party accessed the company's proprietary code to learn how to forge certain cookies,"" Yahoo said in its latest annual filing. Yahoo also said in December that data from more than 1 billion user accounts was compromised in August 2013, making it the largest breach in history. Mayer has also offered to forgo any 2017 annual equity award as the breaches occurred during her tenure, Yahoo said."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback,2017-03-02 00:12:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vW_MBUCtfis/juno-therapeutics-q4-financial-results-overshadowed-by-pipeline-setback-cm755118,The last time Juno Therapeutics NASDAQ JUNO reported quarterly results it received a big boost from its partner Celgene NASDAQ CELG However Juno s stock hasn t performed so well since then The clinical stage biotech announced its fourth quarter and full
JUNO,JUNO:UW,BBG007K3F2J4,Yahoo says about 32 million accounts accessed using 'forged cookies',2017-03-01 23:33:22 +0000,http://sg.finance.yahoo.com/news/yahoo-says-32-million-accounts-232743997.html,"[Reuters] - ""Based on the investigation, we believe an unauthorized third party accessed the company's proprietary code to learn how to forge certain cookies,"" Yahoo said in its latest annual filing. Yahoo also said in December that data from more than 1 billion user accounts was compromised in August 2013, making it the largest breach in history. Mayer has also offered to forgo any 2017 annual equity award as the breaches occurred during her tenure, Yahoo said."
JUNO,JUNO:UW,BBG007K3F2J4,"Yahoo says about 32 mln accounts accessed using ""forged cookies""",2017-03-01 23:25:02 +0000,http://finance.yahoo.com/news/yahoo-says-32-mln-accounts-232502204.html,"Yahoo says about 32 mln accounts accessed using ""forged cookies"""
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback,2017-03-01 23:03:00 +0000,http://www.fool.com/investing/2017/03/01/juno-therapeutics-q4-financial-results-overshadowe.aspx,Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback
JUNO,JUNO:UW,BBG007K3F2J4,Juno ends development of high-profile leukemia drug after deaths,2017-03-01 22:09:02 +0000,http://finance.yahoo.com/news/juno-ends-development-high-profile-220902189.html,Juno ends development of high-profile leukemia drug after deaths
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today,2017-03-01 22:00:00 +0000,http://biz.yahoo.com/cc/6/155866.html,Juno Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics stock declines 4% after decision to not move forward with cancer drug,2017-03-01 21:46:09 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=668465AD-89DB-4A81-860B-5ABB6717877C&siteid=yhoof2,Juno Therapeutics stock declines 4% after decision to not move forward with cancer drug
JUNO,JUNO:UW,BBG007K3F2J4,Juno ends cancer drug trial after patient deaths,2017-03-01 21:26:00 +0000,http://finance.yahoo.com/video/juno-ends-cancer-drug-trial-212600601.html,Juno ends cancer drug trial after patient deaths
JUNO,JUNO:UW,BBG007K3F2J4,"4:13 pm Juno Therapeutics beats by $0.01, beats on revs",2017-03-01 21:13:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#juno,"4:13 pm Juno Therapeutics beats by $0.01, beats on revs"
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2017-03-01 21:10:09 +0000,http://biz.yahoo.com/e/170301/juno8-k.html,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results,2017-03-01 21:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-reports-fourth-quarter-210500393.html,"[Business Wire] - Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2016."
JUNO,JUNO:UW,BBG007K3F2J4,"After-Hours Earnings Report for March 1, 2017 :  AVGO, MNST, OPK, VGR, XON, FSIC, JUNO, ICUI, NKTR, SQM, FGEN, GKOS",2017-03-01 20:11:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICffZYcD1Ho/after-hours-earnings-report-for-march-1-2017-avgo-mnst-opk-vgr-xon-fsic-juno-icui-nktr-sqm-fgen-gkos-cm754988,The following companies are expected to report earnings after hours on 03 01 2017 Visit our Earnings Calendar for a full list of expected earnings releases Broadcom Limited AVGO is reporting for the quarter ending January 31 2017 The electric
JUNO,JUNO:UW,BBG007K3F2J4,Q4 2016 Juno Therapeutics Inc Earnings Release - After Market Close,2017-03-01 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170301.html?t=juno,Q4 2016 Juno Therapeutics Inc Earnings Release - After Market Close
JUNO,JUNO:UW,BBG007K3F2J4,"Final Trade: TGT, MON & more",2017-02-28 22:59:00 +0000,http://finance.yahoo.com/video/final-trade-tgt-mon-more-225900058.html,"Final Trade: TGT, MON & more"
JUNO,JUNO:UW,BBG007K3F2J4,The Duo of Reasons Behind Kite Pharma Inc.'s 26% Move Higher,2017-02-28 21:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u7kc87itgOo/the-duo-of-reasons-behind-kite-pharma-incs-26-move-higher-cm754465,What happened Shares of Kite Pharma NASDAQ KITE a clinical stage biotechnology company focused on developing therapies based on chimeric antigen receptors CARs for the treatment of solid and blood cancers surged as much as 26 during Tuesday s trading session after the
JUNO,JUNO:UW,BBG007K3F2J4,"Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive",2017-02-28 21:13:34 +0000,http://www.investors.com/news/technology/kite-ionis-outplay-med-sector-as-perrigo-tenet-valeant-dive/,"Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at March 2017 Investor Conferences,2017-02-28 21:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-present-march-2017-210500293.html,"[Business Wire] - Juno Therapeutics, Inc. today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update."
JUNO,JUNO:UW,BBG007K3F2J4,The Duo of Reasons Behind Kite Pharma Inc.'s 26% Move Higher,2017-02-28 20:14:00 +0000,http://www.fool.com/investing/2017/02/28/the-duo-of-reasons-behind-kite-pharma-incs-26-move.aspx,The Duo of Reasons Behind Kite Pharma Inc.'s 26% Move Higher
JUNO,JUNO:UW,BBG007K3F2J4,5 Earnings Short-Squeeze Trade Ideas,2017-02-28 18:26:00 +0000,https://www.thestreet.com/story/14019385/1/5-earnings-short-squeeze-trade-ideas.html?puc=yahoo&cm_ven=YAHOO,5 Earnings Short-Squeeze Trade Ideas
JUNO,JUNO:UW,BBG007K3F2J4,"Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More",2017-02-28 13:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G_ZaqJbYxoY/drug-stocks-q4-earnings-lineup-for-mar-1-myl-kerx-more-cm754034,With the curtains almost down on the Q4 earnings season we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years As of Feb 17 2017 411 S amp P 500 members accounting for 88 4 of the index s total market capitalization have
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Inc",2017-02-28 13:51:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rYyidhmFWkw/better-buy-celldex-therapeutics-inc-vs-juno-therapeutics-inc-cm753985,Celldex Therapeutics Inc NASDAQ CLDX and Juno Therapeutics Inc NASDAQ JUNO are two of last year s worst performing biotech stocks Both companies suffered upsetting failures with their leading new drug candidates that pushed the possibility of future product sales
JUNO,JUNO:UW,BBG007K3F2J4,"Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More",2017-02-28 12:17:12 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-lineup-121712792.html,"Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More"
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Incyte,2017-02-24 17:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EW9J4rjmgwU/better-buy-juno-therapeutics-vs-incyte-cm752887,A major fiasco made 2016 a tough year to be a Juno Therapeutics NASDAQ JUNO shareholder Shares of the clinical stage biotech have fallen about 32 over the past 12 months In contrast its well established industry peer Incyte NASDAQ INCY can boast a string of
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Incyte,2017-02-24 15:46:20 +0000,http://www.fool.com/investing/2017/02/24/better-buy-juno-therapeutics-vs-incyte.aspx,Better Buy: Juno Therapeutics vs. Incyte
JUNO,JUNO:UW,BBG007K3F2J4,Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years,2017-02-24 00:44:30 +0000,http://www.fool.com/investing/2017/02/22/looking-back-at-david-gardners-worst-stock-picks-o.aspx,Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?,2017-02-23 14:50:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75Y4PGTBy-M/juno-therapeutics-juno-q4-earnings-whats-in-the-cards-cm751912,Juno Therapeutics Inc JUNO is set to report fourth quarter 2016 results on Mar 1 after the market closes Juno s shares have outperformed the Zacks classified Medical Biomedical and Genetics industry year to date Shares of the company gained 22 3 so far this year while the
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?,2017-02-23 14:00:02 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-q4-earnings-140002276.html,Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?
JUNO,JUNO:UW,BBG007K3F2J4,Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years,2017-02-23 01:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pXXwBpUuml8/looking-back-at-david-gardners-worst-stock-picks-of-the-past-3-years-cm751709,It s not easy putting together a stock portfolio that will beat the broad market but David Gardner has established an impressive track record 160 However not every single one of his picks has been a winner In this episode of Rule Breaker Investing David goes over
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1",2017-02-22 21:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-report-full-fourth-210500523.html,"[Business Wire] - Juno Therapeutics, Inc. will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.-based financial markets."
JUNO,JUNO:UW,BBG007K3F2J4,Coverage initiated on Juno Therapeutics by Wells Fargo,2017-02-22 11:53:54 +0000,http://finance.yahoo.com/q/ud?s=JUNO,Coverage initiated on Juno Therapeutics by Wells Fargo
JUNO,JUNO:UW,BBG007K3F2J4,3 Stocks We'd Buy and Hold for the Next 20 Years,2017-02-10 19:49:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xvz2-WP8iLw/3-stocks-wed-buy-and-hold-for-the-next-20-years-cm746406,Stocks that can stand the test of time and produce market beating returns along the way don t exactly fall out of the sky Our contributors though think that the biotech Celgene NASDAQ CELG the healthcare giant Johnson amp Johnson NYSE JNJ and the medical device
JUNO,JUNO:UW,BBG007K3F2J4,"[$$] Venrock Refuels, and Goes Back on the Hunt",2017-02-09 23:53:18 +0000,https://www.wsj.com/articles/venrock-refuels-and-goes-back-on-the-hunt-1486684393?mod=yahoo_hs,"[$$] Venrock Refuels, and Goes Back on the Hunt"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference,2017-02-08 21:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-present-leerink-partners-210500672.html,"[Business Wire] - Juno Therapeutics, Inc. today announced that it will webcast its presentation at the Leerink Partners 6th Annual Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 15, 2017."
JUNO,JUNO:UW,BBG007K3F2J4,"Is This Why Juno Therapeutics, Inc. Stock Rose 13% in January?",2017-02-08 14:18:00 +0000,http://www.fool.com/investing/2017/02/07/is-this-why-juno-therapeutics-inc-stock-rose-13-in.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Is This Why Juno Therapeutics, Inc. Stock Rose 13% in January?"
JUNO,JUNO:UW,BBG007K3F2J4,"Is This Why Juno Therapeutics, Inc. Stock Rose 13% in January?",2017-02-07 18:19:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9dye-nqSTho/is-this-why-juno-therapeutics-inc-stock-rose-13-in-january-cm744359,What happened Shares of Juno Therapeutics Inc NASDAQ JUNO a clinical stage biotech that reprograms immune cells to battle cancer gained 13 2 in January according to 160 data from S amp P Global Market Intelligence 160 The industry tracking iShares
JUNO,JUNO:UW,BBG007K3F2J4,Cellectis Blood Cancer Gets FDA Nod for Trial,2017-02-07 17:48:00 +0000,http://www.investopedia.com/news/cellectis-allogeneic-gets-fda-ok-study-clls/?partner=YahooSA,Cellectis Blood Cancer Gets FDA Nod for Trial
JUNO,JUNO:UW,BBG007K3F2J4,Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money,2017-02-02 20:44:00 +0000,https://www.thestreet.com/story/13975695/1/side-effect-kills-cancer-patient-in-stemline-therapeutics-drug-trial-the-company-raises-money.html?puc=yahoo&cm_ven=YAHOO,Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Stemline Therapeutics Stock Fell 36.9% This Morning,2017-02-02 17:53:43 +0000,http://www.fool.com/investing/2017/02/02/heres-why-stemline-therapeutics-stock-fell-369-thi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Stemline Therapeutics Stock Fell 36.9% This Morning
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : February 1, 2017",2017-02-01 12:31:39 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-february-1-2017/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : February 1, 2017"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations,2017-01-27 14:00:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-appoints-corsee-d-140000718.html,"[Business Wire] - Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D."
JUNO,JUNO:UW,BBG007K3F2J4,"Commit To Buy Juno Therapeutics At $15, Earn 17.3% Using Options",2017-01-19 19:38:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7oDzVjgDtoE/commit-to-buy-juno-therapeutics-at-15-earn-173-using-options-cm735598,Investors considering a purchase of Juno Therapeutics Inc Symbol JUNO stock but cautious about paying the going market price of 19 70 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
JUNO,JUNO:UW,BBG007K3F2J4,Surprising Analyst 12-Month Target For FBT,2017-01-19 15:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/--htUzDVHwk/surprising-analyst-12-month-target-for-fbt-cm735428,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next,2017-01-13 16:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v9DdXHmQf48/why-juno-therapeutics-crashed-571-in-2016-and-whats-next-cm733296,Image source Getty Images What happened After reporting that it has halted trials of its most advanced cancer drug 160 shares in Juno Therapeutics NASDAQ JUNO lost 57 1 of their value in 2016 according to S amp P Global Market Intelligence So
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next,2017-01-13 15:02:07 +0000,http://www.fool.com/investing/2017/01/13/why-juno-therapeutics-crashed-571-in-2016-and-what.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next
JUNO,JUNO:UW,BBG007K3F2J4,Blog Coverage Redhill Receives QIDP Fast-Track Designation from FDA for its Nontuberculous Mycobacteria Infections Combination Therapy,2017-01-12 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-redhill-receives-qidp-131500483.html,"[Accesswire] - Upcoming AWS Coverage on Juno Therapeutics LONDON, UK / ACCESSWIRE / January 12, 2017 / Active Wall St. blog coverage looks at the headline from RedHill Biopharma Ltd. (NASDAQ: RDHL ) (""RedHill"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China",2017-01-11 01:50:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tTcahUjejpk/kite-pharma-inks-deals-for-car-t-cell-drug-in-japan-china-cm731950,Kite Pharma KITE announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel KTE C19 in Japan In another press release Kite Pharma declared that it has formed a joint venture Fosun Pharma Kite Biotechnology Co
JUNO,JUNO:UW,BBG007K3F2J4,Full Show: Bloomberg Technology (01/09),2017-01-10 00:25:03 +0000,http://www.bloomberg.com/news/videos/2017-01-10/full-show-bloomberg-technology-01-09?cmpid=yhoo.headline,Full Show: Bloomberg Technology (01/09)
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics CEO Bishop on Immunotherapy,2017-01-09 22:52:38 +0000,http://www.bloomberg.com/news/videos/2017-01-09/juno-therapeutics-ceo-bishop-on-immunotherapy?cmpid=yhoo.headline,Juno Therapeutics CEO Bishop on Immunotherapy
JUNO,JUNO:UW,BBG007K3F2J4,Is Celgene Simply the Best Biotech Stock on the Planet?,2017-01-09 20:49:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R6wqV7oA4bo/is-celgene-simply-the-best-biotech-stock-on-the-planet-cm731272,A mic drop at the end of Celgene NASDAQ CELG CEO Mark Alles presentation at the 160 35th Annual J P Morgan NYSE JPM Healthcare Conference might have been appropriate Celgene traditionally kicks off the conference and did so again this year Alles briefly described
JUNO,JUNO:UW,BBG007K3F2J4,Is Celgene Simply the Best Biotech Stock on the Planet?,2017-01-09 19:24:22 +0000,http://www.fool.com/investing/2017/01/09/is-celgene-simply-the-best-biotech-stock-on-the-pl.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Celgene Simply the Best Biotech Stock on the Planet?
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-01-09 18:45:05 +0000,http://biz.yahoo.com/e/170109/juno8-k.html,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma (KITE) to Move Cancer Candidate into Phase I,2017-01-04 13:38:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6lkxpTPHZwc/kite-pharma-kite-to-move-cancer-candidate-into-phase-i-cm729077,Kite Pharma Inc KITE announced that it has filed a Investigational New Drug IND application with the FDA to initiate phase I studies on KITE 718 a TCR candidate targeting MAGE in a solid tumor Kite Pharma s shares have declined 12 8 in the past six months which compares unfavorably
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma (KITE) to Move Cancer Candidate into Phase I,2017-01-04 11:55:11 +0000,http://finance.yahoo.com/news/kite-pharma-kite-move-cancer-115511987.html,Kite Pharma (KITE) to Move Cancer Candidate into Phase I
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference,2017-01-03 21:05:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-present-35th-annual-210500720.html,"[Business Wire] - Juno Therapeutics, Inc. today announced that it will webcast its presentation at the 35th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Tuesday, January 10, 2017."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Becomes Oversold,2016-12-30 22:57:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p2-RrTNnFfc/juno-therapeutics-becomes-oversold-cm728139,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
JUNO,JUNO:UW,BBG007K3F2J4,"Kite Pharma Cancer Drug Poised For Approval In 2017, Says RBC",2016-12-29 21:12:18 +0000,http://www.investors.com/news/technology/kite-pharma-cancer-drug-poised-for-approval-in-2017-says-rbc/,"Kite Pharma Cancer Drug Poised For Approval In 2017, Says RBC"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths,2016-12-28 04:45:10 +0000,http://www.wsj.com/articles/seattle-genetics-cancer-drug-trials-on-hold-after-four-patient-deaths-1482846052?ru=yahoo?mod=yahoo_itp,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths
JUNO,JUNO:UW,BBG007K3F2J4,"Four patients die in Seattle Genetics cancer trial, stock plummets",2016-12-27 21:50:17 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2016/12/four-patients-die-in-seattle-genetics-cancer-trial.html?ana=yahoo,"Four patients die in Seattle Genetics cancer trial, stock plummets"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths,2016-12-27 18:55:10 +0000,http://www.wsj.com/articles/seattle-genetics-cancer-drug-trials-on-hold-after-four-patient-deaths-1482846052?mod=yahoo_hs,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths
JUNO,JUNO:UW,BBG007K3F2J4,Friday's ETF with Unusual Volume: VONV,2016-12-23 19:57:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ISrGFeGI0Ew/fridays-etf-with-unusual-volume-vonv-cm725830,The Vanguard Russell 1000 Value ETF VONV is seeing unusually high volume in afternoon trading Friday with over 308 000 shares traded versus three month average volume of about 39 000 Shares of VONV were trading flat on the day Components of that ETF with the highest volume on
JUNO,JUNO:UW,BBG007K3F2J4,Biotech buying opportunity?,2016-12-22 22:52:00 +0000,http://finance.yahoo.com/video/biotech-buying-opportunity-225200149.html,Biotech buying opportunity?
JUNO,JUNO:UW,BBG007K3F2J4,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016,2016-12-22 16:20:00 +0000,https://www.thestreet.com/story/13935497/1/what-adam-feuerstein-got-right-and-wrong-about-biotech-stock-in-2016.html?puc=yahoo&cm_ven=YAHOO,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
JUNO,JUNO:UW,BBG007K3F2J4,2016's Worst Clinical Failures,2016-12-22 14:36:19 +0000,http://www.fool.com/investing/2016/12/21/2016s-worst-clinical-failures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2016's Worst Clinical Failures
JUNO,JUNO:UW,BBG007K3F2J4,Juno Gets Breakthrough Therapy Status for Lymphoma Drug,2016-12-21 17:59:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aEaGC5UOAmc/juno-gets-breakthrough-therapy-status-for-lymphoma-drug-cm724683,Juno Therapeutics Inc JUNO and partner Celgene Corporation CELG announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate JCAR017 for the treatment of relapsed refractory r r aggressive large B cell non Hodgkin lymphoma NHL
JUNO,JUNO:UW,BBG007K3F2J4,Juno Gets Breakthrough Therapy Status for Lymphoma Drug,2016-12-21 15:40:03 +0000,http://finance.yahoo.com/news/juno-gets-breakthrough-therapy-status-154003126.html,Juno Gets Breakthrough Therapy Status for Lymphoma Drug
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma,2016-12-20 14:22:09 +0000,http://www.publicnow.com/view/31A41C749F7845BEF79E77748FE01B983B6B1099,"[at noodls] - -- Early results recently announced with JCAR017 in non-Hodgkin lymphoma and pediatric acute lymphoblastic leukemia -- Pivotal DLBCL trial expected to begin in 2017 SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE)--Dec. ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Celgene Get Breakthrough Therapy Designation From FDA",2016-12-20 10:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jHkjC1cS9qQ/juno-therapeutics-celgene-get-breakthrough-therapy-designation-from-fda-20161220-00558,"Juno Therapeutics, Celgene Get Breakthrough Therapy Designation From FDA"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell Patent,2016-12-19 14:11:05 +0000,http://www.publicnow.com/view/FFFE37DA90E559BD66BB94B0EEF3675CEE374699,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Dec. 19, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced ..."
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals,2016-12-18 11:51:24 +0000,http://www.fool.com/investing/2016/12/17/better-buy-juno-therapeutics-vs-alnylam-pharmaceut.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' Big News at ASH? It's Still in the CAR-T Race,2016-12-17 14:05:25 +0000,http://www.fool.com/investing/2016/12/16/novartis-big-news-at-ash-its-still-in-the-car-t-ra.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novartis' Big News at ASH? It's Still in the CAR-T Race
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals,2016-12-17 12:56:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0mlwBFNuano/better-buy-juno-therapeutics-vs-alnylam-pharmaceuticals-cm722858,These aren t the best of times for Juno Therapeutics NASDAQ JUNO and Alnylam Pharmaceuticals NASDAQ ALNY Both have experienced major clinical setbacks this year Both biotechs have also lost over half of their market cap since then beginning of 2016 Which of these two
JUNO,JUNO:UW,BBG007K3F2J4,"Federman & Sherwood Reminds Investors of the Securities Class Action Lawsuit Against Juno Therapeutics, Inc.",2016-12-16 17:35:00 +0000,http://finance.yahoo.com/news/federman-sherwood-reminds-investors-securities-173500316.html,"[Business Wire] - On July 13, 2016, a class action lawsuit was filed in the United States District Court for the Western District of Washington against Juno Therapeutics, Inc. . If you purchased Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,Novartis' Big News at ASH? It's Still in the CAR-T Race,2016-12-16 15:59:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nDtWYqA-X6o/novartis-big-news-at-ash-its-still-in-the-car-t-race-cm722485,Novartis NYSE NVS may not get the splashy coverage bestowed on CAR T competitors Juno Therapeutics NASDAQ JUNO and Kite Pharma NASDAQ KITE but that doesn t mean that Novartis isn t still among the leaders in developing this revolutionary new way of fighting cancer
JUNO,JUNO:UW,BBG007K3F2J4,Washington Cuts a Check to Spark Healthcare Innovation,2016-12-14 13:04:05 +0000,http://www.fool.com/investing/2016/12/14/washington-cuts-a-check-to-spark-healthcare-innova.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Washington Cuts a Check to Spark Healthcare Innovation
JUNO,JUNO:UW,BBG007K3F2J4,Why Kite Pharma's Shares Rallied 14.5% In November,2016-12-09 14:59:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jw8SRajAbHk/why-kite-pharmas-shares-rallied-145-in-november-cm719140,IMAGE SOURCE GETTY IMAGES What happened After Juno Therapeutics NASDAQ JUNO disclosed that it had halted a trial evaluating its lead CAR T drug JCAR015 for a second time this year shares in Kite Pharma Inc NASDAQ KITE 160 soared 14 5 last
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics a Bad-News Buy?,2016-12-09 13:49:04 +0000,http://www.fool.com/investing/2016/12/08/is-juno-therapeutics-a-bad-news-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Juno Therapeutics a Bad-News Buy?
JUNO,JUNO:UW,BBG007K3F2J4,Why Kite Pharma's Shares Rallied 14.5% In November,2016-12-09 13:21:06 +0000,http://www.fool.com/investing/2016/12/09/why-kite-pharmas-shares-rallied-145-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Kite Pharma's Shares Rallied 14.5% In November
JUNO,JUNO:UW,BBG007K3F2J4,Bluebird Smartly Strikes While the Iron Is Hot,2016-12-09 13:00:06 +0000,http://www.bloomberg.com/gadfly/articles/2016-12-09/bluebird-bio-share-sale-perfect-timing?cmpid=yhoo.headline,Bluebird Smartly Strikes While the Iron Is Hot
JUNO,JUNO:UW,BBG007K3F2J4,Trump's pledge to rein in drug prices takes bite out of Seattle-area biotech stocks,2016-12-08 22:40:11 +0000,http://www.bizjournals.com/seattle/news/2016/12/08/trump-pledge-to-rein-in-drug-prices-takes-bite-out.html?ana=yahoo,Trump's pledge to rein in drug prices takes bite out of Seattle-area biotech stocks
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics a Bad-News Buy?,2016-12-08 17:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fATkbwkhdv4/is-juno-therapeutics-a-bad-news-buy-cm718743,Shares in Juno Therapeutics NASDAQ JUNO have tumbled since the company reported a voluntary halt to its lead drug program JCAR015 which is intended to treat acute lymphoblastic leukemia JCAR015 attacks cancer in an entirely novel way A chimeric antigen receptor T cell
JUNO,JUNO:UW,BBG007K3F2J4,Why You Should Let Celgene Corporation Invest Your Money,2016-12-07 22:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SYy5mJ8y19A/why-you-should-let-celgene-corporation-invest-your-money-cm718334,How would you like to have an investment manager who quadrupled your initial investment over the last 10 years That s the return that Celgene Corporation NASDAQ CELG achieved But Celgene is a biotech not an investment manager right Actually it s both The company has
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Crashed 19.3% in November,2016-12-07 19:57:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zf9nkGreS_Y/why-juno-therapeutics-crashed-193-in-november-cm718221,Image source Getty Images What happened After reporting that it placed a key trial on voluntarily hold shares in Juno Therapeutics NASDAQ JUNO lost 19 3 of their value in November 160 according to S amp P Global Market Intelligence So what
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Crashed 19.3% in November,2016-12-07 18:01:06 +0000,http://www.fool.com/investing/2016/12/07/why-juno-therapeutics-crashed-193-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Juno Therapeutics Crashed 19.3% in November
JUNO,JUNO:UW,BBG007K3F2J4,"Kite and Juno Plunge on Cancer Data (JUNO, KITE)",2016-12-07 16:10:00 +0000,http://www.investopedia.com/news/kite-juno-cancer-data-fuel-price-dip-juno-kite/?partner=YahooSA,"Kite and Juno Plunge on Cancer Data (JUNO, KITE)"
JUNO,JUNO:UW,BBG007K3F2J4,"Purcell Julie & Lefkowitz LLP Is Investigating Juno Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors",2016-12-07 14:50:00 +0000,http://finance.yahoo.com/news/purcell-julie-lefkowitz-llp-investigating-145000608.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 7, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Reports Positive Phase I Study Data on Lymphoma Drug,2016-12-06 22:57:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ELi2jgUgcd0/juno-reports-positive-phase-i-study-data-on-lymphoma-drug-cm717693,Juno Therapeutics Inc JUNO announced encouraging preliminary clinical data from a phase I study TRANSCEND on its lead pipeline candidate JCAR017 for the treatment of patients with relapsed or refractory r r aggressive non Hodgkin lymphoma NHL Results were presented at the 58th
JUNO,JUNO:UW,BBG007K3F2J4,Is This How Juno Therapeutics Gets Back on Track?,2016-12-06 21:57:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dbJhuH5vzKM/is-this-how-juno-therapeutics-gets-back-on-track-cm717332,Juno Therapeutics NASDAQ JUNO just released a wave of trial data on JCAR014 and JCAR017 that it hopes will reignite investor interest following the recent and disappointing voluntary hold that management placed last month on its lead drug candidate JCAR015 The data may offer
JUNO,JUNO:UW,BBG007K3F2J4,"Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies",2016-12-06 21:31:24 +0000,http://www.investors.com/news/technology/rivals-kite-pharma-juno-therapeutics-tank-on-cancer-data-spark-flies/,"Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies"
JUNO,JUNO:UW,BBG007K3F2J4,The Latest Buzz in Biotech,2016-12-06 21:26:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EpVsy00YKRg/the-latest-buzz-in-biotech-cm717591,In this week s episode of Industry Focus Healthcare Motley Fool analyst Michael Douglass and Fool contributor Todd Campbell go over three of the biggest recent stories in healthcare Shares in Juno Therapeutics NASDAQ JUNO and 160 Amicus Therapeutics
JUNO,JUNO:UW,BBG007K3F2J4,The Latest Buzz in Biotech,2016-12-06 21:19:34 +0000,http://www.fool.com/investing/2016/12/06/the-latest-buzz-in-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Latest Buzz in Biotech
JUNO,JUNO:UW,BBG007K3F2J4,"Teva, FitBit Settle into Tuesday’s 52-Week Low Club",2016-12-06 21:04:50 +0000,http://finance.yahoo.com/news/teva-fitbit-settle-tuesday-52-210450401.html,"Teva, FitBit Settle into Tuesday’s 52-Week Low Club"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Reports Positive Phase I Study Data on Lymphoma Drug,2016-12-06 21:01:09 +0000,http://finance.yahoo.com/news/juno-reports-positive-phase-study-210109748.html,Juno Reports Positive Phase I Study Data on Lymphoma Drug
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH,2016-12-06 21:00:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-highlights-progress-best-210000404.html,"[Business Wire] - Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today provided an update of key data from studies of its investigational chimeric antigen receptor T cell product candidates, presented at the 58th American Society of Hematology Annual Meeting in San Diego, December 3-6, 2016."
JUNO,JUNO:UW,BBG007K3F2J4,Is This How Juno Therapeutics Gets Back on Track?,2016-12-06 20:30:26 +0000,http://www.fool.com/investing/2016/12/06/is-this-how-juno-therapeutics-gets-back-on-track.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is This How Juno Therapeutics Gets Back on Track?
JUNO,JUNO:UW,BBG007K3F2J4,Juno Needs to Back a Different CAR-T Horse,2016-12-06 17:44:07 +0000,http://www.bloomberg.com/gadfly/articles/2016-12-06/juno-therapeutics-jcar015-time-to-give-up?cmpid=yhoo.headline,Juno Needs to Back a Different CAR-T Horse
JUNO,JUNO:UW,BBG007K3F2J4,Biotech's Dumbest CEO Moves in 2016,2016-12-06 15:07:38 +0000,http://www.fool.com/investing/2016/12/05/biotechs-dumbest-ceo-moves-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech's Dumbest CEO Moves in 2016
JUNO,JUNO:UW,BBG007K3F2J4,Leukemia Treatment Achieves Promising Results,2016-12-05 19:57:37 +0000,http://finance.yahoo.com/news/leukemia-treatment-achieves-promising-results-195737119.html,Leukemia Treatment Achieves Promising Results
JUNO,JUNO:UW,BBG007K3F2J4,"Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE)",2016-12-05 18:07:00 +0000,http://www.investopedia.com/news/novartis-kite-cart-cancer-drug-race-nvs-kite/?partner=YahooSA,"Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE)"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma,2016-12-05 18:00:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-presents-data-transcend-180000833.html,"[Business Wire] - Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced encouraging preliminary clinical data for JCAR017 in patients with relapsed or refractory aggressive non-Hodgkin lymphoma in a presentation at the 58th American Society of Hematology Annual Meeting."
JUNO,JUNO:UW,BBG007K3F2J4,Celgene CEO: Excited by opportunities corporate tax refor...,2016-12-05 16:16:00 +0000,http://finance.yahoo.com/video/celgene-ceo-excited-opportunities-corporate-161600631.html,Celgene CEO: Excited by opportunities corporate tax refor...
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics Inc (JUNO) A Good Stock To Buy?,2016-12-05 12:54:45 +0000,http://www.insidermonkey.com/blog/is-juno-therapeutics-inc-juno-a-good-stock-to-buy-497779/,Is Juno Therapeutics Inc (JUNO) A Good Stock To Buy?
JUNO,JUNO:UW,BBG007K3F2J4,"Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out",2016-12-05 12:15:00 +0000,https://www.thestreet.com/story/13913270/1/patient-deaths-safety-concerns-cause-juno-s-car-t-pipeline-to-skid-out.html?puc=yahoo&cm_ven=YAHOO,"Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL,2016-12-03 15:45:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-announces-complete-response-154500813.html,"[Business Wire] - Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced in a presentation at the 58th American Society of Hematology Annual Meeting encouraging early data for JCAR014 in patients with chronic lymphocytic leukemia who failed treatment with ibrutinib."
JUNO,JUNO:UW,BBG007K3F2J4,Adventures in CAR-T Racing: Crashes and Curves Edition,2016-12-02 16:20:01 +0000,http://www.fool.com/investing/2016/12/02/adventures-in-car-t-racing-crashes-and-curves-edit.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Adventures in CAR-T Racing: Crashes and Curves Edition
JUNO,JUNO:UW,BBG007K3F2J4,Cramer issues a warning on biotech stocks — there's new risk that you need to consider,2016-12-02 00:03:26 +0000,http://www.cnbc.com/id/104137986?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104137986,Cramer issues a warning on biotech stocks — there's new risk that you need to consider
JUNO,JUNO:UW,BBG007K3F2J4,Cramer issues a warning on biotech stocks — there's new r...,2016-12-01 23:25:00 +0000,http://finance.yahoo.com/video/cramer-issues-warning-biotech-stocks-232500886.html,Cramer issues a warning on biotech stocks — there's new r...
JUNO,JUNO:UW,BBG007K3F2J4,Bluebird Rockets On Myeloma Drug; Celgene Gets Boost,2016-12-01 22:00:03 +0000,http://www.investors.com/news/technology/bluebird-rockets-on-most-potent-myeloma-drug-celgene-gets-boost/,Bluebird Rockets On Myeloma Drug; Celgene Gets Boost
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Bluebird Bio (BLUE) is Rallying Today,2016-12-01 20:33:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WZ65Qvreclk/heres-why-bluebird-bio-blue-is-rallying-today-cm716578,On Thursday shares of biotech company Bluebird Bio Inc BLUE are rallying up over 17 in midday trading after positive results came in for its experimental anti BCMA CAR chimeric antigen receptor T cell product candidate 160 bb2121 in an early stage study for relapsed refractory
JUNO,JUNO:UW,BBG007K3F2J4,Bluebird Bio Flies; Blood Cancer Drug Impresses In Small Trial,2016-12-01 18:43:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/01/bluebird-bio-flies-blood-cancer-drug-impresses-in-small-trial/?mod=yahoobarrons&ru=yahoo,Bluebird Bio Flies; Blood Cancer Drug Impresses In Small Trial
JUNO,JUNO:UW,BBG007K3F2J4,"Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study",2016-12-01 14:40:07 +0000,http://www.investors.com/news/technology/bluebird-bio-celgene-multiple-myeloma-therapy-strong-in-9-patient-study/,"Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study"
JUNO,JUNO:UW,BBG007K3F2J4,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects",2016-11-30 22:20:00 +0000,https://www.thestreet.com/story/13909407/1/bluebird-celgene-t-cell-therapy-eliminates-multiple-myeloma-with-minimal-side-effects.html?puc=yahoo&cm_ven=YAHOO,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects"
JUNO,JUNO:UW,BBG007K3F2J4,"Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno",2016-11-30 12:13:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-actelion-soars-121312797.html,"Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno"
JUNO,JUNO:UW,BBG007K3F2J4,Do Juno's Struggles Make Kite Pharma a Buy?,2016-11-29 13:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bCzBAUCn2Vc/do-junos-struggles-make-kite-pharma-a-buy-cm714892,Image source Kite Pharma Inc Following Juno Therapeutics NASDAQ JUNO disclosure that it s halted a trial of JCAR015 for a second time this year all eyes shift to Kite Pharma Inc NASDAQ KITE another promising drug developer that s working on a cancer therapy
JUNO,JUNO:UW,BBG007K3F2J4,Do Juno's Struggles Make Kite Pharma a Buy?,2016-11-29 12:01:06 +0000,http://www.fool.com/investing/2016/11/29/do-junos-struggles-make-kite-pharma-a-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Do Juno's Struggles Make Kite Pharma a Buy?
JUNO,JUNO:UW,BBG007K3F2J4,4 Companies That Destroyed Shareholders Last Week,2016-11-26 15:00:36 +0000,http://247wallst.com/investing/2016/11/26/4-companies-that-destroyed-shareholders-last-week-10/,4 Companies That Destroyed Shareholders Last Week
JUNO,JUNO:UW,BBG007K3F2J4,"Stock Market News for November 25, 2016",2016-11-25 17:05:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iO9Oc0Kf0Bo/stock-market-news-for-november-25-2016-cm713985,Benchmarks finished mixed on Wednesday after strong durable orders and Donald Trump s economic agenda boosted the industrial sector Both the Dow and S amp P 500 reached record high levels for the third straight session following continued expectations that Donald Trump will adopt new policies
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : November 25, 2016",2016-11-25 15:18:28 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-juno-therapeutics-inc-november-25-2016/,"ETFs with exposure to Juno Therapeutics, Inc. : November 25, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,"Stock Market News for November 25, 2016",2016-11-25 15:10:03 +0000,http://finance.yahoo.com/news/stock-market-news-november-25-151003500.html,"Stock Market News for November 25, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] The Problem With Lilly Is the Problem With Pharma,2016-11-25 05:17:05 +0000,http://www.wsj.com/articles/the-problem-with-lilly-is-the-problem-with-pharma-1479918700?ru=yahoo?mod=yahoo_itp,[$$] The Problem With Lilly Is the Problem With Pharma
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY's Expedition Fails",2016-11-24 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vsjlil17fE0/juno-implodes-as-rocket-is-put-on-hold-again-llys-expedition-fails-20161124-00241,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY's Expedition Fails"
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY''s Expedition Fails",2016-11-24 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sB3G_4szIAQ/juno-implodes-as-rocket-is-put-on-hold-again-llys-expedition-fails-20161124-00237,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY''s Expedition Fails"
JUNO,JUNO:UW,BBG007K3F2J4,Here’s Why These Two Biotechs Just Took A Hit: Eli Lilly And Co (LLY) And Juno Therapeutics Inc (JUNO),2016-11-24 18:12:11 +0000,http://www.insidermonkey.com/blog/heres-why-these-two-biotechs-just-took-a-hit-eli-lilly-and-co-lly-and-juno-therapeutics-inc-juno-491242/,Here’s Why These Two Biotechs Just Took A Hit: Eli Lilly And Co (LLY) And Juno Therapeutics Inc (JUNO)
JUNO,JUNO:UW,BBG007K3F2J4,"Juno's ROCKET Study on Clinical Hold Again, Shares Down",2016-11-24 14:05:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7KGtGlzc_X0/junos-rocket-study-on-clinical-hold-again-shares-down-cm713620,Juno Therapeutics Inc JUNO announced that it has voluntarily placed a phase II trial of its lead pipeline candidate JCAR015 on hold after two patients suffered cerebral edema earlier in the week One of the patients died and the other has very low chances of recovery The ROCKET trial
JUNO,JUNO:UW,BBG007K3F2J4,"Pre-Market Most Active for Nov 23, 2016 :  LLY, NVO, TGT, MT, BAC, DE, JUNO, BIIB, ERIC, QQQ, XIV, TVIX",2016-11-24 13:54:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ8IhHvVFj8/pre-market-most-active-for-nov-23-2016-lly-nvo-tgt-mt-bac-de-juno-biib-eric-qqq-xiv-tvix-cm713634,The NASDAQ 100 Pre Market Indicator is down 17 96 to 4 855 88 The total Pre Market volume is currently 27 535 190 shares traded The following are the most active stocks for the pre market session Eli Lilly and Company LLY is 11 69 at 64 30 with 6 253 901
JUNO,JUNO:UW,BBG007K3F2J4,"Juno's ROCKET Study on Clinical Hold Again, Shares Down",2016-11-24 12:31:12 +0000,http://finance.yahoo.com/news/junos-rocket-study-clinical-hold-123112135.html,"Juno's ROCKET Study on Clinical Hold Again, Shares Down"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : November 24, 2016",2016-11-24 12:15:09 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-november-24-2016/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : November 24, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,Adaptive Biotechnologies – Seattle's stealthy biotech unicorn – expands in redesigned HQ (Photos),2016-11-24 00:15:07 +0000,http://www.bizjournals.com/seattle/news/2016/11/23/adaptive-biotechnologies-expands-hq-seattle-photos.html?ana=yahoo,Adaptive Biotechnologies – Seattle's stealthy biotech unicorn – expands in redesigned HQ (Photos)
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc (JUNO) Nosedives On Phase III Complications,2016-11-24 00:10:58 +0000,http://www.insidermonkey.com/blog/juno-therapeutics-inc-juno-nosedives-on-phase-iii-complications-490504/,Juno Therapeutics Inc (JUNO) Nosedives On Phase III Complications
JUNO,JUNO:UW,BBG007K3F2J4,Drug bust hits healthcare stocks,2016-11-23 22:16:00 +0000,http://finance.yahoo.com/video/drug-bust-hits-healthcare-stocks-221600920.html,Drug bust hits healthcare stocks
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics (JUNO) Stock Is Crashing Today,2016-11-23 22:03:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ffnla8eEemU/heres-why-juno-therapeutics-juno-stock-is-crashing-today-cm713534,Shares of Juno Therapeutics JUNO plummeted over 26 on Wednesday after it was announced that the biopharmaceutical company is halting the study of an experimental leukemia treatment due the death of two patients Juno s leukemia study has already been linked to three patient deaths back in
JUNO,JUNO:UW,BBG007K3F2J4,What Happened in Biotech in 2016?,2016-11-23 21:44:34 +0000,http://www.fool.com/investing/2016/11/22/what-happened-in-biotech-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What Happened in Biotech in 2016?
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 11/23/2016: LLY,MDGS,JUNO",2016-11-23 21:44:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CYACNgh1h68/health-care-sector-update-for-11232016-llymdgsjuno-cm713550,Health care stocks have turned higher Wednesday afternoon with the NYSE Health Care Index climbing about 0 3 while shares of health care companies in the S amp P 500 were up 0 3 as a group Health care stocks have turned higher Wednesday afternoon with the NYSE Health Care Index climbing
JUNO,JUNO:UW,BBG007K3F2J4,Juno Stock Plummets After 2 Patients Die; Rival Kite Recovers,2016-11-23 21:09:31 +0000,http://www.investors.com/news/technology/juno-stock-plummets-after-2-patients-die-drags-rival-kite-down-too/,Juno Stock Plummets After 2 Patients Die; Rival Kite Recovers
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc Plummeted Today,2016-11-23 21:05:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TYIuyEcYjE/why-juno-therapeutics-inc-plummeted-today-cm713527,Image source Getty Images What happened Juno Therapeutics NASDAQ JUNO is down 26 6 at 1 26 p m EST after announcing that it was placing a hold on one of its CAR T clinical trials after two patients suffered cerebral edemas earlier this week Both have died
JUNO,JUNO:UW,BBG007K3F2J4,[$$] The Problem With Lilly is the Problem With Pharma,2016-11-23 20:00:24 +0000,http://www.wsj.com/articles/the-problem-with-lilly-is-the-problem-with-pharma-1479918700?mod=yahoo_hs,[$$] The Problem With Lilly is the Problem With Pharma
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics (JUNO) Stock Is Crashing Today,2016-11-23 19:49:07 +0000,http://finance.yahoo.com/news/heres-why-juno-therapeutics-juno-194907426.html,Here's Why Juno Therapeutics (JUNO) Stock Is Crashing Today
JUNO,JUNO:UW,BBG007K3F2J4,Five Lessons From Today's Pharma Failures,2016-11-23 19:49:00 +0000,http://www.forbes.com/sites/matthewherper/2016/11/23/five-lessons-from-todays-pharma-failures/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Five Lessons From Today's Pharma Failures
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics halts study after more patient deaths,2016-11-23 19:32:41 +0000,http://sg.finance.yahoo.com/news/juno-therapeutics-halts-study-more-153232780.html,Juno Therapeutics halts study after more patient deaths
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates',2016-11-23 19:17:09 +0000,http://finance.yahoo.com/news/juno-therapeutics-hold-more-impactful-191709607.html,Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates'
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc Plummeted Today,2016-11-23 19:09:55 +0000,http://www.fool.com/investing/2016/11/23/why-juno-therapeutics-inc-plummeted-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Juno Therapeutics Inc Plummeted Today
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 11/23/2016: CLRB,MDGS,JUNO",2016-11-23 19:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lap6GJN8xXs/health-care-sector-update-for-11232016-clrbmdgsjuno-cm713469,Top Health Care StocksTop Health Care Stocks JNJ 0 16 JNJ 0 16 PFE 0 13 PFE 0 13 MRK 2 27 MRK 2 27 ABT 0 49 ABT 0 49 AMGN 0 07 AMGN 0 07 Health care stocks were slightly lower during Wednesday trading with the NYSE Health Care Index slipping about 0 1 while shares of health
JUNO,JUNO:UW,BBG007K3F2J4,More patient deaths in Juno clinical trial casts clouds over cancer drug’s future,2016-11-23 18:50:25 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=7BBAEA0A-B190-11E6-909D-6A360671FDAB&siteid=yhoof2,More patient deaths in Juno clinical trial casts clouds over cancer drug’s future
JUNO,JUNO:UW,BBG007K3F2J4,"Shares of Seattle, Waltham biotech Juno crash after patient deaths",2016-11-23 18:10:09 +0000,http://www.bizjournals.com/boston/news/2016/11/23/shares-of-seattle-waltham-biotech-juno-crash-after.html?ana=yahoo,"Shares of Seattle, Waltham biotech Juno crash after patient deaths"
JUNO,JUNO:UW,BBG007K3F2J4,Analyst on JUNO: This is just a short setback,2016-11-23 18:02:00 +0000,http://finance.yahoo.com/video/analyst-juno-just-short-setback-180200313.html,Analyst on JUNO: This is just a short setback
JUNO,JUNO:UW,BBG007K3F2J4,Eli Lilly & Juno Therapeutics plummet after failed drug t...,2016-11-23 17:21:00 +0000,http://finance.yahoo.com/video/eli-lilly-juno-therapeutics-plummet-172100581.html,Eli Lilly & Juno Therapeutics plummet after failed drug t...
JUNO,JUNO:UW,BBG007K3F2J4,"How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday",2016-11-23 17:10:00 +0000,https://www.thestreet.com/story/13904102/1/how-to-trade-lilly-deere-and-other-most-active-stocks-wednesday.html?puc=yahoo&cm_ven=YAHOO,"How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday"
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes",2016-11-23 17:03:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bnzeddQZs_s/health-care-etfs-fall-as-eli-lilly-juno-add-to-troubled-sectors-woes-cm713294,Major index tracking 160 ETFs paused at Wednesday s open after notching a string of postelection new highs The stock rally had come as investors cheered President elect Donald Trump s proposals for lower taxes and less regulation of businesses SPDR S amp P 500 SPY
JUNO,JUNO:UW,BBG007K3F2J4,"Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks?",2016-11-23 16:47:21 +0000,http://www.insidermonkey.com/blog/cellectar-biosciences-clrb-juno-therapeutics-juno-newmont-mining-nem-and-more-what-is-going-on-with-these-falling-stocks-490075/,"Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks?"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Juno's Stock Drops Following Two More Deaths in Cancer Trial,2016-11-23 16:43:25 +0000,http://www.wsj.com/articles/junos-stock-drops-following-two-more-deaths-in-cancer-treatment-trial-1479915925?mod=yahoo_hs,[$$] Juno's Stock Drops Following Two More Deaths in Cancer Trial
JUNO,JUNO:UW,BBG007K3F2J4,"US STOCKS-Industrials lift Dow to record, techs drag S&P and Nasdaq",2016-11-23 16:37:55 +0000,http://finance.yahoo.com/news/us-stocks-industrials-lift-dow-163755443.html,"US STOCKS-Industrials lift Dow to record, techs drag S&P and Nasdaq"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Tanks 33% on Leukemia Trial Suspension (JUNO),2016-11-23 16:30:00 +0000,http://www.investopedia.com/news/juno-tanks-33-after-2-study-patients-die-juno/?partner=YahooSA,Juno Tanks 33% on Leukemia Trial Suspension (JUNO)
JUNO,JUNO:UW,BBG007K3F2J4,Juno Falls Sharply on Self-Imposed Clinical Hold,2016-11-23 16:09:56 +0000,http://finance.yahoo.com/news/juno-falls-sharply-self-imposed-160956818.html,Juno Falls Sharply on Self-Imposed Clinical Hold
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Juno shares tumble as cancer drug trial halted,2016-11-23 16:01:58 +0000,"http://www.ft.com/cms/s/c3b6afba-b18b-11e6-a37c-f4a01f1b0fa1,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - More than $1bn was wiped from the market value of Juno on Wednesday, after the biotech company revealed it had suspended a clinical trial of its experimental therapy for the second time in five months ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes",2016-11-23 15:36:43 +0000,http://www.investors.com/etfs-and-funds/etfs/health-care-etfs-fall-as-eli-lilly-juno-add-to-troubled-sectors-woes/,"Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes"
JUNO,JUNO:UW,BBG007K3F2J4,"Analysts say Juno's stock tumbles shouldn't spill over to Bluebird, Kite Pharma shares",2016-11-23 15:16:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DD79EBA5-32B4-4627-8943-E15E4AFD3150&siteid=yhoof2,"Analysts say Juno's stock tumbles shouldn't spill over to Bluebird, Kite Pharma shares"
JUNO,JUNO:UW,BBG007K3F2J4,Nasdaq trails major indexes,2016-11-23 14:41:00 +0000,http://finance.yahoo.com/video/nasdaq-trails-major-indexes-144100930.html,Nasdaq trails major indexes
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics stock slides after patients die during ...,2016-11-23 14:14:00 +0000,http://finance.yahoo.com/video/juno-therapeutics-stock-slides-study-141400818.html,Juno Therapeutics stock slides after patients die during ...
JUNO,JUNO:UW,BBG007K3F2J4,UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient deaths,2016-11-23 14:09:47 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=2389B70A-C124-4F28-81C6-89A4AC4A5304&siteid=yhoof2,UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient deaths
JUNO,JUNO:UW,BBG007K3F2J4,US STOCKS-Wall St set for flat open a day after hitting records,2016-11-23 13:57:30 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-set-135730771.html,US STOCKS-Wall St set for flat open a day after hitting records
JUNO,JUNO:UW,BBG007K3F2J4,"Pre-Market Most Active for Nov 23, 2016 :  LLY, DE, RDY, NVO, BIIB, ERIC, MT, SNY, JUNO, QQQ, XIV, TVIX",2016-11-23 13:53:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kID8OF6hPdw/pre-market-most-active-for-nov-23-2016-lly-de-rdy-nvo-biib-eric-mt-sny-juno-qqq-xiv-tvix-cm713147,The NASDAQ 100 Pre Market Indicator is down 12 65 to 4 861 19 The total Pre Market volume is currently 9 642 054 shares traded The following are the most active stocks for the pre market session Eli Lilly and Company LLY is 10 22 at 65 77 with 3 698 726
JUNO,JUNO:UW,BBG007K3F2J4,"A patient died in a trial for a new cancer treatment, and shares of the company behind it are collapsing",2016-11-23 13:52:00 +0000,http://finance.yahoo.com/news/patient-died-trial-cancer-treatment-135200104.html,"A patient died in a trial for a new cancer treatment, and shares of the company behind it are collapsing"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics CAR-T Study Halts Following Additional Patient Deaths,2016-11-23 13:32:00 +0000,https://www.thestreet.com/story/13903738/1/juno-therapeutics-car-t-study-halts-following-another-additional-patient-death.html?puc=yahoo&cm_ven=YAHOO,Juno Therapeutics CAR-T Study Halts Following Additional Patient Deaths
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc Places JCAR015 Phase II ROCKET Trial on Clinical Hold Call scheduled for 8:30 am ET today,2016-11-23 13:30:00 +0000,http://biz.yahoo.com/cc/1/154991.html,Juno Therapeutics Inc Places JCAR015 Phase II ROCKET Trial on Clinical Hold Call scheduled for 8:30 am ET today
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold,2016-11-23 13:21:05 +0000,http://www.publicnow.com/view/DCC03CCD32C5C75517209E73AC16D2CBD09E1FE5,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Nov. 23, 2016-- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Posting Steep Loss After Two Patients Die In Drug Trial,2016-11-23 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/94fB48mQINU/juno-therapeutics-posting-steep-loss-after-two-patients-die-in-drug-trial-20161123-00526,Juno Therapeutics Posting Steep Loss After Two Patients Die In Drug Trial
JUNO,JUNO:UW,BBG007K3F2J4,Juno''s Stock Drops Following Two More Deaths in Cancer Trial,2016-11-23 11:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RUacxLdPgvs/junos-stock-drops-following-two-more-deaths-in-cancer-trial-20161123-00470,Juno''s Stock Drops Following Two More Deaths in Cancer Trial
JUNO,JUNO:UW,BBG007K3F2J4,U.S. Stocks Hit Fresh High,2016-11-23 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GfVjUxMRdDU/us-stocks-hit-fresh-high-20161123-00708,U.S. Stocks Hit Fresh High
JUNO,JUNO:UW,BBG007K3F2J4,Stocks Calm After Dow Record,2016-11-23 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LFi9bKKKhFE/stocks-calm-after-dow-record-20161123-00203,Stocks Calm After Dow Record
JUNO,JUNO:UW,BBG007K3F2J4,What Happened in Biotech in 2016?,2016-11-22 23:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jc0QNGC1rY8/what-happened-in-biotech-in-2016-cm713018,Image source Getty Images It s been a rollercoaster of a year for the biotech industry with the decline that started in the middle of last year continuing into this year a recovery from those lows after a few gyrations a pre election decline on fears of price controls and
JUNO,JUNO:UW,BBG007K3F2J4,3 Beaten-Down Biotech Stocks You Can Buy Right Now,2016-11-22 15:20:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rIFJsAeThpA/3-beaten-down-biotech-stocks-you-can-buy-right-now-cm712563,Biotech stocks were experiencing a downright dismal year Then came the election surprise Now many biotech stocks are enjoying a big rebound That doesn t mean that there still aren t great buying opportunities though Here s why Alexion Pharmaceuticals NASDAQ ALXN
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. bluebird bio,2016-11-18 21:23:31 +0000,http://www.fool.com/investing/2016/11/17/better-buy-juno-therapeutics-vs-bluebird-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Juno Therapeutics vs. bluebird bio
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. bluebird bio,2016-11-17 22:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vGyfin9O4qY/better-buy-juno-therapeutics-vs-bluebird-bio-cm710879,Image source Getty Images This round of our ongoing Better Buy series pits two up and coming biotechs Juno Therapeutics NASDAQ JUNO and bluebird bio NASDAQ BLUE against each other Platforms in the making Both Juno Therapeutics and Bluebird are developing
JUNO,JUNO:UW,BBG007K3F2J4,Analysts Forecast 20% Gains Ahead For The Holdings of FBT,2016-11-17 15:50:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdBzIEMb2nY/analysts-forecast-20-gains-ahead-for-the-holdings-of-fbt-cm710532,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
JUNO,JUNO:UW,BBG007K3F2J4,"Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!",2016-11-17 11:36:00 +0000,https://www.thestreet.com/story/13897080/1/hey-gilead-stop-developing-drugs-and-start-buying-biotech-companies-now.html?puc=yahoo&cm_ven=YAHOO,"Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!"
JUNO,JUNO:UW,BBG007K3F2J4,Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?,2016-11-16 22:22:10 +0000,http://finance.yahoo.com/news/immunotherapy-next-hot-industry-biotech-222210893.html,Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
JUNO,JUNO:UW,BBG007K3F2J4,"ETFs with exposure to Juno Therapeutics, Inc. : November 14, 2016",2016-11-14 18:44:25 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-juno-therapeutics-inc-november-14-2016/,"ETFs with exposure to Juno Therapeutics, Inc. : November 14, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,4 Biotech Stocks to Buy After Clinton’s Defeat,2016-11-14 18:29:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wcolSbFSImw/4-biotech-stocks-to-buy-after-clintons-defeat-cm708827,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The 2016 election certainly was a historic one just not in the way people expected Rather than Hillary Clinton becoming the first female U S president Donald Trump managed to pull off the biggest upset
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics On a Roll in Q3 with Celgene's Cash and Lift of Clinical Hold,2016-11-12 18:26:50 +0000,http://www.fool.com/investing/2016/11/11/juno-therapeutics-on-a-roll-in-q3-with-celgenes-ca.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Juno Therapeutics On a Roll in Q3 with Celgene's Cash and Lift of Clinical Hold
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics On a Roll in Q3 with Celgene's Cash and Lift of Clinical Hold,2016-11-11 20:28:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9gIrlIpjoMY/juno-therapeutics-on-a-roll-in-q3-with-celgenes-cash-and-lift-of-clinical-hold-cm708052,Juno Therapeutics NASDAQ JUNO announced its third quarter earnings results on Wednesday after the market closed Shares of the biotech were already soaring in response to the outcome of the U S elections That uptrend continued after Juno provided an update on its third
JUNO,JUNO:UW,BBG007K3F2J4,Juno 3Q Losses 56 Cents a Share vs 26 Cents (JUNO),2016-11-11 15:46:00 +0000,http://www.investopedia.com/news/juno-3q-loss-56cshare-higher-rd-costs-juno/?partner=YahooSA,Juno 3Q Losses 56 Cents a Share vs 26 Cents (JUNO)
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected,2016-11-11 15:16:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z-EY87SM77g/juno-therapeutics-juno-q3-loss-narrower-than-expected-cm707707,Juno Therapeutics Inc JUNO reported a loss of 58 cents per share including stock based compensation expense in the third quarter of 2016 narrower than the Zacks Consensus Estimate loss of 64 cents However quarterly loss widened from the year ago figure of 53 cents The company
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected,2016-11-11 13:13:01 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-q3-loss-131301370.html,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : November 11, 2016",2016-11-11 12:12:44 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-juno-us-november-11-2016/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : November 11, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,​Juno Therapeutics CEO reports progress in China despite scarce resources,2016-11-10 22:20:09 +0000,http://www.bizjournals.com/seattle/news/2016/11/10/juno-therapeutics-ceo-reports-progress-in-china.html?ana=yahoo,​Juno Therapeutics CEO reports progress in China despite scarce resources
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016",2016-11-10 14:47:03 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-juno-us-earnings-analysis-q3-2016-by-the-numbers-november-10-2016/,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 9-Nov-16 10:00pm GMT,2016-11-10 05:16:37 +0000,http://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-051637511.html,Edited Transcript of JUNO earnings conference call or presentation 9-Nov-16 10:00pm GMT
JUNO,JUNO:UW,BBG007K3F2J4,"NetEase, Taser, SunPower, SolarCity, Juno Report Earnings Late",2016-11-10 02:17:03 +0000,http://www.investors.com/news/solarcity-sunpower-netease-taser-juno-earnings-late-what-to-expect/,"NetEase, Taser, SunPower, SolarCity, Juno Report Earnings Late"
JUNO,JUNO:UW,BBG007K3F2J4,Why These Biotechs Are Soaring Today,2016-11-09 22:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZJGGZxGdoIE/why-these-biotechs-are-soaring-today-cm706827,Image source Getty Images What happened Juno Therapeutics NASDAQ JUNO Vertex Pharmaceuticals NASDAQ VRTX BioMarin Pharmaceutical NASDAQ BMRN and Celgene NASDAQ CELG were all up at least 10 as of 2 58 p m after Donald Trump won the U
JUNO,JUNO:UW,BBG007K3F2J4,Seattle biotech shares soar after Donald Trump victory,2016-11-09 22:40:13 +0000,http://www.bizjournals.com/seattle/news/2016/11/09/biotech-stock-trump-election-republican-drug-price.html?ana=yahoo,Seattle biotech shares soar after Donald Trump victory
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today,2016-11-09 22:00:00 +0000,http://biz.yahoo.com/cc/2/154752.html,Juno Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports Third Quarter 2016 Financial Results,2016-11-09 21:21:13 +0000,http://www.publicnow.com/view/F5C30FE84085A7F2DD6841D3B22E7AE15EB5252B,"[at noodls] - - Strong cash position of $1.04 billion - - JCAR015 Phase II ROCKET trial continues enrollment - - JCAR015 U.S. approval projected as early as the first half of 2018 - - Data to be presented at ASH, including ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2016-11-09 21:18:30 +0000,http://biz.yahoo.com/e/161109/juno8-k.html,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
JUNO,JUNO:UW,BBG007K3F2J4,Why These Biotechs Are Soaring Today,2016-11-09 21:10:59 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-are-soaring-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Are Soaring Today
JUNO,JUNO:UW,BBG007K3F2J4,Q3 2016 Juno Therapeutics Inc Earnings Release - After Market Close,2016-11-09 12:07:05 +0000,http://biz.yahoo.com/research/earncal/20161109.html?t=juno,Q3 2016 Juno Therapeutics Inc Earnings Release - After Market Close
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics a Bargain or a Value Trap?,2016-11-08 18:59:00 +0000,http://www.fool.com/investing/2016/11/07/is-juno-therapeutics-a-bargain-or-a-value-trap.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Juno Therapeutics a Bargain or a Value Trap?
JUNO,JUNO:UW,BBG007K3F2J4,"Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More",2016-11-08 18:15:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iAhLrDR2TQ8/drug-stock-earnings-to-watch-on-nov-9-myl-ions-more-cm705436,It s nearing the closing bell of the third quarter 2016 earnings season with approximately 423 S amp P 500 members representing 84 6 of the index s total market capitalization having reported quarterly results as of Nov 4 An impressive 72 8 of these companies managed to record an
JUNO,JUNO:UW,BBG007K3F2J4,"Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More",2016-11-08 13:12:01 +0000,http://finance.yahoo.com/news/drug-stock-earnings-watch-nov-131201176.html,"Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More"
JUNO,JUNO:UW,BBG007K3F2J4,Is Juno Therapeutics a Bargain or a Value Trap?,2016-11-07 19:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/27Yn1uKBC5U/is-juno-therapeutics-a-bargain-or-a-value-trap-cm705173,Image source Getty Images What happened Shares of the clinical stage biotech Juno Therapeutics NASDAQ JUNO tumbled by more than 18 in October 160 according to data from S amp P Global Market Intelligence JUNO data by
JUNO,JUNO:UW,BBG007K3F2J4,The Unsung Heroes of CAR-T,2016-11-05 16:13:21 +0000,http://www.fool.com/investing/2016/11/04/the-unsung-heroes-of-car-t.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Unsung Heroes of CAR-T
JUNO,JUNO:UW,BBG007K3F2J4,The Unsung Heroes of CAR-T,2016-11-04 18:18:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Oct_HkXF40A/the-unsung-heroes-of-car-t-cm704290,Image source Getty Images Biotech investors are prone to frenzies The potential to hit ridiculously far home runs with biopharma stocks provides all the kindling necessary for hold onto your hats volatility In the past investors stampeded toward gene therapy and DNA vaccines
JUNO,JUNO:UW,BBG007K3F2J4,Why Celgene Corp Is a Better Buy Than Gilead Sciences,2016-11-03 21:08:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tsknLK6xbUg/why-celgene-corp-is-a-better-buy-than-gilead-sciences-cm703624,Image source Getty Images Over the past five years there have perhaps been no large cap biotech companies that have been as successful as Celgene Corp NASDAQ CELG and Gilead Sciences NASDAQ GILD New drug launches have resulted in sales and profit surging higher at
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics",2016-11-03 17:09:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5JHxYILJL-c/better-buy-ziopharm-oncology-inc-vs-juno-therapeutics-cm703401,Image source Getty Images Immunotherapy or using the body s immune system to fight diseases and cancers has become a sizzling investment opportunity for biopharma companies and investors alike While there s been interest in everything from DNA vaccines to checkpoint antibodies
JUNO,JUNO:UW,BBG007K3F2J4,"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics",2016-11-03 15:54:30 +0000,http://www.fool.com/investing/2016/11/03/better-buy-ziopharm-oncology-inc-vs-juno-therapeut.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics"
JUNO,JUNO:UW,BBG007K3F2J4,Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings?,2016-11-03 14:10:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v_398me66Yw/will-juno-therapeutics-juno-disappoint-in-q3-earnings-cm703257,Juno Therapeutics Inc JUNO will be reporting third quarter 2016 results on Nov 9 after the market closes Last quarter the company posted a negative earnings surprise of 27 5 The company started trading in Dec 2014 So far it has had a poor track record with the company
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016,2016-11-03 13:18:12 +0000,http://www.publicnow.com/view/6946445B6FB704F584B8FEA169F118ACCD9F8293,"[at noodls] - -- Updated JCAR017 NHL data to be presented -- Analyst and Investor Event and Webcast on Monday, December 5, at 8:30 p.m. Pacific Time SEATTLE--(BUSINESS WIRE)--Nov. 3, 2016-- Juno Therapeutics, Inc. (NASDAQ: ..."
JUNO,JUNO:UW,BBG007K3F2J4,Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings?,2016-11-03 12:43:12 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-disappoint-q3-124312778.html,Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings?
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report Third Quarter 2016 Financial Results on Wednesday, November 9",2016-11-02 20:21:50 +0000,http://www.publicnow.com/view/EE53BD65F6A3450015513E701B8759A05F98FDB5,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Nov. 2, 2016-- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the third quarter 2016 on Wednesday, November 9, 2016, after the close of U.S.-based financial ..."
JUNO,JUNO:UW,BBG007K3F2J4,Washington is at risk of losing a promising company. Here's how Inslee and Bryant plan to intervene (Video),2016-11-01 18:40:11 +0000,http://www.bizjournals.com/seattle/blog/techflash/2016/11/inslee-bryant-governor-biotechnology-politics-tax.html?ana=yahoo,Washington is at risk of losing a promising company. Here's how Inslee and Bryant plan to intervene (Video)
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals,2016-10-29 13:17:08 +0000,http://www.fool.com/investing/2016/10/28/better-buy-juno-therapeutics-vs-inovio-pharmaceuti.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals,2016-10-28 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/krzgjMLMMMY/better-buy-juno-therapeutics-vs-inovio-pharmaceuticals-cm700126,Juno Therapeutics NASDAQ JUNO and Inovio Pharmaceuticals NASDAQ INO are two clinical stage biotechs that could produce unusually high returns for investors that is if things go as planned With this in mind let s take a closer look at these two companies to consider
JUNO,JUNO:UW,BBG007K3F2J4,Bulls piling into Juno Therapeutics,2016-10-21 16:29:02 +0000,http://finance.yahoo.com/news/bulls-piling-juno-therapeutics-162902260.html,Bulls piling into Juno Therapeutics
JUNO,JUNO:UW,BBG007K3F2J4,"Commit To Purchase Juno Therapeutics At $15, Earn 10.3% Using Options",2016-10-19 16:47:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-mfnhgrXdH0/commit-to-purchase-juno-therapeutics-at-15-earn-103-using-options-cm695394,Investors considering a purchase of Juno Therapeutics Inc Symbol JUNO shares but tentative about paying the going market price of 26 82 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
JUNO,JUNO:UW,BBG007K3F2J4,Surprising Analyst 12-Month Target For FBT,2016-10-17 13:41:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr-UILaU7EY/surprising-analyst-12-month-target-for-fbt-cm693974,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
JUNO,JUNO:UW,BBG007K3F2J4,"Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall",2016-10-12 20:22:01 +0000,http://www.investors.com/news/technology/biotechs-worst-performing-stocks-wednesday-prothena-supernus-fall/,"Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall"
JUNO,JUNO:UW,BBG007K3F2J4,Humana sinks on Medicare rating,2016-10-12 19:38:00 +0000,http://finance.yahoo.com/video/humana-sinks-medicare-rating-193800004.html,Humana sinks on Medicare rating
JUNO,JUNO:UW,BBG007K3F2J4,"Wednesday's ETF Movers: GDX, FBT",2016-10-12 17:42:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pqj-zScKgcM/wednesdays-etf-movers-gdx-fbt-cm692497,In trading on Wednesday the Gold Miners ETF GDX is outperforming other ETFs up about 1 1 on the day Components of that ETF showing particular strength include shares of B2Gold BTG up about 4 1 and shares of Torex Gold Resources TXG CA up about 3 5 on the day
JUNO,JUNO:UW,BBG007K3F2J4,Stocks Close Roughly Flat Following Fed Minutes - U.S. Commentary,2016-10-12 16:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fA7WKM-Z2Kg/stocks-close-roughly-flat-following-fed-minutes--us-commentary-20161012-00776,Stocks Close Roughly Flat Following Fed Minutes - U.S. Commentary
JUNO,JUNO:UW,BBG007K3F2J4,Stocks Continue To Show A Lack Of Direction - U.S. Commentary,2016-10-12 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MFnOssxx3hg/stocks-continue-to-show-a-lack-of-direction--us-commentary-20161012-00372,Stocks Continue To Show A Lack Of Direction - U.S. Commentary
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Starts ZUMA-6 Combo Trial on Lymphoma Drug,2016-10-10 15:21:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fZsNzfAhNjo/kite-pharma-starts-zuma-6-combo-trial-on-lymphoma-drug-cm691012,Kite Pharma Inc KITE announced the initiation of ZUMA 6 a phase Ib II combination study on its lead pipeline candidate KTE C19 in combination Genentech s Tecentriq atezolizumab 160 for the treatment of chemorefractory diffuse large B cell lymphoma DLBCL Note that Kite has
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Starts ZUMA-6 Combo Trial on Lymphoma Drug,2016-10-10 13:21:01 +0000,http://finance.yahoo.com/news/kite-pharma-starts-zuma-6-132101620.html,Kite Pharma Starts ZUMA-6 Combo Trial on Lymphoma Drug
JUNO,JUNO:UW,BBG007K3F2J4,"New CAR-T Cell Therapy May Cure Tumors (JUNO, KITE)",2016-10-07 00:15:00 +0000,http://www.investopedia.com/news/new-cart-cell-therapy-may-cure-tumors-juno-kite/?partner=YahooSA,"New CAR-T Cell Therapy May Cure Tumors (JUNO, KITE)"
JUNO,JUNO:UW,BBG007K3F2J4,Is Celgene the Smartest Buyer in Biotech?,2016-10-02 00:13:39 +0000,http://www.fool.com/investing/2016/09/30/is-celgene-the-smartest-buyer-in-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Celgene the Smartest Buyer in Biotech?
JUNO,JUNO:UW,BBG007K3F2J4,Is Celgene the Smartest Buyer in Biotech?,2016-10-01 01:21:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8zdnk8Aiqdw/is-celgene-the-smartest-buyer-in-biotech-cm687412,Image source Getty Images Celgene NASDAQ CELG is well known for its superstar drugs including 160 blood cancer drug Revlimid which hit 5 8 billion in sales last year and could well reach 10 billion in 2020 160 But what fewer investors realize is how the company
JUNO,JUNO:UW,BBG007K3F2J4,Stocks Move To The Upside Amid Jump In Oil Prices - U.S. Commentary,2016-09-28 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mZWppK_wbBU/stocks-move-to-the-upside-amid-jump-in-oil-prices--us-commentary-20160928-00938,Stocks Move To The Upside Amid Jump In Oil Prices - U.S. Commentary
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Catches Eye: Stock Jumps 13%,2016-09-28 14:24:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xSlaopecx-w/juno-therapeutics-juno-catches-eye-stock-jumps-13-cm685860,Juno Therapeutics Inc JUNO was a big mover last session as the company saw its shares rise almost 13 on the day The news led to far more shares changing hands than in a normal session resulting in solid volume This breaks the recent trend for the company as the stock is now trading
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Catches Eye: Stock Jumps 13%,2016-09-28 12:30:12 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-catches-eye-123012443.html,Juno Therapeutics (JUNO) Catches Eye: Stock Jumps 13%
JUNO,JUNO:UW,BBG007K3F2J4,Stocks Seeing Modest Weakness Following Yellen Comments - U.S. Commentary,2016-09-28 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-tiFcv6cqwo/stocks-seeing-modest-weakness-following-yellen-comments--us-commentary-20160928-00715,Stocks Seeing Modest Weakness Following Yellen Comments - U.S. Commentary
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Inc Scores Big on Positive Clinical Trial (KITE),2016-09-27 20:22:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5dp-bSd8uFc/kite-pharma-inc-scores-big-on-positive-clinical-trial-kite-cm685594,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Kite Pharma Inc 160 NASDAQ KITE closed Monday at 54 98 marking an 11 decline for the year for KITE stock owners Today Kite is trading just shy of 60 a
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval,2016-09-27 20:20:24 +0000,http://www.investors.com/news/technology/kite-pharma-soars-as-cancer-drug-trial-supportive-of-fda-approval/,Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics Is Shooting 10% Higher Today,2016-09-27 18:22:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9E2pkLfyhC0/heres-why-juno-therapeutics-is-shooting-10-higher-today-cm685510,Image source Stockmonkeys com via Flickr What happened After competitor Kite Pharma NASDAQ KITE reported solid efficacy for its chimeric antigen receptor T cell therapy KTE C19 Juno Therapeutics NASDAQ JUNO shares are rallying 10 at 11 30 a m EDT Tuesday So
JUNO,JUNO:UW,BBG007K3F2J4,"American Express Company (AXP), Rockwell Collins Inc. (COL) & More: Here’s Why These Stocks Are Trending Today",2016-09-27 17:37:57 +0000,http://www.insidermonkey.com/blog/american-express-company-axp-rockwell-collins-inc-col-more-heres-why-these-stocks-are-trending-today-477146/,"American Express Company (AXP), Rockwell Collins Inc. (COL) & More: Here’s Why These Stocks Are Trending Today"
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Reports Favorable Data from Lymphoma Study,2016-09-27 16:24:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdGfddAUwhU/kite-pharma-reports-favorable-data-from-lymphoma-study-cm685355,Kite Pharma Inc KITE announced encouraging top line data from a pre planned interim analysis of a pivotal phase II portion of the ZUMA 1 study on its lead pipeline candidate KTE C19 an anti CD19 CAR based therapy The candidate is being evaluated for the treatment of patients
JUNO,JUNO:UW,BBG007K3F2J4,Here's Why Juno Therapeutics Is Shooting 10% Higher Today,2016-09-27 15:31:00 +0000,http://www.fool.com/investing/2016/09/27/heres-why-juno-therapeutics-is-shooting-higher-tod.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Juno Therapeutics Is Shooting 10% Higher Today
JUNO,JUNO:UW,BBG007K3F2J4,Why Kite Pharma's Stock Is Soaring Today,2016-09-27 15:23:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GAm2JvTaXJI/why-kite-pharmas-stock-is-soaring-today-cm685297,What happened Shares of Kite Pharma NASDAQ KITE a clinical stage biotech developing cell based cancer therapies rose by more than 13 in premarket trading today The biotech s surge higher was sparked by a positive interim data readout for the 160 chimeric
JUNO,JUNO:UW,BBG007K3F2J4,Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today,2016-09-27 15:13:00 +0000,https://www.thestreet.com/story/13753511/1/here-s-a-reason-why-juno-therapeutics-juno-stock-is-surging-today.html?puc=yahoo&cm_ven=YAHOO,Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today
JUNO,JUNO:UW,BBG007K3F2J4,Kite Pharma Flies On Lymphoma Treatment Data; Thor Industries Earnings Top,2016-09-27 13:45:17 +0000,http://www.investors.com/news/kite-pharma-reports-bullish-cancer-drug-news-thor-industries-earnings-due/,Kite Pharma Flies On Lymphoma Treatment Data; Thor Industries Earnings Top
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19,2016-09-27 13:42:47 +0000,http://finance.yahoo.com/news/juno-therapeutics-viewed-sympathy-play-134247295.html,Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19
JUNO,JUNO:UW,BBG007K3F2J4,Why Kite Pharma's Stock Is Soaring Today,2016-09-27 13:24:00 +0000,http://www.fool.com/investing/2016/09/27/why-kite-pharmas-stock-is-flying-high-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Kite Pharma's Stock Is Soaring Today
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Kite Pharma's Lead Cancer Candidate Shows Promising Results,2016-09-26 22:18:21 +0000,http://www.wsj.com/articles/kite-pharmas-lead-cancer-candidate-shows-promising-results-1474928298?mod=yahoo_hs,[$$] Kite Pharma's Lead Cancer Candidate Shows Promising Results
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : September 23, 2016",2016-09-23 13:01:42 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-juno-us-september-23-2016/,"Juno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : September 23, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data,2016-09-21 22:21:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Q58her_YxE/juno-therapeutics-and-kite-pharma-the-danger-of-alarmingly-thin-data-cm682896,Image source Getty Images As Juno Therapeutics NASDAQ JUNO and Kite Pharma NASDAQ KITE ramp up for a potential 2017 or early 2018 launch of their lead CAR T therapies investor caution is advised 160 Although the companies cancer killing immune cell therapies
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data,2016-09-21 21:03:19 +0000,http://www.fool.com/investing/2016/09/21/juno-therapeutics-and-kite-pharma-the-danger-of-al.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data
JUNO,JUNO:UW,BBG007K3F2J4,Has Juno Finally Beached Its Downtrend?,2016-09-21 15:55:00 +0000,http://realmoney.thestreet.com/articles/09/21/2016/has-juno-finally-beached-its-downtrend?puc=yahoo&cm_ven=YAHOO,Has Juno Finally Beached Its Downtrend?
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-13 11:33:27 +0000,http://biz.yahoo.com/e/160913/juno8-k.html,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
JUNO,JUNO:UW,BBG007K3F2J4,DEADLINE TODAY: Khang & Khang LLP Announces Extended Class Period in Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm,2016-09-12 15:56:00 +0000,http://finance.yahoo.com/news/deadline-today-khang-khang-llp-155600487.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / September 12, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"DEADLINE ALERT & UPDATED CLASS PERIOD - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016",2016-09-12 14:15:00 +0000,http://finance.yahoo.com/news/deadline-alert-updated-class-period-141500863.html,"[PR Newswire] - NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Juno Therapeutics, Inc. (""Juno"" ..."
JUNO,JUNO:UW,BBG007K3F2J4,9/12/2016 DEADLINE: Lundin Law PC Announces Extended Class Period in Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm,2016-09-11 03:15:00 +0000,http://finance.yahoo.com/news/9-12-2016-deadline-lundin-031500553.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 10, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Juno Therapeutics, Inc. - JUNO",2016-09-10 02:07:00 +0000,http://finance.yahoo.com/news/juno-72-hour-deadline-alert-020700425.html,"[Business Wire] - Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - JUNO",2016-09-10 00:30:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-003000399.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / September 9, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. (""Juno"" or the ""Company"") (NASDAQ: ..."
JUNO,JUNO:UW,BBG007K3F2J4,Monday is Juno Therapeutics Shareholders' Last Chance to Apply for Lead Plaintiff Status in Pending Securities Fraud Lawsuit,2016-09-09 23:01:00 +0000,http://finance.yahoo.com/news/monday-juno-therapeutics-shareholders-last-230100679.html,"[Accesswire] - BOSTON, MA / ACCESSWIRE / September 9, 2016 / Block & Leviton LLP reminds investors in Juno Therapeutics, Inc. (""Juno"" or the ""Company"") (NASDAQ: JUNO) that Monday, September 12, 2016 ..."
JUNO,JUNO:UW,BBG007K3F2J4,3-DAY DEADLINE ALERT: Lundin Law PC Announces Extended Class Period in Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm,2016-09-09 19:06:00 +0000,http://finance.yahoo.com/news/3-day-deadline-alert-lundin-190600289.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 9, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Will These Cancer Therapies Pay Off? (KITE, JUNO)",2016-09-09 17:11:00 +0000,http://www.investopedia.com/news/will-these-cancer-therapies-pay-kite-juno/?partner=YahooSA,"Will These Cancer Therapies Pay Off? (KITE, JUNO)"
JUNO,JUNO:UW,BBG007K3F2J4,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 16:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GS4sTUgfaFs/3-reasons-bluebird-bio-inc-stock-dipped-137-in-august-cm676996,Image source Getty Images What Shares of bluebird bio Inc NASDAQ BLUE 160 a clinical stage biotech developing cellular therapies fell 13 7 in August according to data from S amp P Global Market Intelligence A larger than expected loss in the second
JUNO,JUNO:UW,BBG007K3F2J4,"The Law Offices of Howard G. Smith Announces an Expanded Class Period in the Securities Class Action on Behalf of Juno Therapeutics, Inc. Investors",2016-09-09 15:31:00 +0000,http://finance.yahoo.com/news/law-offices-howard-g-smith-153100159.html,"[Business Wire] - Law Offices of Howard G. Smith announces that a new class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc. securities between May 9, 2016 and July 7, 2016, inclusive ."
JUNO,JUNO:UW,BBG007K3F2J4,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 14:24:51 +0000,http://www.fool.com/investing/2016/09/09/3-reasons-bluebird-bio-inc-stock-dipped-137-in-aug.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August"
JUNO,JUNO:UW,BBG007K3F2J4,DEADLINE ALERT: Khang & Khang LLP Announces Extended Class Period in Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm,2016-09-09 03:37:00 +0000,http://finance.yahoo.com/news/deadline-alert-khang-khang-llp-033700407.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / September 8, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Stock Up On Latest CAR-T Data; Kite Slips,2016-09-08 20:47:15 +0000,http://www.investors.com/news/technology/juno-therapeutics-stock-up-on-latest-car-t-data-kite-slips/,Juno Therapeutics Stock Up On Latest CAR-T Data; Kite Slips
JUNO,JUNO:UW,BBG007K3F2J4,Why Do You Guys Run an Education Company?,2016-09-08 20:20:11 +0000,http://finance.yahoo.com/tumblr/blog-why-do-you-guys-run-an-education-company-202017320.html,Why Do You Guys Run an Education Company?
JUNO,JUNO:UW,BBG007K3F2J4,"Important Shareholder Update And Deadline Alert: Expanded Class Period In Shareholder Class Action Filed Against Juno Therapeutics, Inc. - JUNO",2016-09-08 18:25:00 +0000,http://finance.yahoo.com/news/important-shareholder-deadline-alert-expanded-182500011.html,"[PR Newswire] - RADNOR, Pa., Sept. 8, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts shareholders of Juno Therapeutics, Inc. (JUNO) (""Juno"" or the ""Company"") that the class period in the securities fraud lawsuit filed against the Company and certain of its executive officers has been expanded to include purchasers of Juno's securities between May 9, 2016 and July 7, 2016, inclusive (the ""Class Period""). Juno shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq."
JUNO,JUNO:UW,BBG007K3F2J4,"Health Care Sector Update for 09/08/2016: JUNO,GTXI,MDGS",2016-09-08 17:57:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/73yuvs1lgvw/health-care-sector-update-for-09082016-junogtximdgs-cm676431,Top Health Care StocksTop Health Care Stocks JNJ 0 15 JNJ 0 15 PFE 0 37 PFE 0 37 MRK 0 21 MRK 0 21 ABT 0 38 ABT 0 38 AMGN 0 11 AMGN 0 11 Health care stocks were holding on to small gains this afternoon with the NYSE Health Care Index posting a 0 1 advance while shares of
JUNO,JUNO:UW,BBG007K3F2J4,"3 Stocks to Watch Thursday: Hewlett Packard Enterprise Co (HPE), Tractor Supply Company (TSCO) and Juno Therapeutics Inc (JUNO)",2016-09-08 15:21:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8R2rRbEwI_s/3-stocks-to-watch-thursday-hewlett-packard-enterprise-co-hpe-tractor-supply-company-tsco-and-juno-therapeutics-inc-juno-cm676229,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Wednesday 160 was a mixed day for U S stocks as the dollar rose in value The S amp P 500 posted a very slight loss the Dow Jones Industrial Average lost less than 0 1 and
JUNO,JUNO:UW,BBG007K3F2J4,"4-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-09-08 15:13:00 +0000,http://finance.yahoo.com/news/4-day-deadline-lundin-law-151300708.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 8, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016",2016-09-08 14:25:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-142500957.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / September 8, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court Western District of ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Nintendo, Juno Therapeutics Among 5 Stocks Making Headlines Thursday",2016-09-08 12:01:07 +0000,http://www.insidermonkey.com/blog/nintendo-juno-therapeutics-among-5-stocks-making-headlines-thursday-472894/,"Nintendo, Juno Therapeutics Among 5 Stocks Making Headlines Thursday"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Two Biotech CEOs Make $1M Stock Sales,2016-09-08 11:10:00 +0000,http://www.barrons.com/articles/two-biotech-ceos-make-1m-stock-sales-1473333046?mod=yahoobarrons&ru=yahoo,[$$] Two Biotech CEOs Make $1M Stock Sales
JUNO,JUNO:UW,BBG007K3F2J4,"Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Juno Therapeutics, Inc.",2016-09-08 08:23:00 +0000,http://finance.yahoo.com/news/glancy-prongay-murray-llp-files-082300240.html,"[Business Wire] - Glancy Prongay & Murray LLP announces that it has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of persons and entities that acquired Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,CORRECTING and REPLACING JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy,2016-09-07 20:39:03 +0000,http://www.publicnow.com/view/32A8478CD2A90463E4145E1A6A55311673487299,"[at noodls] - Patients who received a dose of CD19 targeted defined composition engineered T cells after chemotherapy went into complete remission SEATTLE--(BUSINESS WIRE)--Sep. 7, 2016-- In the contact information ..."
JUNO,JUNO:UW,BBG007K3F2J4,JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy,2016-09-07 20:19:02 +0000,http://www.publicnow.com/view/092840741C9DEED70A513E361044AB57801F3123,"[at noodls] - Patients who received a dose of CD19 targeted defined composition engineered T cells after chemotherapy went into complete remission SEATTLE--(BUSINESS WIRE)--Sep. 7, 2016-- In a paper published today ..."
JUNO,JUNO:UW,BBG007K3F2J4,"APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-09-07 15:58:00 +0000,http://finance.yahoo.com/news/approaching-deadline-khang-khang-llp-155800590.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / September 7, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"September 12th Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of Deadline in the Class Action Lawsuit Against Juno Therapeutics, Inc.",2016-09-07 14:30:00 +0000,http://finance.yahoo.com/news/september-12th-deadline-alert-law-143000476.html,"[Business Wire] - Law Offices of Howard G. Smith reminds investors of the upcoming September 12, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"HB ALERT: Hagens Berman Reminds Juno Therapeutics Inc. (NASDAQ: JUNO) Investors of September 12, 2016 Lead Plaintiff Deadline",2016-09-07 13:30:00 +0000,http://finance.yahoo.com/news/hb-alert-hagens-berman-reminds-133000584.html,"[GlobeNewswire] - SAN FRANCISCO, Sept. 07, 2016-- Hagens Berman Sobol Shapiro LLP reminds investors in Juno Therapeutics Inc. that the Lead Plaintiff Deadline is September 12, 2016.. If you purchased or otherwise acquired ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Final Deadline Reminder For Juno Therapeutics, Inc. Shareholders - JUNO",2016-09-07 13:05:00 +0000,http://finance.yahoo.com/news/final-deadline-reminder-juno-therapeutics-130500289.html,"[Accesswire] - RADNOR, PA / ACCESSWIRE / September 7, 2016 / Kessler Topaz Meltzer & Check, LLP alerts Juno Therapeutics, Inc. (Nasdaq: JUNO) (""Juno"" or the ""Company"") shareholders that a class action ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at September 2016 Investor Conferences,2016-09-06 20:19:02 +0000,http://www.publicnow.com/view/24466829BEFD807802EB5F63AFAA192BED60496C,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Sep. 6, 2016-- Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature ..."
JUNO,JUNO:UW,BBG007K3F2J4,"6-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-09-06 17:11:00 +0000,http://finance.yahoo.com/news/6-day-deadline-lundin-law-171100838.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 6, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics Shareholders Reminded of September 12, 2016 Deadline in Pending Securities Fraud Class Action",2016-09-06 16:10:00 +0000,http://finance.yahoo.com/news/juno-therapeutics-shareholders-reminded-september-161000231.html,"[Accesswire] - BOSTON, MA / ACCESSWIRE / September 6, 2016 / Investors in Juno Therapeutics, Inc. (""Juno"" or the ""Company"") (NASDAQ: JUNO) are reminded that the deadline for seeking lead plaintiff ..."
JUNO,JUNO:UW,BBG007K3F2J4,"UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016 -- JUNO",2016-09-06 15:01:00 +0000,http://finance.yahoo.com/news/upcoming-deadline-law-offices-vincent-150100813.html,"[GlobeNewswire] - NEW YORK, Sept. 06, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors ..."
JUNO,JUNO:UW,BBG007K3F2J4,"UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-09-03 03:37:00 +0000,http://finance.yahoo.com/news/upcoming-deadline-khang-khang-llp-033700478.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / September 2, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – JUNO",2016-09-03 00:30:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-003000361.html,"[GlobeNewswire] - NEW YORK, Sept. 02, 2016-- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. and certain of its officers. The class action, filed in United States District ..."
JUNO,JUNO:UW,BBG007K3F2J4,3 Biotech Stocks That Could Make Big Moves In September,2016-09-02 20:12:40 +0000,http://www.investors.com/news/technology/3-biotech-stocks-that-could-make-big-moves-in-september/,3 Biotech Stocks That Could Make Big Moves In September
JUNO,JUNO:UW,BBG007K3F2J4,"APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-09-02 15:05:00 +0000,http://finance.yahoo.com/news/approaching-deadline-lundin-law-pc-150500969.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 2, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Juno Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 – JUNO",2016-09-02 14:39:06 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-143906739.html,"[GlobeNewswire] - NEW YORK, Sept. 02, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Juno Therapeutics Inc. between ..."
JUNO,JUNO:UW,BBG007K3F2J4,"GPM Reminds Investors of the September 12th Deadline in the Class Action Lawsuit Against Juno Therapeutics, Inc. and Encourages Investors to Contact the Firm",2016-09-02 14:30:00 +0000,http://finance.yahoo.com/news/gpm-reminds-investors-september-12th-143000396.html,"[Business Wire] - Glancy Prongay & Murray LLP reminds investors of the September 12, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016",2016-09-02 14:00:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-140000169.html,"[GlobeNewswire] - NEW YORK, Sept. 02, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States Disctirct Court Western District ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Kessler Topaz Meltzer & Check, LLP Reminds Juno Therapeutics, Inc. Investors of Deadline",2016-09-02 13:05:00 +0000,http://finance.yahoo.com/news/kessler-topaz-meltzer-check-llp-130500346.html,"[Business Wire] - Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc. investors that a shareholder class action lawsuit has been filed on behalf of purchasers of the Company’s securities between June 4, 2016 and July 7, 2016, inclusive ."
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Novartis Carts Itself Off,2016-09-01 15:10:00 +0000,http://www.barrons.com/articles/novartis-carts-itself-off-1472742605?mod=yahoobarrons&ru=yahoo,[$$] Novartis Carts Itself Off
JUNO,JUNO:UW,BBG007K3F2J4,Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble,2016-08-31 20:43:44 +0000,http://www.investors.com/news/technology/novartis-closing-cell-therapy-unit-car-t-stocks-tumble/,Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble
JUNO,JUNO:UW,BBG007K3F2J4,Juno and Kite hit today,2016-08-31 18:39:00 +0000,http://finance.yahoo.com/video/juno-kite-hit-today-183900358.html,Juno and Kite hit today
JUNO,JUNO:UW,BBG007K3F2J4,Future of immunotherapy,2016-08-31 18:34:00 +0000,http://finance.yahoo.com/video/future-immunotherapy-183400939.html,Future of immunotherapy
JUNO,JUNO:UW,BBG007K3F2J4,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?",2016-08-31 17:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/novartis-disbands-cell-therapy-unit-whats-ahead-for-kite-juno/?mod=yahoobarrons&ru=yahoo,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?"
JUNO,JUNO:UW,BBG007K3F2J4,Sell Juno Therapeutics: BTIG Says It's Trailing The Competition,2016-08-31 13:19:47 +0000,http://finance.yahoo.com/news/sell-juno-therapeutics-btig-says-131947918.html,Sell Juno Therapeutics: BTIG Says It's Trailing The Competition
JUNO,JUNO:UW,BBG007K3F2J4,BTIG Is 'Generally Skeptical' On Kite Pharma Expectations,2016-08-31 13:17:00 +0000,http://finance.yahoo.com/news/btig-generally-skeptical-kite-pharma-131700761.html,BTIG Is 'Generally Skeptical' On Kite Pharma Expectations
JUNO,JUNO:UW,BBG007K3F2J4,"Novartis Dissolves CAR-T Unit, Cutting 120 Positions",2016-08-31 12:32:00 +0000,http://www.forbes.com/sites/matthewherper/2016/08/31/novartis-dissolves-car-t-unit-cutting-120-positions/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"Novartis Dissolves CAR-T Unit, Cutting 120 Positions"
JUNO,JUNO:UW,BBG007K3F2J4,"IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-30 15:12:00 +0000,http://finance.yahoo.com/news/important-equity-alert-khang-khang-151200924.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 30, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Purcell Julie & Lefkowitz LLP Is Investigating Juno Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors",2016-08-30 12:06:00 +0000,http://finance.yahoo.com/news/purcell-julie-lefkowitz-llp-investigating-120600312.html,"[PR Newswire] - NEW YORK, Aug. 30, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ..."
JUNO,JUNO:UW,BBG007K3F2J4,Oxis International Comments On New York Times Article About Cancer Immunotherapy,2016-08-29 17:13:05 +0000,http://www.publicnow.com/view/C28B097EDBD95FB2C7F882ACF21BDE766CE6D578,"[at noodls] - LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB:OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, ..."
JUNO,JUNO:UW,BBG007K3F2J4,"UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-29 16:40:00 +0000,http://finance.yahoo.com/news/upcoming-deadline-lundin-law-pc-164000480.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement,2016-08-29 16:33:02 +0000,http://www.publicnow.com/view/26902C37CD9B1ADF5895861FB1573535213FA7DB,"[at noodls] - LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), announced today that its research partners ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Juno Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016",2016-08-29 14:09:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-140900696.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
JUNO,JUNO:UW,BBG007K3F2J4,"Class Action Lawsuit Filed Against Juno Therapeutics, Inc. On Behalf Of Shareholders - JUNO",2016-08-29 14:00:00 +0000,http://finance.yahoo.com/news/class-action-lawsuit-filed-against-140000359.html,"[Accesswire] - RADNOR, PA / ACCESSWIRE / August 29, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a class action lawsuit has been filed in the United States District Court for the Western District ..."
JUNO,JUNO:UW,BBG007K3F2J4,"APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-29 09:45:00 +0000,http://finance.yahoo.com/news/approaching-deadline-khang-khang-llp-094500035.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 29, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,Could Toxicity Issues Topple CAR-T Cancer Therapies?,2016-08-27 22:11:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zQy7FTp3Zfw/could-toxicity-issues-topple-car-t-cancer-therapies-cm671230,Image source  Getty Images.  There's no more promising area in cancer research right now than CAR T immune therapies. Desperately ill cancer patients    many with no other options
JUNO,JUNO:UW,BBG007K3F2J4,Could Toxicity Issues Topple CAR-T Cancer Therapies?,2016-08-27 15:42:00 +0000,http://www.fool.com/investing/2016/08/27/could-toxicity-issues-topple-car-t-cancer-therapie.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Could Toxicity Issues Topple CAR-T Cancer Therapies?
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno Therapeutics, Inc. - JUNO",2016-08-27 02:07:00 +0000,http://finance.yahoo.com/news/juno-shareholder-alert-former-louisiana-020700821.html,"[GlobeNewswire] - NEW ORLEANS, Aug. 26, 2016-- Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2016-08-26 21:12:30 +0000,http://biz.yahoo.com/e/160826/juno8-k.html,"JUNO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
JUNO,JUNO:UW,BBG007K3F2J4,"IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-25 21:22:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-212200742.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 25, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Securities Class Action Against Juno Therapeutics, Inc.",2016-08-25 17:10:00 +0000,http://finance.yahoo.com/news/juno-investors-notice-lieff-cabraser-171000964.html,"[Business Wire] - The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the securities of Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-24 15:08:00 +0000,http://finance.yahoo.com/news/equity-alert-khang-khang-llp-150800577.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 24, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016",2016-08-24 14:23:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-142300595.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / August 24, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court Western District of ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016",2016-08-24 13:51:00 +0000,http://finance.yahoo.com/news/juno-investor-alert-law-offices-135100327.html,"[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-23 15:05:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-150500467.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 23, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Juno Therapeutics, Inc. - JUNO",2016-08-23 13:05:00 +0000,http://finance.yahoo.com/news/shareholder-reminder-deadline-class-action-130500459.html,"[Accesswire] - RADNOR, PA / ACCESSWIRE / August 23, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc. (Nasdaq: JUNO) (""Juno"" or the ""Company"") shareholders ..."
JUNO,JUNO:UW,BBG007K3F2J4,Anbang Insurance Plans IPO of Life-Insurance Unit,2016-08-23 08:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sXGRgQScd9I/anbang-insurance-plans-ipo-of-lifeinsurance-unit-20160823-00569,Anbang Insurance Plans IPO of Life-Insurance Unit
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics Rebound Will Continue, Vetr Crowd Says",2016-08-22 18:18:05 +0000,http://finance.yahoo.com/news/juno-therapeutics-rebound-continue-vetr-181805981.html,"Juno Therapeutics Rebound Will Continue, Vetr Crowd Says"
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-22 17:20:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-172000969.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 22, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,Lawsuit for Investors in shares of Juno Therapeutics Inc announced by Shareholders Foundation,2016-08-22 14:15:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-shares-juno-therapeutics-141500984.html,"[GlobeNewswire] - SAN DIEGO, Aug. 22, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Juno Therapeutics Inc over alleged Securities ..."
JUNO,JUNO:UW,BBG007K3F2J4,"EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-19 21:07:00 +0000,http://finance.yahoo.com/news/equity-alert-lundin-law-pc-210700661.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 19, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016",2016-08-19 15:04:00 +0000,http://finance.yahoo.com/news/juno-shareholder-alert-law-offices-150400035.html,"[PR Newswire] - NEW YORK, Aug. 19, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf ..."
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-18 19:15:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-191500159.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 18, 2016 / Khang & Khang LLP (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now,2016-08-18 15:38:00 +0000,http://www.fool.com/investing/2016/08/18/2-cancer-therapy-stocks-that-are-ridiculously-chea.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now
JUNO,JUNO:UW,BBG007K3F2J4,"Brower Piven Alerts Shareholders of Upcoming Deadline in Class Action Lawsuit and Encourages Those with Substantial Losses from Investment in Juno Therapeutics, Inc. to Contact the Firm",2016-08-18 10:00:00 +0000,http://finance.yahoo.com/news/brower-piven-alerts-shareholders-upcoming-100000662.html,"[Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-17 15:29:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-152900013.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 17, 2016 / Lundin Law PC (the ""Firm"") announces a class action lawsuit has been filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Juno Therapeutics, Inc.",2016-08-17 13:00:00 +0000,http://finance.yahoo.com/news/shareholder-reminder-kessler-topaz-meltzer-130000504.html,"[Business Wire] - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc. shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between June 4, 2016 through July 7, 2016, inclusive ."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-15 19:45:00 +0000,http://finance.yahoo.com/news/shareholder-notice-khang-khang-llp-194500477.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 15, 2016 / Khang & Khang LLP (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Juno Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016",2016-08-15 15:07:00 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-150700932.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-13 03:40:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-034000544.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 12, 2016 / Lundin Law PC (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Shareholder Alert by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Juno Therapeutics, Inc.",2016-08-13 02:07:00 +0000,http://finance.yahoo.com/news/juno-shareholder-alert-former-louisiana-020700010.html,"[Business Wire] - Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - JUNO",2016-08-13 00:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-000000108.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / August 12, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. (""Juno"" or the ""Company"") (NASDAQ: JUNO) ..."
JUNO,JUNO:UW,BBG007K3F2J4,"DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-11 19:04:00 +0000,http://finance.yahoo.com/news/deadline-approaching-khang-khang-llp-190400801.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 11, 2016 / Khang & Khang LLP (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO INVESTORS ALERT: Lieff Cabraser Reminds Investors of Securities Class Action Against Juno Therapeutics, Inc.",2016-08-11 17:40:00 +0000,http://finance.yahoo.com/news/juno-investors-alert-lieff-cabraser-174000869.html,"[Business Wire] - The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the securities of Juno Therapeutics, Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-11 16:46:00 +0000,http://finance.yahoo.com/news/deadline-alert-lundin-law-pc-164600007.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 11, 2016 / Lundin Law PC (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action against Juno Therapeutics, Inc. (JUNO) and Lead Plaintiff Deadline: September 12, 2016",2016-08-11 14:23:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-142300488.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / August 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court Western District of ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-10 22:45:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-224500577.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 10, 2016 / Khang & Khang LLP (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"JUNO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016",2016-08-10 15:25:00 +0000,http://finance.yahoo.com/news/juno-investor-alert-law-offices-152500539.html,"[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc."
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm",2016-08-10 15:12:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-151200169.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 10, 2016 / Lundin Law PC (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Kessler Topaz Meltzer & Check, LLP Reminds Juno Therapeutics, Inc. Shareholders of Important Deadline in Class Action Lawsuit",2016-08-10 13:00:00 +0000,http://finance.yahoo.com/news/kessler-topaz-meltzer-check-llp-130000125.html,"[Marketwired] - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed in the United States District Court for the Western District of Washington against Juno ..."
JUNO,JUNO:UW,BBG007K3F2J4,"ETF’s with exposure to Juno Therapeutics, Inc. : August 9, 2016",2016-08-09 17:46:14 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-juno-therapeutics-inc-august-9-2016/,"ETF’s with exposure to Juno Therapeutics, Inc. : August 9, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,[$$] Kite Pharma's Stock Upside Seen Slipping to $77,2016-08-09 16:58:00 +0000,http://www.barrons.com/articles/kite-pharmas-stock-upside-seen-slipping-to-77-1470761916?mod=yahoobarrons&ru=yahoo,[$$] Kite Pharma's Stock Upside Seen Slipping to $77
JUNO,JUNO:UW,BBG007K3F2J4,IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm,2016-08-09 15:34:00 +0000,http://finance.yahoo.com/news/important-investor-notice-khang-khang-153400375.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / August 9, 2016 / Khang & Khang LLP (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – JUNO",2016-08-08 20:24:15 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-encourages-202415907.html,"[GlobeNewswire] - STEVENSON, Md., Aug. 08, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 16:33:28 +0000,http://www.capitalcube.com/blog/index.php/juno-therapeutics-inc-juno-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
JUNO,JUNO:UW,BBG007K3F2J4,Edited Transcript of JUNO earnings conference call or presentation 4-Aug-16 9:00pm GMT,2016-08-05 20:37:03 +0000,http://finance.yahoo.com/news/edited-transcript-juno-earnings-conference-203703332.html,Edited Transcript of JUNO earnings conference call or presentation 4-Aug-16 9:00pm GMT
JUNO,JUNO:UW,BBG007K3F2J4,"INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses In Excess of $50,000 to Contact the Firm",2016-08-05 16:23:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-162300382.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 5, 2016 / Lundin Law PC (the ""Firm"") announces that a class action lawsuit was filed against Juno Therapeutics Inc. (""Juno"" or the ""Company"") ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno (JUNO) Q2 Loss Wider-than-Expected, Focus on Pipeline",2016-08-05 12:56:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8uLnKdhU2go/juno-juno-q2-loss-wider-than-expected-focus-on-pipeline-cm660954,"Juno Therapeutics Inc.JUNO reported a loss of 67 cents per share (including stock based compensation expense) in the second quarter of 2016, wider than the Zacks Consensus Estimate of a loss of 51 cents per share and the year"
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports Second Quarter 2016 Financial Results,2016-08-04 20:22:24 +0000,http://www.publicnow.com/view/0D7D3932BB2D3971BFB85723A43A9349E988A996,[at noodls] - - Strong cash position of $1.11 billion - - JCAR015 Phase II ROCKET trial resumes enrollment - - JCAR015 U.S. approval projected as early as the first half of 2018 - - Preliminary JCAR017 Phase I NHL data ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets,2016-08-04 20:22:23 +0000,http://www.publicnow.com/view/014760EF1178BF45251296AE37A29D8BCDEA024F,"[at noodls] - - Collaboration Includes BCMA CAR Constructs with Fully-Human Binding Domains - - Potential to Accelerate Juno's Multiple Myeloma Program - SEATTLE & NEW YORK & EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug. ..."
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics Inc. Stock Fell 24% in July,2016-08-04 15:58:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VUUOMbqmfsY/why-juno-therapeutics-inc-stock-fell-24-in-july-cm660388,"Image source  Getty Images.  What  Shares of Juno Therapeutics, Inc. (NASDAQ  JUNO)  a clinical stage biopharmaceutical company developing cell based cancer immunotherapies, fell 24% in July, according to data from S&P"
JUNO,JUNO:UW,BBG007K3F2J4,Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?,2016-08-02 12:57:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zHbARuM0OIY/juno-juno-q2-earnings-will-the-stock-disappoint-cm658584,"Juno Therapeutics Inc.JUNO will be reporting second quarter 2016 results on Aug 4, after the market closes . Juno, which started trading from Dec 2014, had delivered a negative earnings surprise of 17.91% in the last quarter. Let's see"
JUNO,JUNO:UW,BBG007K3F2J4,Better Buy: Anavex Life Sciences Corp. vs. Juno Therapeutics,2016-08-01 23:52:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/33yqiTE1CmA/better-buy-anavex-life-sciences-corp-vs-juno-therapeutics-cm658455,"Image source  Getty Images  The market began 2016 with little appetite for biotech stocks, driving the iShares Biotechnology ETF  down nearly 30%. On the whole, sentiment has improved somewhat, with the industry tracking"
JUNO,JUNO:UW,BBG007K3F2J4,3 Index Funds to Buy in August,2016-08-01 15:55:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X4XdkaJPlYg/3-index-funds-to-buy-in-august-cm658034,"Image source  Getty Images.  Index funds are increasingly gaining popularity among investors, and for good reason. The best index funds provide transparency, tax efficiency, and diversification for a conveniently low cost, so investing"
JUNO,JUNO:UW,BBG007K3F2J4,3 Biotech Stocks to Buy on Sale,2016-07-30 15:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/afqjsDuAQgU/3-biotech-stocks-to-buy-on-sale-cm657720,"Image source  Getty Images.  Since last summer, the market has distributed indiscriminate beatings across the biotechnology industry, and companies without approved products to sell have been hardest hit. The iShares Biotechnology ETF (NASDAQ"
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report Second Quarter 2016 Financial Results on Thursday, August 4",2016-07-28 20:28:18 +0000,http://www.publicnow.com/view/F804E2F5D918FDAF1F65170DC4FD4FD86E0F866C,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Jul. 28, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2016 on Thursday, August 4, 2016, after the close of U.S.-based financial ..."
JUNO,JUNO:UW,BBG007K3F2J4,Akamai Technologies Inc. (AKAM) Is Sinking After Q2 Revenues Disappoint,2016-07-27 09:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RiPZqA3nBdA/akamai-technologies-inc-akam-is-sinking-after-q2-revenues-disappoint-20160727-00782,Akamai Technologies Inc. (AKAM) Is Sinking After Q2 Revenues Disappoint
JUNO,JUNO:UW,BBG007K3F2J4,"One Biotech Plays Red Light, Green Light With the FDA",2016-07-26 14:25:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_GWVdMHS-cw/one-biotech-plays-red-light-green-light-with-the-fda-cm654719,Juno Therapeutics (NASDAQ  JUNO) is at the forefront of researching next generation cancer treatments but its research and development program was dealt a blow recently when the Food and Drug Administration halted a key trial following
JUNO,JUNO:UW,BBG007K3F2J4,Pharma Industry Outlook: Fundamentals Remain Strong,2016-07-23 06:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zOTtWHV_3Ns/pharma-industry-outlook-fundamentals-remain-strong-cm653685,"It's been a rough start to the year for pharma and biotech with several factors weighing on the sector including media and political focus on the high price of drugs, mixed first quarter results, slower than expected new product"
JUNO,JUNO:UW,BBG007K3F2J4,"Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug",2016-07-20 22:14:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fCDAojoE2sY/biotech-stock-roundup-celgene-in-immuno-oncology-deal-zafgen-drops-lead-drug-cm652235,"This week, there were the usual regulatory and pipeline updates in the biotech sector. Biosimilars are taking center stage with quite a few companies in the news this week related to their progress in this area. Meanwhile, Zafgen ZFGN"
JUNO,JUNO:UW,BBG007K3F2J4,"Celgene (CELG), Jounce Strike Immunotherapy Collaboration",2016-07-20 16:15:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rhfn4hcryO8/celgene-celg-jounce-strike-immunotherapy-collaboration-cm651994,"Biotech company Celgene CorporationCELG continues to pursue deals in the highly lucrative immuno oncology space. In its latest deal, Celgene has paired up with Cambridge, MA based privately held company Jounce Therapeutics, Inc. covering a global strategic collaboration focused"
JUNO,JUNO:UW,BBG007K3F2J4,"Commit To Purchase Juno Therapeutics At $20, Earn 17.5% Using Options",2016-07-19 17:09:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aS042Vj0RPU/commit-to-purchase-juno-therapeutics-at-20-earn-175-using-options-cm651408,"Investors considering a purchase of Juno Therapeutics Inc (Symbol JUNO) stock, but cautious about paying the going market price of $28.38 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract"
JUNO,JUNO:UW,BBG007K3F2J4,Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest,2016-07-17 19:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lbChnGP2j4g/forget-the-me-too-cancer-drugs-these-breakthroughs-are-where-you-want-to-invest-cm650271,"Image source  Getty Images.  The most powerful man in the field of cancer treatment, FDA oncology chief Dr. Richard Pazdur, recently gave some excellent business advice to drugmakers that applies equally well to"
JUNO,JUNO:UW,BBG007K3F2J4,"3 Stocks to Watch on Friday: CytRx Corporation (CYTR), Juno Therapeutics Inc (JUNO) and Line Corp (ADR) (LN)",2016-07-15 20:13:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tlue3NjF0zI/3-stocks-to-watch-on-friday-cytrx-corporation-cytr-juno-therapeutics-inc-juno-and-line-corp-adr-ln-cm649994,"The stock market continued its rally as the Bank of England surprised investors by opting to not raise its lending rate. The  S&P 500 improved by 0.5% Thursday,"
JUNO,JUNO:UW,BBG007K3F2J4,Why Juno Therapeutics (JUNO) Could Be Positioned for a Slump,2016-07-15 15:18:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70IhYUlX_vg/why-juno-therapeutics-juno-could-be-positioned-for-a-slump-cm649765,"Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid"
JUNO,JUNO:UW,BBG007K3F2J4,"Why Wynn Resorts, Limited (WYNN), Juno Therapeutics Inc (JUNO) and Brocade Communications Systems, Inc. (BRCD) Are 3 of Today’s Worst Stocks",2016-07-15 11:09:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mkcS5d2h9_0/why-wynn-resorts-limited-wynn-juno-therapeutics-inc-juno-and-brocade-communications-systems-inc-brcd-are-3-of-todays-worst-stocks-cm649572,"Mostly inspired by reports that the Bank of England wouldn't be cutting its interest rates after all, the bulls found another reason to fan the"
JUNO,JUNO:UW,BBG007K3F2J4,Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics,2016-07-15 06:18:06 +0000,http://www.publicnow.com/view/F127A34C4B56C50FA293A0A7EB35774EA829716D,"[at noodls] - 15 July 2016 LSE: VER RedoxTherapies to Continue to Pursue Development of Vipadenant (V2006) Vernalis plc ('Vernalis' or the 'Company') notes the announcement by Juno Therapeutics, Inc. ('Juno') (NASDAQ: ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Watch Out For BCLI, RARE''s Phase 3 Trial Hits Goal, JUNO Opens Wallet",2016-07-15 00:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kDlnww1MR4w/watch-out-for-bcli-rares-phase-3-trial-hits-goal-juno-opens-wallet-20160715-00004,"Watch Out For BCLI, RARE''s Phase 3 Trial Hits Goal, JUNO Opens Wallet"
JUNO,JUNO:UW,BBG007K3F2J4,"Oxis 'TriKE' Drug Shows Promise, Receives ""Editors' Choice"" Honor from Science Translational Medicine",2016-07-14 20:18:08 +0000,http://www.publicnow.com/view/B32C174D963958F6C64FEE6D5A0406B3B901828F,"[at noodls] - LOS ANGELES / ACCESSWIRE / June 30, 2016 / Oxis International Inc. (OTCQB: OXIS and OXI.PA), which recently began enrolling and treating patients in an FDA-approved Phase 1/Phase 2 clinical trial of its ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition of RedoxTherapies,2016-07-14 20:18:08 +0000,http://www.publicnow.com/view/ADDE365FF2342B10C85F6FC2531C01CAC683E7E6,[at noodls] - - Acquiring a Small Molecule to Help Overcome the Tumor Microenvironment - - Intend to Use in Combination with Engineered T Cells - -Vipadenant Has Been Dosed in over 250 People - - Upfront Payment of ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno being sued over leukemia drug study,2016-07-13 17:56:53 +0000,http://sg.finance.yahoo.com/news/juno-being-sued-over-leukemia-171009627.html,Juno being sued over leukemia drug study
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Pulls Back Of Highs But Remains Firmly Positive,2016-07-13 12:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xLV1rKV6qQ/juno-therapeutics-pulls-back-of-highs-but-remains-firmly-positive-20160713-00726,Juno Therapeutics Pulls Back Of Highs But Remains Firmly Positive
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Is Surging After FDA Lifts Clinical Hold,2016-07-13 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lNdSIk51LM8/juno-therapeutics-juno-is-surging-after-fda-lifts-clinical-hold-20160713-00531,Juno Therapeutics (JUNO) Is Surging After FDA Lifts Clinical Hold
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics (JUNO) Is Surging After FDA Lifts Clinical Hold,2016-07-13 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ndTIQET-mgQ/juno-therapeutics-juno-is-surging-after-fda-lifts-clinical-hold-20160713-00532,Juno Therapeutics (JUNO) Is Surging After FDA Lifts Clinical Hold
JUNO,JUNO:UW,BBG007K3F2J4,"SAGE On A High, JUNO Rockets As FDA Lifts Clinical Hold, FDA Panel Nod For AMGN",2016-07-12 23:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ji0yZbPjQVA/sage-on-a-high-juno-rockets-as-fda-lifts-clinical-hold-fda-panel-nod-for-amgn-20160712-01341,"SAGE On A High, JUNO Rockets As FDA Lifts Clinical Hold, FDA Panel Nod For AMGN"
JUNO,JUNO:UW,BBG007K3F2J4,Study of promising cancer treatment allowed to resume,2016-07-12 21:37:02 +0000,http://sg.finance.yahoo.com/news/study-promising-cancer-treatment-allowed-213653726.html,Study of promising cancer treatment allowed to resume
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial,2016-07-12 21:13:03 +0000,http://www.publicnow.com/view/BEB1A29087B8A51E2DE9784DAABC80B7CB0B0811,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Jul. 12, 2016-- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today ..."
JUNO,JUNO:UW,BBG007K3F2J4,Correction to Juno to Resume Clinical Trial Article,2016-07-12 19:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CBc9SB_L2As/correction-to-juno-to-resume-clinical-trial-article-20160712-01284,Correction to Juno to Resume Clinical Trial Article
JUNO,JUNO:UW,BBG007K3F2J4,Juno to Resume Clinical Trial of Anticancer Treatment,2016-07-12 18:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mkP4Sh3j3Xw/juno-to-resume-clinical-trial-of-anticancer-treatment-20160712-01278,Juno to Resume Clinical Trial of Anticancer Treatment
JUNO,JUNO:UW,BBG007K3F2J4,"FDA Removes Clinical Hold On Juno Therapeutics' Cancer Drug Trial, Shares Up 27%",2016-07-12 17:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dv2_h_OvF0I/fda-removes-clinical-hold-on-juno-therapeutics-cancer-drug-trial-shares-up-27-20160712-01254,"FDA Removes Clinical Hold On Juno Therapeutics' Cancer Drug Trial, Shares Up 27%"
JUNO,JUNO:UW,BBG007K3F2J4,"FDA Removes Clinical Hold On Juno Therapeutics'' Cancer Drug Trial, Shares Up 27%",2016-07-12 17:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZdPQV0D_WHE/fda-removes-clinical-hold-on-juno-therapeutics-cancer-drug-trial-shares-up-27-20160712-01253,"FDA Removes Clinical Hold On Juno Therapeutics'' Cancer Drug Trial, Shares Up 27%"
JUNO,JUNO:UW,BBG007K3F2J4,Study of promising cancer therapy halted due to deaths,2016-07-08 20:21:21 +0000,http://sg.finance.yahoo.com/news/juno-halts-midstage-drug-study-115456120.html,Study of promising cancer therapy halted due to deaths
JUNO,JUNO:UW,BBG007K3F2J4,"Gap, Synchrony and Polycom jump; PriceSmart sinks",2016-07-08 20:17:25 +0000,http://sg.finance.yahoo.com/news/gap-synchrony-polycom-jump-pricesmart-201725386.html,"Gap, Synchrony and Polycom jump; PriceSmart sinks"
JUNO,JUNO:UW,BBG007K3F2J4,Juno shares dive as clinical test halted after 2 deaths,2016-07-08 17:01:02 +0000,http://sg.finance.yahoo.com/news/juno-shares-dive-clinical-test-170102908.html,Juno shares dive as clinical test halted after 2 deaths
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Posting Steep Loss In Afternoon Trading,2016-07-08 13:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WL-IxhSbFn0/juno-therapeutics-posting-steep-loss-in-afternoon-trading-20160708-00478,Juno Therapeutics Posting Steep Loss In Afternoon Trading
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Inc. (JUNO) Is Sinking After FDA Puts Study On Hold,2016-07-08 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4vNV09LjgVI/juno-therapeutics-inc-juno-is-sinking-after-fda-puts-study-on-hold-20160708-00336,Juno Therapeutics Inc. (JUNO) Is Sinking After FDA Puts Study On Hold
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial,2016-07-07 20:21:06 +0000,http://www.publicnow.com/view/6D8A6CB8A18F1613B2C167C64F48504364CE5739,"[at noodls] - SEATTLE--(BUSINESS WIRE)--Jul. 7, 2016-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Shares Plunge as Drug Trial Placed on Hold After Patient Deaths,2016-07-07 17:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9tUHt486t8A/juno-shares-plunge-as-drug-trial-placed-on-hold-after-patient-deaths-20160707-01069,Juno Shares Plunge as Drug Trial Placed on Hold After Patient Deaths
JUNO,JUNO:UW,BBG007K3F2J4,ArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer,2016-06-30 07:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fgSuMEaT_bo/arqule-presents-anticancer-activity-for-its-arq-087-in-rare-liver-cancer-20160630-00222,ArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer
JUNO,JUNO:UW,BBG007K3F2J4,Highlighted Drug Makers From This Year''s Cancer Conference,2016-06-06 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-wWQHxfb2iY/highlighted-drug-makers-from-this-years-cancer-conference-20160606-00776,Highlighted Drug Makers From This Year''s Cancer Conference
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL,2016-06-04 21:38:04 +0000,http://www.publicnow.com/view/A3A61E3EE1B6706B190790E99E61087B9B5D0644,[at noodls] - - Durable responses and survivals observed in subset of patients who do not go to transplant - - Comparable survival outcomes to transplant patients - - Lower side effects in patients with minimal disease ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability,2016-06-04 14:28:02 +0000,http://www.publicnow.com/view/93DE7D44AB014189271F2306374109C83AC75196,"[at noodls] - - Durable remissions in adult ALL, NHL, and CLL patients with JCAR014 - - 100% complete molecular remission as measured by flow cytometry in pediatric ALL patients with JCAR017 and fludarabine/cyclophosphamide- ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at June 2016 Investor Conferences,2016-05-31 20:33:11 +0000,http://www.publicnow.com/view/C125178B427C62CCBF484C749C7C759B755C4D0D,"[at noodls] - SEATTLE--(BUSINESS WIRE)--May 31, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Highlight Advancing Immuno-oncology Portfolio at the 2016 American Society of Clinical Oncology Annual Meeting,2016-05-18 22:12:05 +0000,http://www.publicnow.com/view/1CDA6F406BA2AAFF6E4ADAFF6A7364B0A039ED4C,"[at noodls] - - New efficacy, safety, and durability data for JCAR014 in ALL, NHL, and CLL - - First clinical results for JCAR017 with fludarabine/cyclophosphamide pre-conditioning regimen in pediatric ALL - SEATTLE--(BUSINESS ..."
JUNO,JUNO:UW,BBG007K3F2J4,Editas Medicine Announces First Quarter 2016 Results and Update,2016-05-16 11:42:09 +0000,http://www.publicnow.com/view/CDC81C192ACFA17DEF5AB20628C2E520B9C1C418,[at noodls] - Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone Strengthened effort to develop medicines for cystic ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Reports First Quarter 2016 Financial Results,2016-05-09 20:38:16 +0000,http://www.publicnow.com/view/5AF3005AF363B25BA336E333F9D2FCA29E919869,"[at noodls] - -- Strong cash position of $1.13 billion -- -- 2016 cash burn and operating burn guidance reaffirmed -- -- In April, Celgene exercised opt-in right for the CD19 program -- -- Encouraging early clinical ..."
JUNO,JUNO:UW,BBG007K3F2J4,Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics,2016-05-04 11:40:07 +0000,http://www.publicnow.com/view/A44D9AE2FE8E997DBFE439E9F58303EB33F8ABFC,"[at noodls] - CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,2016-05-03 20:20:10 +0000,http://www.publicnow.com/view/C6E83E739AA671067F6C5AD6779661FE3A1C380E,"[at noodls] - SEATTLE--(BUSINESS WIRE)--May 3, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2016 Health Care Conference at ..."
JUNO,JUNO:UW,BBG007K3F2J4,"Juno Therapeutics to Report First Quarter 2016 Financial Results on Monday, May 9",2016-05-02 20:30:08 +0000,http://www.publicnow.com/view/00B1AAF97E33BFC43B4C2267FDE918214B8E1E39,"[at noodls] - SEATTLE--(BUSINESS WIRE)--May 2, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2016 on Monday, May 9, 2016, after the close of U.S.-based financial ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno’s Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancers,2016-04-20 19:29:04 +0000,http://www.publicnow.com/view/49A65076F627F4E3AD5421C8BCB54F8075071714,[at noodls] - - Promising complete remission and complete molecular remission rates for CD22 CAR T cell product candidate in pediatric and young adult ALL - - Early signs of activity in the WT-1 TCR program in mesothelioma ...
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics Announces Data Presentations at the American Association for Cancer Research Annual Meeting,2016-04-14 13:19:33 +0000,http://www.publicnow.com/view/B3B06A77FFCDE2D3505BC37EFF2EB357CA2165C8,"[at noodls] - -- First clinical data for the WT-1 TCR product candidate in solid organ tumors -- -- Updated clinical data for CD22 CAR T cell product candidate in pediatric ALL -- SEATTLE--(BUSINESS WIRE)--Apr. 14, ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics and WuXi AppTec Announce New Company to Develop Novel Cell-Based Cancer Immunotherapies in China,2016-04-12 17:34:11 +0000,http://www.publicnow.com/view/BD0948A5F0CBC4A315481578A94A7DEA7BE837E3,"[at noodls] - SEATTLE and SHANGHAI, April 7, 2016 /PRNewswire/ -- Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, ..."
JUNO,JUNO:UW,BBG007K3F2J4,Juno Therapeutics reports 2Q loss,2015-08-12 20:18:51 +0000,http://sg.finance.yahoo.com/news/juno-therapeutics-reports-2q-loss-201851445.html,Juno Therapeutics reports 2Q loss
